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PREFACE AND DECLARATION 
 
The series of studies presented in this thesis was based on 4 years of prospective 
data collection in the Department of Diagnostic Radiology and Organ Imaging, 
Prince of Wales Hospital.  
 
I was responsible for the research protocol design, literature review, study 
implementation, supervision, data analysis and manuscript preparation of the studies 
described in sections 4 to 7. Ethical approval for all studies was obtained from the 
Ethics Committee of our institution. The work of the thesis includes a total of eight 
original studies, which have resulted in 18 immediately related peer-reviewed 
publications, 17 ancillary peer-reviewed publications and 19 presentations in 
international and local scientific conferences. 
 
This thesis has not previously been submitted to another university or institute for a 
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PRECIS  
 
Title: Marrow fat and perfusion in osteoporosis  
MR allows non-invasive means of evaluating the non-mineralized components of 
bone, particularly the bone marrow. This thesis focuses on potential changes 
occurring in bone marrow perfusion and marrow fat in osteoporosis, - changes which 
may improve our understanding of osteoporosis pathophysiology.  We know from 
histology studies that as osteoporosis develops and bone tissue is lost, it is replaced 
by fat filling the vacated marrow space. MR allows non-invasive quantification of this 
fat component. Although fat content may be increasing, it is not known whether any 
change in fat composition occurs with osteoporosis i.e. does the type of fat within 
bone change. Epidemiological studies have indicated a link between arterial disease 
and osteoporosis. It is not known, however, whether any changes occur in bone 
perfusion in osteoporosis and how these may be related to increasing fat within the 
marrow.  
 
The hypothesis to be tested is that: ” Advanced magnetic resonance (MR) 
techniques can be applied to investigate the non-mineralised components of bone 
tissue in osteoporosis thereby providing more information on bone physiology both in 
health and disease”   
 
This thesis is based on a series of eight studies designed to study the relationship 
between bone marrow perfusion, bone marrow fat content, bone marrow fat 
composition and bone mineral density. These studies showed that as bone mineral 
density decreased, bone marrow perfusion decreased. A strong reciprocal 
relationship was found between decreasing bone marrow perfusion and increasing 
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marrow fat. The reduction in perfusion occurred only with bone and did not affect the 
extra-osseous tissues alongside bone with the same arterial supply.  This indicates 
that the reduction in bone perfusion is not simply a reflection of a more generalized 
circulatory impairment in subjects with osteoporosis. This same effect is seen in both 
males and females and in the proximal femora as well as the spine. 
 
In animal-based studies, we found that reduction in bone perfusion was apparent as 
little as two weeks after orchidectomy or oorphorectomy and closely paralleled 
features of impaired endothelial function as well as decreased bone mineral density 
and a hitherto unrecognized reduction in red marrow fraction within the medullary 
canal. Nitric oxide synthase, produced by the endothelium, is a potent stimulator of 
angiogenesis and osteoblastic activity.  Mesenchymal stem cell differentiation may 
switch from osteoblastogenesis to adipocytogenesis under hypoxic conditions, while 
haematopoetic stem cells also supply endothelial stem cells. Potentially endothelial 
dysfunction, mesenchymal stem cell differentiation and haematopoetic stem cell 
maturation may be implemented in the development of osteoporosis.  
 
In normal subjects, blood perfusion was markedly reduced in the femoral head 
compared to the femoral neck. In osteoporotic subjects, a further reduction in blood 
perfusion occurred in both areas. Overall perfusion indices reduced relatively more 
in the femoral neck than the femoral head region. These changes in bone perfusion 
help explain why subjects with osteoporosis have impaired healing of femoral neck 
fractures though do not seem to be at increased risk of avascular necrosis. At a 
micro-architectural level, reduced bone perfusion may also help explain the impaired 
healing of microfractures seen in subjects with osteoporosis, a feature likely to 
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contribute to reduce bone strength, microfracture accumulation and eventually 
clinical insufficiency fracture.  
 
Marrow fat was increased in subjects with osteoporosis. Our studies showed that 
percentage marrow fat content increased even allowing for the quantitative effect 
increased marrow fat has on the bone densitometry measurements.  This effect was 
shown to be of negligible clinical significance. We found a strong reciprocal 
relationship between increasing fat and decreasing bone perfusion in both the 
proximal femur and vertebral body. Although fat content increased, very little 
difference in marrow fat composition was apparent between normal subjects and 
those with osteoporosis. We found no difference was apparent in either the N3/N6 
marrow fat ratio or the spectrum of individual fatty acids in the marrow of subjects 
with either normal bone mineral density or osteoporosis. This suggests that 
alternation of marrow fat composition is not likely to be a direct contributory factor in 
osteoporosis. Also marrow fat increase was shown to be due to an increase in 
number rather than size of marrow fat cells. This suggests that marrow fat increases 
as a result of a switch in mesenchymal cell maturation to adipocytes rather than 
osteoblasts.        
 
Below average perfusion indices in the acetabulum and adductor muscle is 
predictive of more pronounced bone loss at the femoral neck over the ensuing four 
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To summarise, in the eight studies presented, it was shown that osteoporosis is 
associated with a significant reduction in bone perfusion and a reciprocal increase in 
marrow fat content though no change in marrow fat composition. Reduction in bone 
perfusion is most likely due to an accompanying reduction in functioning marrow 
fraction. Marrow fat increase is most likely the result of a switch in mesenchymal cell 
maturation to adipocytes rather than osteoblasts.  The studies present in this thesis 
confirmed the initial hypothesis that “Advanced magnetic resonance techniques can 
be applied to investigate the non-mineralised components of bone tissue in 
osteoporosis thereby providing more information on bone physiology both in health 
and disease”. 
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This introduction provides background information to help understand the studies 
presented in this thesis. The bone disorder osteoporosis is explained as are some of 
the currently associated problems associated with osteoporosis diagnosis and 
management. The rationale for performing the studies undertaken in this thesis is 
outlined. The necessary information on bone, bone marrow, bone blood supply and 
methods of assessment to help understand the studies presented in this thesis is 
then provided. Only that information immediately pertinent to the studies undertaken 




1.2 Some current dilemmas with osteoporosis.  
1.3 Rationale for doing studies presented in this thesis  
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1.4 Bone – mineralised component   
1.5 Bone mass, bone density and methods of assessment  
1.6 Bone marrow  
1.7  Bone marrow fat 
1.8 Non-invasive assessment of bone marrow fat 
1.9 Bone blood flow and perfusion (especially vertebral body and proximal femur)  






The World Health Organization (WHO) defines osteoporosis as a disease 
characterized by reduced bone mass and micro-architectural deterioration of bone 
leading to increased susceptibility to fracture (Figure 1). Osteoporosis is 
characterized by a reduction in trabecular number and thickness and cortical bone 
thinning (Figure 2) .  
Osteoporosis is associated with increased fracture risk. This fracture risk increases 
with advancing age, especially in women and particularly affects those bones that 
depend more on trabecular bone for there strength such as the vertebral body, 
proximal humerus, distal radius, and to a lesser extent, the proximal humerus and 
calcanei. The sacrum and pubic bones, although not possessing a particularly large 
amount of trabecular bone, are also affected a stress is concentrated in these areas 
during weightbearing. As osteoporosis, in the absence of fracture, has no recognized 
adverse effect on general health, one can reasonably argue that the sole purpose of 
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osteoporosis screening, identification and treatment is to prevent fracture (Figure 1).  
 
Figure 1. Increased 
susceptibility to hip and 
vertebral fractures and, 
to a lesser degree,  
distal radial fractures,  
in the elderly and 
mostly consequent 
upon osteoporosis. 
Proximal femoral and 
vertebral fractures are 
uncommon in the 
young or middle-aged. 
(adapted from Copper 
and Melton 1992) 
 
Osteoporosis is a very common disease affecting 1:4 females and 1.8 males over 
the age of 65 years. While most American women under the age of 50 years of age 
have normal bone mineral density (BMD), 27% are osteopenic and 70% osteoporotic 
by the age of 80 years (Cooper et al. 1999). Osteoporotic fractures lead to severe 
morbidity and mortality as well as high economic cost. Osteoporotic fracture alone 
costs the USA about $18 billion/ year and the UK about £1.7 billion/year (Cooper C 




Figure 2. CT image of A) normal hip in 48-year-old man and B) severely osteoporotic hip in 74-
year-old female. In the normal hip (A), note how the cortex in the proximal femur is normally 
relatively thin compared to the shaft with a good trabecular network. In the osteoporotic hip (B), 
there is almost complete absence of (tensile) trabeculae in the femoral neck and proximal shaft 
region. It is easily comprehended how patients with osteoporosis are prone to insufficiency 
fracture.    
 
After peak bone mass is reached during the third decade of life, there is a 
progressive physiological decline in bone mass of about 0.5% per year (Tenenhouse 
A et al. 2000). Around the time of the menopause, accelerated bone loss occurs of 
about 2-3% per year. This accelerated bone loss, which is particularly prevalent in 
females, though also seen in men, settles down over the next five to ten years to a 
slower decline of about 1.0% per annum. Osteoporosis is more specifically a disease 
of reduced bone strength rather than reduced bone density. As evidenced by the 
WHO definition of osteoporosis, reduced bone density is an important feature of 
osteoporosis rather than the sole defining hallmark of this disease. However, bone 
mineral density is the most readily available surrogate marker of bone strength 
currently and, though densitometry testing, bone mineral density measurements and 
T-scores are widely applied to diagnose and monitor osteoporosis.  
A B 
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Although decreasing BMD is strongly associated with increased fracture risk and the 
most applicable surrogate marker of fracture risk, in reality, most fractures occur in 
subjects who are osteopenic (low bone mass) rather than osteoporotic. This 
ambiguity can be attributed to many more people being osteopenic than osteoporotic 
and bone density being but one facet of bone strength.  For example, one large 
study showed that 48% of post-menopausal women with non-traumatic or mildly 
traumatic fracture over a 9-year follow-up period had a baseline bone density in the 
osteopenic range while 8% had a normal baseline bone density (Sornay-Rendu E et 
al. 2005). In other words, 56% of patients in this study with fracture did not have 
osteoporosis as defined by T-score. In another similar study, 44% of all non-
vertebral fractures occurred in women with a T score above -2.5 (Schuit SC et al. 
2004).  
It is not clear why some people develop osteopososis and others of comparable age 
gender and lifestyle do not. Many risk factors for osteoporosis have been identified 
such as increasing age, thin build, female gender, family history, smoking, alcohol, 
arterial calcification, steroid medication, thiazide diuretics though a common linking 
pathway has not been found. This main theme of the studies presented in this thesis 
is to further explore the physiology behind osteoporosis particularly looking primarily 
at the non-osteoid components of bone (marrow and perfusion). MR imaging has 
provided us a means of studying these bone components which have not been 
studied in detail previously in respect to osteoporosis.  
1.2 SOME CURRENT DILEMMAS WITH OSTEOPOROSIS:  
A.  Osteoporosis is being diagnosed too late. Current methods of diagnosing 
osteoporosis rely on bone being lost. Bone needs to be lost before 
densitometry can detect reduced bone mass or high resolution imaging 
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techniques can detect structural changes in bone architecture. Osteoporosis 
results in progressive cortical thinning, trabecular thinning and loss of 
trabeculae (Figure 5). Once trabeculae have been lost, many do not seem to 
recover. The increase in bone density which occurs with treatment seems to 
occur as a result of thickening of residual trabeculae and cortices rather than 
regeneration of previously reabsorbed trabeculae.   
 
Figure 5. High resolution 
Xtreme CT images of 
distal radius showing A) 
normal and B) 
osteoporotic bone. 
Cortices and trabeculae 
are thinned and 
trabeculae  reduced in 
number in osteoporotic 
bone. There are large 
areas in osteoporotic 
bone devoid of 
trabeculae. With 
osteoporotic treatment, 
these holes in the 
trabecular network do not 
seem to re-fill. (Courtesy 
of Prof Qin Lin) 
 
 
 In other words, once holes appear in the trabecular bone network, they do not 
necessarily re-fill with improvement in BMD. As a result treated osteoporotic 
bone will remain structurally inferior to normal bone. Currently, we have no 
means of diagnosing osteoporosis before significant bone loss occurs. Could 
changes in marrow fat or perfusion predate loss of bone mass such that one can 




B.  The pathogenesis of osteoporosis remains unknown. Many risks factors for 
osteoporosis have been identified (female gender, increasing age, family 
history, smoking, alcohol, drugs) though no universal common pathway has 
been identified. At a metabolic level, many links between osteoporosis, 
vascularity and fat have been inentified including, for example, the inflammatory 
cytokine IL-6 which can give rise to bone loss and atherosclerosis and is 
secreted by adipocytes (McLean RR 2009).  Not knowing the true cause of 
osteoporosis limits the development of effective therapy. Do vascular or marrow 
elements hold the key to the pathogenesis of osteoporosis?   
C. Monitoring treatment effect is slow. Effect of treatment can only be realized 12-
18 months minimum after initiation as bone metabolizes slowly and it takes time 
before any true effect on bone density can be recognized. To see whether this 
effect is maintained and to show fracture reduction usually takes at least five 
years such that whole programme moves along at a slow pace. Do changes in 
vascularity or marrow composition predate change in bone mass thereby 
allowing one to determine the efficacy or otherwise or treatment at a much 
earlier stage?  
 
1.2. HYPOTHESIS TO BE TESTED AND RATIONALE FOR DOING STUDIES 
PRESENED IN THIS THESIS 
The hypothesis to be tested is that: ” Advanced magnetic resonance (MR) 
techniques can be applied to investigate the non-mineralised components of 
bone tissue in osteoporosis thereby providing more information on bone 
physiology both in health and disease”   
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With this aim in mind there were two main reasons for undertaking the studies 
presented in this thesis.  
First, little is known about what happens to the bone marrow in osteoporosis. For 
example, in 2002, the year we started these studies, not a single abstract dealt with 
bone marrow, perfusion or marrow fat out of over 2000 abstracts presented at the 
Bone and Mineral Research Annual meeting. Yet per unit volume, bone is composed 
mainly not of mineralized tissue but of soft tissue as in marrow tissue. Second, MR 
imaging provided a means of non-invasively evaluating the bone marrow. 
Understandably, the vast majority of research on the pathogenesis of osteoporosis 
has focused on studying the mineralized elements of bone particularly bone 
formation and resorption pathways. At the outset of our studies, we had no idea as 
to the relationship between bone mass and marrow perfusion and in fact our initial 
thoughts were the osteoporosis may even be associated with increased rather than 
decreased bone perfusion as the relationship between hyperaemia and increased 
osteoclastic activity is well recognized. We were also interested in marrow fat as 
osteoblasts and marrow fat share a common pre-cursor cell and bone marrow in the 
adult is comprised mainly of fat. Fat surrounds cortical bone and, more importantly, 
surrounds biologically active trabecular bone within the bone marrow.  
 
1.4  BONE – MINERALISED COMPONENT  
Bone is a specialized type of connective tissue which provides structural support, 
protection and plays a major role in the regulation of haematostais and calcium 
balance. The organic matrix of bone is osteoid. Osteoid is primarily (95%) composed 
of Type I collagen fibers while the remaining 5% comprises chondroitin sulfate 
proteoglycans and a variety of other non-collagenous proteins (Marks SC et al. 
 24 
2002). This largely collagenous matrix is hardened through mineralization where 
calcium hydroxyapatite crystals [Ca5(PO4)3(OH)] are deposited into the organic 
matrix. Mineralization increases resistance to compression. Mature mineralized bone 
is therefore composed of Type I collagen fibers (40% by volume) interspersed with 
calcium hydroxyapatite crystals [Ca5(PO4)3(OH)] (45% by volume) and water (15% 
by volume) bound to collagen or free (Hadjidakis DJ et al . 2006). 
Cortical or compact bone forms the compact outer shell of bone. It accounts of  80% 
of mineralised bone mass, is composed of tightly packed collagen fibrils organized 
around central nutrient canals, has a slow turnover rate and high resistance to 
bending and torsion. Trabecular or cancellous bone consists of a honeycomb of 
bone struts irregularly criss-crossing the marrow cavity. Cortical bone measures 1-
8mm in thickness  being thickest on the anterior shaft of the tibia. Trabecular bone is 
much thinner at between 200-400µm (i.e. 0.2 -0.5mm). Trabecular bone is the 
dynamic component of bone by virtue of its large surface area and thin architecture. 
Although trabecular bone represents 20% of mineralised bone mass, it includes 80% 
of the overall bone surface area (Hadjidakis DJ et al. 2006) and is 10-20 times more 
metabolically more active than cortical bone.  
Although longitudinal bone growth largely ceases at the end of adolescence, human 
bone is continually remodeled throughout adulthood with about 10% of adult bone 
being remodeled each year (Theill L et al. 2002). Bone remodeling serves to repair 
microdamage and adapt bone structure to mechanical strains and functional 
requirements. Bone remodeling is a highly regulated process that is orchestrated by 
three cell types: osteocytes, osteoblasts, and osteoclasts.  
Osteocytes. Osteoblasts trapped within osteoid are called osteocytes. They have 
long cell processes which help to form a network of thin calaliculi permeating the 
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entire bone matrix (Hadjidakis DJ et al. 2006). The exact function of osteocytes is 
not clear though it is likely they respond to bone strain and enhance bone 
remodeling by recruiting osteoclasts to sites where bone resorption is required 
(Hadjidakis DJ et al. 2006). (Figure 6).  
 
Figure 6. Connections between osteocytes and bone remodeling compartment containing 
osteocystes (OC) and osteoblasts OB). The BMC is lined by specialized cells outside of which 
lie the capillaries or venous sinuses. (Modified from Martin TJ, Seeman E 2008) 
 
Osteoblasts.  An osteoblast is a mononuclear cell that produces osteoid matrix and 
facilitates mineralization of this osteoid. Osteoblasts arise from mesenchymal stem 
cells located in the bone marrow and periosteum. These multipotent mesenchymal 
stem cells in the marrow can also differentiate into adipocytes, chondrocytes, 
fibroblasts, or myoblasts. Osteoblasts do not function individually but they are found 
in clusters along the surface of the bone they are producing (Hadjidakis DJ et al. 
2006). (Figure 6).   
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Osteoclasts. Bone resorption is carried out by osteoclasts. Unlike osteoblasts, 
osteoclasts do not derive from the mesenchymal cell line but instead derive from the 
haemopoetic stem cell line (which also gives rise to erythroblasts, megakaryoblasts, 
myeloblasts and monoblasts) (Hadjidakis DJ et al. 2006). They are usually found on 
the bone surface alongside osteoblasts (Figure 6).  
Bone remodeling compartments. Bone remodeling takes place in specialized 
vascular structures on the bone surface known as bone remodeling compartments 
(BMC’s) (Hauge EM et al. 2001) (Figure 6). The inner lining of the BMC is made up 
of the bone surface lined with either osteoclast or osteoblast cells depending on the 
state of the remodeling cycle. There is a thin layer of specialized cells showing 
positive immunoreactivity to a whole array of markers. The venous sinusoid lies 
outside this cell layer. It is unclear whether osteoblast or osteoclast precursors enter 
the BMC from the adjacent marrow space or whether they arise in the BMC de novo. 
Much still remains to be discovered about the physiology of the BMC (Eriksen EF et 
al. 2007) 
The importance of the RANKL/OPG system for the regulation of osteoclast activity is 
well established. Osteoclastogenesis is mainly controlled by a triad of proteins 
consisting of a receptor RANK (receptor-activated nuclear-kappa), a ligand 
(receptor-activated nuclear-kappa B ligand, RANK-L), and a decoy receptor 
osteoprotegerin (Hadjidakis DJ et al. 2006). RANK is a protein found on the 
membranes of osteoclast precursors and mature osteoclasts.  RANK-L is produced 
by a range of cells including osteoblasts and activated T-cells. Osteoprotegerin is 
also secreted by a range of cells including osteoblasts.  Binding of RANK-L to RANK 
promotes osteoclastogenesis and inhibits osteoclast apoptosis. Binding of RANK-L 
to osteoprotegerin prevents osteoclastogenesis and promotes osteoclast apoptosis. 
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Osteoclast number and activity is therefore largely controlled by the balance 
between RANK, RANK-L and osteoprotegerin (Hadjidakis DJ et al. 2006).  
There are a large number of growth factors regulating controlling osteoblast 
differentiation and maturation (such as parathyroid hormone, growth hormone, 
thyroid hormone, insulin, prolactin as well as the sex hormones) while an even larger 
number of growth factors are produced by osteoblasts which may serve with self-
regulation (such as bone morphogenetic protein, canonical Wnt, core binding factor-
1, fibroblast growth factor, platelet-derived growth factor, transforming growth factor-
beta, Osterix, Col1, alkaline phosphatase, osteocalcin, osteopontin, and osteonectin) 
(Nakashima K et al. 2003, Hadjidakis DJ et al. 2006). 
 
Bone shape: Longitudinal bone growth largely ceases in humans at the time of 
skeletal maturity which for the main long bones of the lower limbs is about 17 years 
in females and 18 years in males. Although longitudinal bone growth stops, bone, 
nevertheless, continues to be remodeled throughout life. Overall bone cross-
sectional area and cortical thickness is maintained by a balance between bony 
apposition and deposition on the endosteal and periosteal margins of the cortex. The 
general tendency is for bone to widen with aging. Slight increases in bone cross-
sectional area allows one to maintain bone strength with the same bone mass 
(Seeman et al. 2007). Increase in bone cross-sectional area results from a 
predominance of periosteal bone deposition and endosteal bone apposition 
(Seeman et al. 2007). This adaptive response is mainly seen in the weightbearing 
bones and varies with age and gender (Seeman et al. 2007).   
In the shafts of long bones, the cortex is thick, the marrow cavity relatively small and 
the number of trabeculae in the marrow cavity relatively sparse. This thick cortex 
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affords rigidity to the bone. At the ends of long bones, and in other bones such as 
the vertebral bodies or calcanei, the cortex is relatively thin and the marrow cavity 
wide. A large marrow cavity allows the bone to expand while still maintaining a 
reasonable weight. Large bones and expanded ends of long bones are there to 
maintain body size, maintain stability and support joints. When the marrow cavity is 
large, the cortex is relatively thin. To main the overall strength of the bone, the 
relatively thinned cortex of the expanded bone is supported by a well-developed 
trabecular network crisscrossing the medullary canal. In general, wherever the 
cortex is thin, the trabecular network is well-developed and visa versa.  
 
1.5  BONE MASS, BONE DENSITY, AND METHODS OF ASSESSMENT  
Mass is the weight of an object. Density is mass per unit volume (mass /volume). 
Common tissue densities are shown in Table 1 (Weiss LP et al 1987, Goodsitt MM 
et al 1994) as well as peak bone mineral densities as measured by DXA (Lynn HS et 
al 2008) and the composition of fat, cortical bone and lean muscle (White DR et al 
1965).  
Bone mass equates to bone mineral content (BMC) and is the amount of bone 
mineral present in a structure measured in grams. Bone mineral density (BMD) is the 
amount of bone per unit volume and is measured in grams/cm3. Densitometry 
devices do not measure true bone mineral density since this should be ‘mass of 
bone per unit volume of bone’ i.e. exclusive of marrow or other non-osseous tissue. 
Since densitometry techniques such as DXA or QCT measure a combination of bone 
and bone marrow, the value obtained is termed ‘apparent bone mineral density’ 
though this has become synonymous with bone mineral density (BMD) (Faulkner K 
2005).  
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Densitometry results are reported as T and Z scores, both of which rely on the 
standard deviation (s.d.) of the measurement. In a normally distributed population, 
approximately 68% people will fall within ± 1 s.d. of the mean, 95% within ± 2 s.d’s 
and 99.7% within ± 3 s.d’s of the mean. An Z score is the number of s.d’s difference 
that a patient’s BMD is above or between the mean BMD of age-matched controls. 
Therefore, a Z score of 0 indicates a BMD equal to a person of the same age while a 
Z score of > -2.0 indicates a BMD > 2 s.d’s below the mean for subjects of the same 
age or a BMD less than the BMD of 97% of subjects of the same age. An T score is 
the number of s.d’s difference that a patient’s BMD is above or between the mean 
BMD of a control group of healty young adults. A T score of 0 indicates a BMD equal 
to the young adult mean while a T score of >-1.0 indicates a BMD <1 s.d than the 
young adult mean or in other words a BMD < 68% of the BMD young adult 
population.  
TABLE !: Density and Chemical Composition of common tissues  
 TISSUE  DENSITY  COMPOSITION (element fraction by weight) 
H C N O Na Mg P S K Ca 
Red marrow  1.02g/cm
3
 ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ 
Blood  1.05g/cm
3
 10.2 11.0 3.3 74.5 0.1 0.0 0.1 0.2 0.0 0.0 
Fatty Marrow 0.95 g/cm
3
 ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ 
Adipose tissue  0.92 g/cm
3
 11.4 59.8 0.7 27.8 0.1 0.0 0.0 0.1 0.0 0.0 
Lean Muscle  1.00g/cm
3
 10.2 12.3 3.50 72.9 0.08 0.02 0.2 0.5 0.5 0.01 
Cortical bone  1.85g/cm
3
 3.4 15.5 4.0 44.1 0.06 0.21 10.2 0.31 0.0 22.2 
Trabecular bone  1.70g/cm
3
 ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ 
ANATOMINAL AREA 
Lumbar spine  0.99 ± 0.10g/cm
2
  
Total hip 0.89 ± 0.11g/cm
2
 




Table 1: Densities and chemical composition of common tissues (from Hubbell JH et al. 
2009) as well as peak BMD of lumbar spine and hip region (as measured by DXA). The 
density of water is 1.0g/cm3. Measurements from DXA are in g/cm2 rather than g/cm3 as DXA 
measures areal rather than volumetric density.  
 
There are several methods of measuring bone densitometry including radiography, 
quantitative ultrasound, dual x-ray absorptiometry, and quantitative computed 
tomography. As dual x-ray absorptiometry (DXA) and quantitative computed 
tomography (QCT) were the methods used in the studies presented in the thesis, 
only these two methods will be described.   
 
 
Dual x-ray absorptiometry.  
In all clinical studies in this thesis, bone density was assessed by DXA. Dual x-ray 
absorptiometry (DXA), as the name implies, measures the relative tissue absorption 
of a dual energy x-ray spectrum (Figure 7).  The dual energy spectrum is produced 
in one of two ways. Either a cerium filter is applied to absorb the mid-energy 
spectrum waves of an x-ray beam yielding effective energies of 40 and 70keV or a 
dual energy x-ray source is utilized rapidly switching between low (~ 70kVp) and 
high (~ 140kVp) tube potentials (Damilakis J 2007). DXA is a projectional imaging 
technique which measures areal density as g/cm2. Area BMD is measured by 
dividing bone mineral content (BMC) by the projected area of the scan. Since its 
introduction into clinical practice in 1987, DXA has become the most widely accepted 
means of measuring BMD. DXA measures ‘integral’ bone mineral density since it is 
unable to distinguish between cortical and trabecular bone. Most centers measure 
anteroposterior lumbar spine (L1-L4) and hip BMD.  
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Figure 7A. DXA machine during 
examination of the hips. Lower limbs are 
internally rotated to align femoral necks 
more parallel to the table top. 
 
Figure 7B. Schematic representation of 
open DXA machine. The x-ray tube 
(arrow) produces dual energy x-ray 
beam which after transmission is  
detected by the detectors (open arrow)  
 
 
Figure 7C. Position during examination 
of AP lumbar spine. Hips are flexed to 
smooth our lumbar lordosis.  
 
Bone mineral density as measured by DXA is an important predictor of osteoporotic 
fracture risk (Johnell O et al. 2005). In a 14 year prospective study of over 1,500 
patients aged more than 60 years, the risk of hip fracture was increased 3.6-fold in 
women and 3.4-fold in men for each s.d. reduction in femoral neck baseline BMD 
measurement (Nguyen ND et al. 2005).  
In pre- and peri-menopausal women, the lumbar spine is the optimal site for serial 
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monitoring of changes in BMD due to its greater rate of bone mineral density change 
while the hip is the best site for predicting proximal femoral fracture (Sahota O et al. 
2000, Marshall D et al. 1996) (Figure 8). However, in post-menopausal women, 
serial measurement of lumbar spine BMD is less reliable since it is heavily influenced 
by new bone formation related to spinal degenerative disease. Hence lumbar spine 
BMD measurement by DXA will often be see to increase over time rather than 
decrease in elderly subjects. In elderly subjects, therefore, hip BMD is the better 
reflection of true BMD change on serial examinations rather than lumbar spine BMD 
(Figure 9).  
 
Figure 8. AP DXA lumbar spine. L1-L4 
vertebrae are analyzed.  
 
 
Figure 9. DXA hip. Either the femoral neck BMD 
or total hip BMD are commonly used for 
analysis. One measure does not have any 
particular advantage over the other.  
 
 
Reduction in BMD can occur either as a result of an decease in BMC or an increase 
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in bone area. For example, between 30-50 years of age, BMD decreases by 0.4% 
per annum due to an annual decline in BMC of 0.2% per annum and an annual 
increase in bone cross-sectional area of 02% per annum (Hui SL et al. 2002, Looker 
AC et al. 1998).  
 
BMD estimation by DXA is influenced by precision and accuracy errors. Precision 
errors are mainly equipment and positioning related and are measured by analyzing 
reproducibility (coefficient of variation) of repeated measurements in the same 
subject group.  Accuracy errors are more subtle and less easily detected then 
precision errors, being the result of calibration and geometric assumptions, and 
variable distribution of muscle, fat and bone tissue among different subjects. For 
example, overestimation of BMD measurements can occur in subjects with spinal 
degenerative disease, scoliosis, vertebral collapse or aortic calcification. Similarly, it 
has recently been recognized that underestimation of BMD measurement by DXA 
may occur if there is accumulation of marrow fat. Phantom DXA studies have 
suggested a BMD correction of 0.003 g/cm2 per 1% marrow fat content (Bolotin H et 
al. 2003). For example, if vertebral marrow increases from 25% to 75% fat fraction, 
measured BMD by DXA should be decreased by 50 x 0.003g/cms2 = 0.15g/cm2. In 
Study 3 of this thesis we re-evaluate this correction factor and show that correction 
factor for every % increase in marrow fat should be less than that proposed by 
Bolotin.  
 
Quantitative computed tomography (QCT). 
Computed tomography methods used to assess bone mass and architecture include 
standard QCT, volumetric QCT, peripheral QCT (pQCT), high resolution pQCT and 
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microCT (Figures 8 and 9). QCT was used in Study 7 to measure the density of rat 
vertebrae. We have shown in a further study (not presented in this thesis) that QCT 
using a clinical CT scanner has several distinct advantages over pQCT when 
measuring density in experimental animals (Wang YX et al 2008)  
 
Figure 10: Quantitative CT 
examination of the L2 vertebral 
body. The graded calibration 
phantoms which are examined at 




Peripheral QCT (Figure 11) uses a specialized peripheral QCT system (pQCT) and 
is used in humans to measure the size and bone mineral density of peripheral bones 
(the distal radius and distal tibia). PQCT offers isotropic spatial resolution of 
approximately 500µm. This resolution is sufficient to allow cortical and trabecular 
bone mineral density to be analyzed separately. In small animals, pQCT can also be 
used to assess bone mineral density of the spine. However, since rat vertebrae are 
considerably smaller than the distal radius or tibia in humans, the resolution of pQCT 
is not sufficient to allow cortical and trabecular bone to be analyzed separately in 
small animals. pQCT measures volumetric density and measurements are reported 









We have not studied bone remodeling per se in this thesis though it will be briefly 
discussed here as it is an important facet of bone metabolism related to bone density 
and an independent predictor of fracture risk. Currently, the gold standard for bone 
remodeling is dynamic quantification by tetracycline labeling followed by bone biopsy 
at the iliac crest. This method of is not ideal as it is invasive and assessment of any 
treatment response involves multiple biopsies. Also, it is more or less limited to the 
iliac crest and this site is not necessarily representative of other skeletal sites and is 
also subject to large measurement error [Compston JE et al 1991]. A alternative 
method is to use urinary and serum markers of bone turnover and these are helpful 
in the in the early detection of treatment response [Garnero et al 1999]. However, 
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they too are subject to wide variability and are limited in providing a measure of total 
skeletal metabolism and as such may not reflect what is happening at specific sites 
such as the spine and hip.  
It is apparent that a non-invasive method which could measure bone metabolism at 
a specific site would be very helpful. PET imaging has shown promise in this area. 
Using 
18
F-fluoride, PET imaging does allow a non-invasive quantitative assessment 
of bone metabolism at specific skeletal sites of the skeleton [Cook GJR et al 2000, 
Frost ML et al 2003] with significant correlation been shown between PET-derived 
regional skeletal kinetic parameters and bone formation or mineral apposition rate 
assessed on bone histomorphometry [Messa C et al 1993, Piert M et al  2001]. 
Whether MR imaging has this potential has not been addressed in this thesis.  
  
1.6 BONE MARROW 
The bone marrow is found in the central cavity of bones interspersed and supported 
by the bony trabeculae and a fibrous tissue retinaculum. The bone marrow is a large 
organ accounting for about 4% body weight in humans (Travlos GS et al. 2006) such 
that in a 70kg man, the bone marrow would weigh 2.8kg making it one of the 
heaviest organs behind the bony skeleton, the skin, and subcutaneous fat (Hwang S 
et al. 2007).   
 
The bone marrow cavity is made up of trabecular bone, marrow fat, non-fatty cellular 
elements, water and vascular channels though the actual composition does vary 
considerably with age, anatomical location and physiological state (Hwang S et al. 
2007).  The non-fatty cellular elements comprise stem cells, haemopoetic cells 
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(erythrocytes, granulocytes, lymphocytes, monocytes and platelets) and their 
precursors. Erythropoesis takes place in distinct anatomical units (‘erythroblastic 
islands’); granulopoesis takes place in less distinct foci and platelet production 
(megakaryocytosis) occurs adjacent to the sinus epithelium (Travlos GS 2006). 
Upon maturation haemopoetic cells transverse the wall of the venous sinuses to 
enter the bloodstream while platelets enter the bloodstream by cytoplastic processes 
from megakaryocytes penetrating the sinus wall into the sinus lumen (Travlos GS 
2006).   
 
At birth, the bone marrow is nearly entirely haemopoetic expect for the epiphysis and 
apophyses which contain predominantly fat. With maturation, the marrow converts to 
a predominantly fatty marrow in a symmetrical centripetal fashion (Hwang S et al. 
2007). Red marrow converts to fatty marrow from the periphery to the central 
skeleton. Superimposed on this centripedal pattern, red marrow converts to fatty 
marrow in the tubular bones proceeding from diaphysis to metaphysis (Hwang S et 
al. 2007, Hartsock RJ et al. 1965) (Figure 12).  By about 10 years of age, marrow 
conversion of red to fatty marrow has begun in the diaphyses and spread to the 
metaphyses particularly in the distal diaphyses (Hwang S et al. 2007) (Figure 12). By 
20 years, nearly all of the long bone marrow is completely fatty except for the 
proximal metaphyses (Hwang S et al. 2007) (Figure 12).  By thirty years, some red 
marrow remains only in the proximal metaphyses, and the axial skeletal (pelvis, 
spine, scapulae, clavicles, sternum and skull).  In the event of an increased 
functional demand for haematopoesis, this sequence of events can reconvert with 
fatty marrow reconverting to red marrow in a reverse, symmetrical centrifugal 
manner (Poulton TB et al. 1993).    
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Figure 12: From birth, red marrow converts to fatty marrow from the periphery to the central 
skeleton. Superimposed on this centripedal pattern, red marrow converts to fatty marrow in 
the tubular bones proceeding from diaphysis to metaphysis until by the age of 20 years only 
the proximal metaphysic contains appreciable red marrow. (Adapted from Moore SG et al, 
1990).   
 
Bone marrow temperature is slightly lower (1.6-4.80C) than normal body temperature. 
The propensity of red marrow to remain in the warmer more central parts of the 
skeleton may be related to temperature. It has been noted that the armadillos 
markedly increases its marrow fat during the winter months which is then replaced 
by red marrow during the warmer summer months (Weiss LP et al. 1956). The 
composition of reindeer marrow fat has been shown to change with under-nutrition 
during the winter months changing back to a different composition during the 
summer months (Soppela P et al. 2001). 
Although red and fatty marrow are of course a continuum, what is generally termed 
‘red’ marrow contains about 60% haematopoetic cells and about 40% fat cells 
(Figure 13 and 14). ‘Fatty’ marrow, on the other hand, contains about 5% 
haematopoetic cells and about 95% adipocytes (Steiner RM et al. 1993, Hwang S et 
al. 2007). In other words, neither red marrow or fatty marrow are 100% 
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haematopoetic or fatty marrow with fatty marrow being more ‘pure’ then red marrow 
(Figure 13 and 14).  
 
 
Figure 13. Histology of 
predominantly red marrow. 
There is still quite an 




Figure 14. Histology of 
predominantly fatty marrow. 





Figure 15: Cellular composition of red marrow and fatty marrow. O = red marrow; O = 
yellow marrow. Red and yellow marrow are, of course, a continuum though what is termed 
‘yellow’  marrow is more pure than ‘red’ marrow which still contains quite a lot of fat. 
(Modified from Hwang S et al 2007). 
 
The broad chemical composition of red marrow is about 50% lipid, 35% water and 
15% protein (Steiner RM et al. 1993, Hwang S et al. 2007) (Figure 15). Adipocytes 
understandably contain more fat than haematopoetic cells while haematopoetic cells 
contain slightly more water and protein than adipocytes. The broad chemical 
composition of fatty marrow is therefore about 80% lipid, 15% water and 5% protein 
(Steiner RM et al. 1993, Hwang S et al. 2007) (Figure 15). This is important since 
MR spectroscopy uses the fat;water ratio to determine the fat fraction in tissues. The 
amount of water actually present is assumed to be constant though this may not 
necessary be the case.   
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Figure 16: Chemical composition of red marrow and fatty marrow. Haematopoetic marrow 
contains more water than fatty marrow. (Modified from Hwang S 2007).  
 
The viscosity of the bone marrow in the proximal aspects of the bones such as the 
proximal femur is several times greater (123-400cP) than the distal bones such as 
the distal radius or calcaneus (37.5 – 44cP) (Gurkan UA et al. 2008). These figures 
can be compared to the viscosity of water which is 1cP. 
 
1.7  BONE MARROW FAT 
Adult trabecular bone, the most metabolically active component of bone, is bathed in 
fat i.e. fat forms the main microenvironment of trabecular bone. The endosteal and, 
to a lesser degree, the cortical margins of bone cortex are also in contact with fat. 
Bone metabolism may well react to changes in its microenvironment and potentially 
may react to changes in fat composition. We undertook Study 6 in this thesis to 
explore this possibility. To comprehend Study 6, some background information on fat 
and bone marrow fat is necessary. All fats are composed of carbon, hydrogen and 
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Figure 17. Basic structure 
of carbon, oxygen and 
hydrogen with saturated 
and unsaturated molecule.  
 
 
Two carbon atoms next to each other can share either a single or double bond.  
Carbons atoms held together by a single bond are 'saturated' because they are 
saturated with hydrogen. Two carbons connected by a double bond are 'unsaturated' 
because each carbon atom can also potentially attach to one more hydrogen atom.  
Fatty tissue is made up of fat (~80%), water (~15%) and protein (~5%). The main 
constituent of fat is fatty acids. There are at least 80 identified fatty acids but only 
about 30 common fatty acids. Fatty acids are chains of carbon atoms with hydrogen 
atoms attached to each carbon and an acid (carboxyl, -OH) group at one end. The 
two important determining factors as to the type of fatty acid are the number of 
carbon atoms in the fatty acid chain and whether single or double bonds exist 
between the carbons. 
Fatty acids with less than four carbons are known as short-chain fatty acids, fatty 
acids with between 6-18 carbon atoms are known as medium-chain fatty acids while 
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fatty acids with 18–28 carbon atoms are known as long chain fatty acids. Fatty acids 
with no double bones in the chain are called saturated while those with one double 
bond are called monounsaturated fatty acids (MUFA) and those with two or more 
double bonds are called polyunsaturated fatty acids (PUFA) (Figure 18).  
 
 
Figure 18: Schematic 
representation of 
short chain saturated 




Saturated fatty acids and unsaturated fatty acids have different characteristics.  
Saturated fats, as expected, have limited opportunity for interaction with other atoms 
and tend to be stable and more inert. As bending occurs at double bonds, saturated 
fatty acids tend to be straighter unsaturated fatty acids (Figure 19). Straight chains fit 




Figure 19: Schematic 
representation showing how 
saturated fatty acids form 
straight chains, 
monounsaturated fatty acids 
are slightly curved while 
polyunsaturated fatty acids 
are very curved.  
 
 
Since bending occurs at double bonds, monounsaturated or polyunsaturated fatty 
acids do not to form straight chains and don’t fit snugly together (Figure 19 and 20). 
As a result, they tend to be liquid at room temperature like vegetable oil. Because of 
the double bond, they are also less stable. The more double bonds present, the 
more likely a fatty acid is going to be liquid at room temperature and the more 
unstable that fatty acid is likely to be (Figure 20). For these and other reasons, 
polyunsaturated fatty acids tend to be the most metabolically active fatty acids and 






linoleic acid (18:2, 
n=6) which has 2 
double bonds the 
first of which is 
located at carbon 6 












Most fats in the body and in food are in the form of triglyceride molecules. 
Triglyceride molecules comprise one glycerol molecule (or glycerin, a sugar alcohol) 
with three fatty acids attached (Figure 21).  
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Figure 22: Schematic 
representation ‘cis’ and 
‘trans’ fat orientation. 
Cis and trans fatty acids. Unsaturated fats with the same composition can have a 
different configuration according to which side of the double bond the hydrogen 
atoms align. This concept is important because the shape of the whole triglyceride 
molecule, and its properties and characteristics, is affected by what happens at each 
double bond. In a 'cis' formation, the hydrogen atoms align on the same side while in 
a 'trans' formation; the hydrogen atoms align on opposite sides of the double bond 
(Figure 22).   
 
Most naturally occurring unsaturated fatty acids contain cis bonds. Most fatty acids 
with a trans configuration (‘trans fats’) are the result of human processing. The 
double bonds in trans fatty acids are easily broken, allowing the formation of free 
radicals - highly reactive molecules with an unpaired electron (Figure 23). In the 
studies presented, we have not assessed the relationship between ‘cis’ and ‘trans’ 
marrow fats and osteoporosis.  
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Figure 23: Schematic 
representation showing how 
cis- or trans- orientation can 
dramatically alter the shape 
of a fatty acid although the 
chemical composition 
remains the same. 
 
 
Nomenclature of fatty acids. Fatty acids vary in chain length as well as the position 
and number of double bonds along the chain (Leonard AE et al. 2004).  The number 
of carbon atoms in the chain varies from 4 (butyric acid) to 80 (though most have 
been 8 and 28 carbons atoms). Fatty acid nomenclature allows one to appreciate 
fatty acid structure. To describe the structure of a fatty acid molecule, one must give 
the length of the carbon chain (number of carbon atoms), the number of double 
bonds and also the position of these double bonds (which will define the biological 
reactivity of the fatty acid molecule).  
The briefest description is to include only the number of carbon atoms and number 
of double bonds (e.g., C18:0). C18:0 (or 18:0 for short) indicates that the carbon 
chain of the fatty acid contains 18 carbon atoms with no double bonds. C18:1 would 
indicate an 18 carbon chain with one double bond while C18:3 indicates an 18 
carbon chain with three double bonds. More detailed description also indicates the 
location of the first double bond. For example, α-linolenic acid (18:3, n=6) indicates 
an 18 chain fatty acid with three double bonds, the first of which is located at carbon 
6 position from the methyl (-CH3) group. Linoleic acid (18:2, n=6) indicates an 18 
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chain fatty acid with two double bonds, the first of which is located at carbon 6 
position from the methyl (-CH3) group. 
One can appreciate how the same basic fatty acid can have many different 
expressions. For example, not all C:18 fatty acids are identical. It may have one or 
more double bonds in the fatty acid, making it mono- or polyunsaturated rather than 
saturated. Also each double bond can have a cis or trans confirmation significantly 
changing the physical properties and reactivity of the fatty acid (Figure 23).  
 
Essential fatty acids. All but two of the fatty acids can be produced endogenously.  
Two fatty acids can only be obtained from the diet. These are α-linolenic acid (18:3, 
n=3) and linoleic acid (18:2, n=6).  They are called ‘essential’ fatty acids as they are 
only obtainable from diet since humans do not possess the ability to synthesize a 
double bond prior to carbon 9 in the fatty acid chain (Poulsen RC, 2007). 
 
The first of the essential fatty acids is α-linolenic acid (18:3, n=3). This, as the name 
shows, has an 18-carbon backbone and three carbon-carbon bonds, the first of 
which is located at carbon-3 when counting from the methyl (-CH3) terminus. This is 
the parent compound for the n-3 (or omega 3, ω3). polyunsaturated fatty acid series. 
The other essential fatty acid is linoleic acid (18:2, n=6) (Figure 20). This has an 18-
carbon backbone and two carbon-carbon bonds, the first of which is located at 
carbon-6 when counting from the methyl terminus. This is the parent compound for 
the n-6 (or omega 6, ω6) polyunsaturated fatty acid series. Most of the long chain 
polyunsaturated fatty acids have their first double bond located at either carbon-3 (i.e. 
n-3) or carbon-6 (i.e. n-6) while a few long chain polyunsaturated fatty acids are n-9. 
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In general, n-3 polyunsaturated fatty acids are protective to health while n-6 
polyunsaturated fatty acids adversely affect health.  
n-3/n-6 ratio. The fatty acid profile in your body in many respects mirrors the fatty 
acid composition of your diet over the proceeding months to years. As noted, the two 
essential fatty acids (α-linolenic acid and linoleic acid), which form the parent 
compunds of the n-3 and n-6 fatty acid series, cannot be synthesized endogenously. 
The best dietary source of α-linolenic acid is fish oil as well as fresh green 
vegetables. Linoleic acid, on the other hand, is present in edible plant oils, such as 
corn oil and soybean oil, and in the seeds of most plants except coconut, cocoa and 
palm. Conola oil (derived from rapeseed) contains relatively more n-6 than n-3 fatty 
acids. Desaturation enzymes synthesize the other longer chain fatty acids from 
these two parent fatty acids, though these longer chain fatty acids can also be 
obtained from the diet. The n-3 and n-6 fatty acids chain complete with each other 
for the limited pool of desaturation enzymes. Hence the n-3/n-6 ratio is in a state of 
flux very much dependent on dietary intake. The typical western diet nowadays 
contains much less of the parent compound for n-3 fatty acids (α-linolenic acid) than 
the parent compound for n-6 fatty acids (linoleic acid). The n-3/n-6 ratio is 
considered to be of importance to health with, as mentioned, a high n-3/n-6 ratio 
being advantageous to health while a low n-3/n-6 ratio being  disadvantageous to 
health.  
 
Fatty acids and their metabolites are closely involved in a range of biological activity 
such as prostaglandin production, inflammatory mediator production, haemostasis, 
neurotransmitter production, regulation of vascular reactivity and tone as well as cell 
membrane production. Long chain polyunsaturated fatty acids, in particular, are the 
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most unstable and hence the most metabolized fatty acids. They are the precursors 
of a variety of biological products including prostaglandins, leukotrienes, 
thromboxanes, lipoxins, resolvins and protectins (Poulsen RC et al 2008). One can 
now appreciate how the concentration of fatty acids as well as the configuration of 
these fatty acids can potentially influence many biological activities. 
 
1.8. NON-INVASIVE ASSESSMENT OF BONE MARROW FAT  
Little information about bone marrow composition can be obtained from radiographs. 
Computed tomography (CT) provides much more detail in this respect though is still 
limited in assessment. Nowadays, the main imaging methods by which bone marrow 
is structurally and functionally assessed in vivo are magnetic resonance 
spectroscopy (MRS) and nuclear medicine studies including positron emission 
tomography (PET). In our experiments we used MR spectroscopy to quantify the 
amount of marrow fat. PET imaging was not used in these experiments but will 
nevertheless be briefly discussed since PET imaging can provide a measure of 
marrow metabolism.      
MR spectroscopy is the most widely used method to quantitatively assess marrow 
fat. MR spectroscopy (MRS) is fundamentally similar to magnetic resonance imaging 
(MRI).  Basically, conventional MR imaging measures signals emitted by nuclei 
within small pixels selected though phase and frequency encoding along magnetic 
field gradients. This high resolution spatial mapping enables the signal to be 
transferred into high detail structural images. The signal emitted from each pixel is a 
product of the water, fat and other chemicals, typically amino acids, contained within 
that pixel within a frequency scale between fat and water.  
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MRS uses the same basic principles as MRI but rather than generating an image, 
focuses on analyzing the frequencies of the signals emitted from the area of interest. 
In this way, MRS can extract information about the chemicals that reside within a 
particular frequency scale in both a qualitative and quantitative manner. Because 
you are analyzing particular frequencies, rather than a range of frequencies, the area 
examined with MRS is larger than individual pixels as analyzed by MRI. In other 
words, MRI provides very high structural information about a small area by studying 
a range of frequencies. MRS, on the other hand, analyses individual frequencies 
within an area much larger than that of an individual pixel.  
 
MR spectroscopy can be used to measure a large number of nuclei (such as 
hydrogen, phosphorus and carbon) through, in the bone marrow, we focus on 
hydrogen nuclei, since hydrogen is these are by far the most abundant nucleus and 
also emits the most intense radiofrequency signal within an external  magnetic field. 
MRS of hydrogen nuclei is known as proton MRS or 1H-MRS. The size of a typical 
pixel used from standard MRI imaging is 1-2mm2 while that of a voxel used in MR 
spectroscopy is 1.5ml.  
 
There are two methods of proton magnetic resonance spectroscopy: single voxel 
and multivoxel, with or without spectroscopic imaging. Single voxel proton magnetic 
resonance spectroscopy provides a rapid biochemical profile of a localized volume 
within a region of interest. Spectroscopic imaging provides biochemical information 
about multiple, small and contiguous volumes focalized on a particular region of 
interest that may allow the mapping of metabolic tissue distribution. By using this 
method, the data obtained may be superimposed on a standard MR image, thereby 
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allowing correlation of between the structural changes and the distribution of 
metabolites within that area. Multivoxel MRS is also known as chemical shift imaging 
(CSI). In the studies presented in this thesis, single voxel MRS was used.  
MR spectroscopy, rather than analyzing frequencies per se, in effect concentrates 
more on the differences in frequencies between nuclei.  Depending on their 
microenvironment, different nuclei will resonate at slightly different frequencies. MRS 
readout utilizes a “parts per million or "ppm” scale to describe the "position" of the 
resonance frequencies on the x-axis. The ppm is calculated by dividing the 
difference in frequency (in Hertz) of two peaks (with one peak being the reference) 
by the operating frequency of the MR scanner (in Hertz). This makes comparison of 
a peak location found on the spectrum of a 1.5T scanner comparable to that found at 
that location on a 7.0T MR scanner. In other words, the same metabolite will appear 
at the same location on the ppm scale irrespective of whether the MR unit used was 
1.0 T, 1.5T, 3T or 7T strength. The signal intensity (amplitude on the y-axis) and line 
width provide an area under the peak which can be used to quantify the amount of 
observed chemical.  
 
The two sequences commonly used in clinical proton magnetic resonance 
spectroscopy to localize the volume or interest are PRESS (point-resolved 
spectroscopy) and STEAM (stimulated echo acquisition mode). Both sequences 
stimulate protons within the volume of interest with minimal signal contamination 
from outside the region of interest. The STEAM technique generates a cubic or 
rectangular voxel by using three orthogonal slice selective 90-degree pulses and is 
useful when a short T1 is required. The PRESS technique also generates a cubic or 
rectangular voxel using three orthogonal slice selective pulses, although these differ 
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in that a 90-degree pulse is followed by two 180-degree pulses. Although the voxel 
generated by PRESS is not as precisely defined as that of STEAM, the signal to 
noise ratio of PRESS is twice that of STEAM. In the bone marrow, PRESS is 
therefore preferable to STREAM since precise definition of the volume of interest is 
not an overriding issue. For MRS performed in other areas such as the brain, the 
water signal is suppressed allowing other metabolites to be measured and longer 
echo times (> 135 milliseconds) used. This leads to smaller numbers of metabolites 
being detected and with better definition of peaks. This high definition of peaks is not 
necessary in the bone marrow since the two main components present are water 
and fat. 
Other non-spectroscopic yet precise methods of quantifying fat fraction have recently 
been introduced such as the three-point IDEAL (Iterative Decomposition of water 
and fat with Echo Asymmetry and Least-squares estimation) or the 2-point Dixon 
method which involves sequential suppression or fat and water. There is good 
correlation between all methods with regard quantification of fat in sample.   
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Figure 24. Bernard et al used MRS to quantify the amount of fat in eleven different samples 
(only three of which are represented for illustration) with varying amounts of fat ranging from 
pure water to pure fat. The fact that oil and water do not mix does not influence the result as 
MR fat quantification methods determine the amount of fat and water in the sample as a whole.  
The accuracy of MRI spectroscopic and non-spectroscopic methods in detecting the 
relative amount of water and fat in a sample has been tested against 11 different 
emulsions of increasing fat content. These test bottles contained increasing amounts 
of fat from zero (pure water) to pure fat (soya oil) (Figure 24). This study confirmed a 
high correlation (r 2>0.92) between MR methods of fat quantification and the % fat 
volume fraction within test bottles (Bernard C et al. 2008).  
MR methods of quantifying fat in tissue use the water;fat ratio. This produces 
accurate results in vitro as shown above when tested against tissue samples 
(Bernard C et al. 2008). The limitation, however, is that the amount of water present 
is assumed to be constant. This in reality may not be the case. MR methods of 
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quantifying fat have not been quantified in vivo and we have specifically assessed 
this in our studies to date.  
In our studies, we used MR spectroscopy rather than non-spectroscopic methods to 
quantify marrow fat fraction largely because proton MR spectroscopy is more widely 
available and online post-processing tools exist which enable ready quantification of 
fat fraction. 
 
In our experiments, we undertook MR spectroscopy first of the vertebral body (Study 
1 and 2) and later of the proximal femur (Study 4).  For the vertebral body, the width 
(w), depth (d) and height (h) of the L3 vertebral body were measured on MR images 
to define a volume of interest (VOI). A VOI with dimensions w/2  d/2  h/2 cm3 was 
located centrally in the vertebral body. After local shimming and gradient 
adjustments, data was acquired at a spectral bandwidth of 1,000 Hz with 512 data 
points and 64 non-water suppressed signals were obtained using a point resolved 
spectroscopic sequence (TR/TE, 3000/25 msec). For the proximal femur, three 
separate standardized volumes of interest (VOI) were placed in the femoral head 
(1·5 × 1·5 × 1·5 cm3), femoral neck (1·0 × 1·5 × 1·5 cm3), and sub-trochanteric 
region of the femoral shaft (1·0 × 1·0 × 3·0 cm3). After local shimming and gradient 
adjustments, data was acquired at a spectral bandwidth of 1,000 Hz with 512 data 
points and 64 non-water suppressed signals obtained using a point resolved 
spectroscopic sequence (TR/TE, 3000/25 msec).  
 
One of the main advantages that nuclear medicine and PET imaging has is to 
assess bone marrow metabolism using 18F-fluorodeoxyglucose positron emission 
tomography (FDG-PET) imaging. Basu et al has combined segmented volumetric 
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data from magnetic resonance imaging and quantitative metabolic information from 
positron emission tomography (PET) and shown how a combined structure function 
approach can be achieved by combining structural information from MRI with 
function PET information (Basu S et al. 2007). Vertebral body volume at L1, L3, and 
L5 was calculated. The red and fat marrow areas were then segmented within these 
vertebrae using specialized software and respective red and yellow volume 
calculated in addition to bone volume. Mean of maximum standardized uptake 
values (mean SUVmax) for bone marrow were calculated in L1, L3 and L5 and then 
my relating this to the amount of marrow overall as well as the red and fatty marrow 
components, the activity of red and fatty marrow could be calculated. The mean 
volume of the lumbar vertebral body was 15.6±1.4 cm3 of which about 50% was red 
marrow and 50% fatty marrow.  The mean SUV max of bone marrow, fatty marrow 
and haematopoetic marrow was 1.5 ± 0.3, 0.38 ± 0.1 and 2.6 ± 0.6 respectively. 
Metabolic volumetric product (MVP) of bone marrow was also calculated by 
multiplying bone marrow volume by bone marrow SUV. The MVP for lumbar 
vertebrae, fatty marrow and haematopoetic marrow was 23.4 ± 5.9, 2.9 ± 0.9 and 
20.5± 5.9 respectively. 
 
1.9. BONE BLOOD FLOW AND PERFUSION  
Although the terms blood flow and perfusion are often used interchangeably, they 
refer to different physiological processes (Figure 25). Blood flow is flow within 
vessels i.e. intravascular flow. Perfusion, on the other hand, is a measure of blood 
flow together with capillary permeability and interstitial diffusion. Perfusion therefore 
is also dependent on a host of other variables such as capillary surface area, 
capillary exchange, interstitial space, interstitial pressure, interstitial diffusion, and 
 57 
venous flow.  
 
Figure 25. Schematic 
representation of blood 
flow and perfusion. 
Perfusion is a more 
encompassing term 
than blood flow. 
 
Since the marrow is encased in bone, arteries and veins must transverse compact 
bone to enter and exit the marrow compartment. The number of vessels supplying 
bone varying considerably. The arteries supplying the marrow originate from two 
systems which anastomose within the marrow. The smaller periosteal arteries supply 
the cortex and penetrate towards the marrow. The larger nutrient arteries pass 
through the cortical bone entering the marrow cavity (Travlos GS, 2006) (Figure 26). 
After entry in the marrow cavity, the artery splits into ascending and descending 
branches which run parallel along the central part of the marrow cavity (Travlos GS, 
2006). The artery branches to give rise to a multitude of small thin-walled arterioles 
that extend outwardly towards the cortex. The arterioles open up and anastomose 
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with a plexus of venous sinuses which are more akin to small lakes rather than 
channels. The venous sinuses are thin-walled and composed of flat endothelial cells 
with a discontinuous basement membrane (Travlos GS, 2006, Lichtman MA, 1981). 
This endothelial lining is highly permeable to many solutes but restricts the 
endothelial movement of cells. The venous sinuses drain via collecting venules back 
to the nutrient or emissary veins (Figure 26). Thus there is a circular flow pattern to 
blood flow within the marrow cavity i.e. in towards the centre, out to the periphery 
and then back to the centre again. This structural arrangement leads to a higher 
number of vessels and sinuses in the periphery and also slower flow at the periphery 
of the marrow cavity.  
 
Cortical bone receives the majority (approximately two-thirds) of its blood supply 
from the medulla and the remainder from the periosteal arteries (Knothe Tate ML 
1998). The flat bones possess more numerous nutrient channels through which pass 
both small and large nutrient vessels (Travlos GS, 2006).  
 
The bone marrow does not have a lymphatic drainage. The bone marrow is 
innervated with myelinated and non-myelinated cells entering through the nutrient 
foramina and following the course of the arteries and arterioles. Nerves bundles 
supply the arteriole smooth muscle with some branches terminating in haemopoetic 
cells (Travlos GS, 2006). 
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Figure 26: Schematic representation of bone blood 
supply. Two anastomosing systems are present – 
the periosteal and nutrient arterial systems. Nutrient 
arteries branch into arterioles which drain to a 
network of capillary sinusoids (not shown). 
Sinusoids are akin to venous lakes. Sinusoids drain 
to venules which coalesce to form emissary veins 
exiting via the same nutrient foramina.  
The medullary canal is wholly supplied by the 
nutrient arteries. Approximately, the inner two-thirds 
of the cortex is supplied by nutrient arteries while 
the outer one-third is supplied by the periosteal 
arteries (modified from Diagnogis of Bone and Joint 
Disorders, 4th Edition, Ed Resnick D. WB Sauders 
Volume 3, page 2381).  
 
 
The intramedullary pressure is normally about one-fourth systolic pressure. (Shaw 
NE 1963).  For example if the systolic blood pressue in 120mmHg, one would expect 
to find the marrow pressure to be 30mmHg. Notwithstanding this, there does also 
seems to be some regulatory mechanism, probably maintained by the innervated 
marrow cavity arteries, that maintains a fairly constant marrow pressure within the 
physiological blood pressure range. Marrow pressure will only drop significantly after 
systolic pressure falls below 80mmHg (Gurkan UA et al, 2008).  
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Vertebral body blood supply:  
In Study 1 marrow perfusion of the L3 vertebral body was measured using MR 
perfusion imaging while in Study 2 marrow perfusion of the L3 vertebral body and 
paraspinal musculature was measured using MR perfusion imaging.  The vertebral 
bodies and the erector spinae muscles are both supplied by the paired segmental 
lumbar arteries. Each lumbar artery courses around the waist of the vertebral body 
and passes backwards as a single trunk to cross its respective intervertebral 
foramen. Each lumbar artery gives off two sets of branches to the vertebral body. 
The first of these are the short centrum branches which penetrate vascular foramina 
at regular intervals. The second are the long ascending and descending branches 
which form dense networks around the vertebral bodies and giving rise to the 
metaphyseal branches close to the endplates (Figure 27). At the level of the exit 
foramen, the lumbar artery divides sending branches to the spinal canal, the 
paraspinal muscles, the posterior spinal elements and the vertebral body (Figure 27) 
(Crock HV et al. 1976, Ratcliffe JF 1980, Williams A et al. 2005, Kato H et al. 1999).  
The erector spinae muscle complex lies in the space between the transverse and 
spinous processes of the vertebrae. In the upper lumbar region it is composed to 
three columns which are, from medial to lateral, spinalis, longissimus and iliocostalis 
(Williams A et al. 2005) (Figure 27) 
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Figure 27A. Schematic 
representation of vertebral arterial 
supply. The short centrum 
branches and the longer ascending 
and descending branches arising 
from the lumbar arteries are 
shown. E = Epiphyseal or lumbar 
artery; M = metaphyseal artery. 
 
 
Figure 27B: Schematic 
representation of vertebral arterial 
supply. Each lumbar artery divides 
to send a nutrient artery to the 
posterior aspect of the vertebral 
body and additional arteries to 
supply the paravertebral muscles. 
L = lumbar artery. QL = quadratus 
lumborum, S = spinalis, L= 
longissimus, IL = iliocostalis.  
 
 
Proximal femur blood supply: In Study 4, the blood supply of the proximal femur, 
acetabulum and adductor musculature was measuring using MR perfusion imaging. 
Both the proximal femur and the adductor thigh musculature are both supplied by the 
profunda femoris artery. The proximal femur is supplied primarily via the medial 
femoral circumflex artery, the first branch of the profunda femoris artery (Gautier E et 
al. 2000) (Figure 28) while the adductor thigh musculature is supplied by perforating 
muscular branches which arise from the profunda femoris artery just distal to the 
medial femoral circumflex artery (Angrigiani C et al. 2001). The lateral circumflex 
femoral artery also arises from the profunda femoris artery just distal to the medial 
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circumflex femoral artery. The two circumflex arteries form an extracapsular arterial 
ring at the base of the femoral neck (Figure 28). From here, ascending cervical 
branches penetrate the capsule of the hip joint to form the retinacular arteries just 
deep to the synovial membrane covering the neck of femur. As the retinacular 
arteries ascend along the femoral neck, they give off metaphyseal branches that 
penetrate the femoral neck. They also provide the lateral epiphyseal arteries which 
continues roughly along the line of the fused epiphyseal plate to the fovea and many 
smaller lateral epiphyseal braches which supply the femoral head around the margin 
of the articular cartilage. Some medial epiphyseal branches arise from the artery of 
the ligamentum teres (a continuation (or branch) of either the obturator artery or less 
commonly the medial femoral circumflex artery) supplying a small portion of the 
head than the lateral epiphyseal arteries (Weathersby HT 1959) (Figure 28). The 
acetabulum is supplied the internal iliac artery via the superior gluteal, inferior gluteal 
and obturator arteries (Beck M et al. 2003). 
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Figure 28: Schematic diagram of 
proximal femoral perfusion. The 
proximal femur is primarily supplied 
by the medial and lateral circumflex 
femoral arteries – the first and 
second branches of the profunda 
femoris artery. 
 
1. Medial circumflex femoris a.  
2. Profunda femoris a.  
3. Lateral circumflex femoris a.   
4. Ascending nutrient a. branch. 
5. Muscular br. profunda fem. a. 
6. Artery of ligamentum teres    
 




1.10 NON-INVASIVE ASSESSMENT OF BONE BLOOD FLOW AND 
PERFUSION 
Only recently did non-invasive methods of measuring bone blood flow become 
available, namely MR perfusion imaging and nuclear medicine studies including PET 
imaging. Two reasons mainly contributed to bone marrow blood flow being difficult to 
measure. First, the present of a bone cortex ensures that the implantation of any 
intraosseous instrument will by its very nature alter intramedullary status, flow and 
pressure. Second, each bone is served by a multitude of arterial and venous 
channels Early researchers tried venous sampling (Cumming JD et al. 1960), 
thermocouple devices (Shaw NE et al. 1963), plethysmography (Edholm DG et al. 
1945) and intravenous dye. In the 1950’s and 1960’s, the availability of 
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radiopharmaceuticals lead to radioactive tracers (86Stronium, 45Calcium, 43Potassium, 
86Rubium, 18Fluoride, 24Sodium, 86Sulphur) being used to assess blood flow by a 
large number of researchers (Edholm DG et al. 1953 , Frederickson JM et al. 1955, 
Cumming JD et al. 1960, Holling HE et al. 1961, Weinmann DT et al. 1963, Copp DH 
et al. 1965, Van Dyke et al. 1965, Shim SS et al. 1967). Other researches have used 
xenon (Lahtinen T et al. 1981) while more lately PET imaging with various tracers 
such as radioactive oxygen (150) labelled to carbon dioxide (Martiat P et al. 1987) or 
water (Piert M et al. 1998) and radioactive 18F labeled to fluoride (Piert M et al. 1998, 
Blake GM et al. 2001) have been used to assess bone blood flow or perfusion.  
Microspheres are the gold substance used to assess blood flow in animal models 
(Gross PM et al. 1979, Chen LT et al. 1986, Schoutens A et al. 1990, Iversen O et al. 
1992). From the injection site in the left ventricle microspheres are distributed 
homogenously in arterial blood and are dispersed to the peripheral vascular systems 
where, due to their large size, they become lodged in either arterioles or capillaries. 
Because of their homogenous distribution, the number of spheres lodged in an organ 
is directly proportional to the blood flow of the organ. Blood flow is calculated as 
number of spheres in an organ compared to an arterial reference sample. The 
number of spheres is calculated either by their radioactivity, colour or fluorescence 
(Anetzberger H et al 2004). Microspheres are only used in preclinical studies and 
cannot be used in humans since they occlude vascular beds. Also as microspheres 
do not diffuse into the interstitial space they provide a measure of tissue blood flow 
rather than perfusion.   
 
Whatever the method used, it is clear that bone blood flow or perfusion 
measurement is very much dependent on the physical and pharmokinetic 
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characteristics of the tracer being used. When deciding on a use of a tracer to 
measure blood flow or tissue perfusion, one should take into account the tracer 
distribution to the tissue (which should be proportional to arterial input), capillary 
permeability, lack of any binding capacity, absence of metabolism and washout 
(which should be proportional to the venous return. The ideal tracer should also not 
enhance or diminish blood flow or perfusion of the tissue under investigation.    
 
Bone perfusion assessed by MR imaging 
MRI is the most widely used method of assessing tissue perfusion. Dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI) (or MR perfusion 
imaging)  involves the rapid acquisition of serial MRI images before, during, and after 
the administration of an MR contrast agent. The contrast agent used in these studies 
was Gd-DOTA (DOTAREM).  
Gadolinium is an ionic macrocyclic thermodynamically stable molecule (Port M et al. 
2008) (Figure 29). These properties make it safer than open chain non-ionic 
gadolinium contrast agents with respect to the development of nephrogenic 
sclerosing fibrosing (NSF). NSF always develops in patients with chronic or acute 
renal disease (Knopp EA et al. 2008). Of those with chronic kidney disease, an 
estimated glomerular filtration rate (eGFR) of 30 ml/min/1.73 m2 or less seems to be 
a prerequisite for developing NSF (Knopp EA et al. 2008). The plasma elimination 
half life of gadolinium compounds is about 1.5 hours but is dramatically increased 
(up to and beyond thirty hours) in subjects with severe renal failure. Persistence of a 
high concentration of Gd3+ chelate in the body increases the likelihood of 
dissociation of Gd3+  from its chelate though this is more common in non-ionic open 
chain molecules rather than in the in cyclic arrangement of DOTAREM where the 
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Gd3+ is more shielded from its chemical microenvironment (Figure 26). Subjects 
undergoing perfusion MR imaging are at likely to be at greater risk of NSF since a 
double or treble dose of contrast medium is often employed to improve signal:noise 
ratio when assessing areas with relatively poor perfusion. In the clinical studies 
presented in this thesis, which were performed only on healthy subjects, we ensured 
that there was no history of renal disease and only performed perfusion MR imaging 
provided renal function was normal serologically within twelve months of the MR 
examination.  
 
Figure 29:  Macrocyclic 
molecular structure of 
Gd-DOTA (DOTAREM). 
Note how the Gd3+ ion is 
effectively isolated within 
the chelate complex so 
that it cannot react 
normally with other 
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DOTAREM is a small hydrophilic complex with a pharmacokinetic profile quite similar 
to water-soluble iodinated contrast agent i.e. it conforms to a two compartmental 
model (intravascular space and interstitial space) without metabolism and is 
excreted by passive renal glomerular filtration (Figure 30). It does not pass through 
the cell membrane and therefore is not subject to enzymatic activity and does not 
bind to proteins in the intervascular or interstitial spaces.  
Quantification of contrast agent concentration in tissues necessitates the acquisition 
of a T1-value of the target tissues before DCE MRI, i.e. the native T1 value of each 
pixel within the imaged area, or T1 value within a region of interest (ROI) if the signal 
to noise ratio does not allow pixel-by-pixel analysis. Gadolinium chelate contrast 
agents (such as DOTAREM) rapidly diffuse into the extravascular interstitial space 
(also called the ‘leakage space’), at a rate determined by blood flow, capillary 
permeability, capillary surface area and interstitial pressure, interstitial space and 
interstitial flow. Gadolinium exerts a paramagnetic effect on nearby water protons, 
causing them to relax more rapidly on T1-weighted imaging.
 As a result, T1 signal 
intensity increases proportionate to the concentration of gadolinium chelate. 
Pharmacokinetic modeling ideally requires a nearly linear relationship between 
gadolinium chelate concentration and signal intensity. Exact linearity is never 
achieved and can only be approximated with low doses of gadolinium chelate 
(Donahue MJ et al. 2006). Linearity, while desirable, is not an absolute necessity as 
many physiological phenomena can be observed with slightly non-linear gadolinium 
concentration-signal intensity pharmokinetics.  
Unlike conventional enhanced MRI, which simply provides a snapshot of 
enhancement at a single time point, DCE-MRI permits a depiction of the wash-in and 
wash-out contrast kinetics within the tissue under investigation. DCE-MRI or 
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perfusion imaging is a very robust imaging technique which can be applied to almost 
any tissue. Empirical measures such as maximal signal intensity enhancement and 
enhancement slope can be readily obtained. This data is also amenable to two-
compartment pharmacokinetic modeling from which parameters based on the rates 
of exchange between both compartments can be generated.  DCE MRI has been 
used to evaluate the pathophysiological status of many diseases where circulatory 
disturbances occur such as tumours, inflammation, and osteonecrosis (Galbraith SM 
et al. 2002). 
For DCE MRI studies, many variables should be standardized such as the dose of 
contrast agent, method of contrast administration, speed and duration of image 
acquisition, spatial resolution and coverage, and data analysis. Spatial sampling 
(single or multiple slices, in-plane spatial resolution, and slice thickness) and 
temporal sampling (the rate at which the time-varying signal intensity curve is 
sampled) are interrelated variables that are limited by the signal-to-noise ratio and 
the inherent contrast of the target tissue. The purpose of DCE MRI is not to provide 
ultimate spatial resolution. Greater spatial resolution requires longer sampling times 
and therefore slower temporal sampling rates. Faster temporal sampling, as in the 
case of blood volume mapping, is usually restricted to one or two slices. Faster 
imaging rates and smaller voxel sizes decrease SNR and counterbalance the 
sensitivity and reliability of dynamic contrast enhanced MRI.   
It is in these respects that DCE MRI differs significantly from conventional post-
contrast MRI examinations in that particular care must be exercised to ensure 
uniformity of positioning and examination technique, contrast agent injection rate, 
dosage and timing of image acquisition. The protocol should be precise and detailed, 
and the examination and analysis carried out by experienced, personnel familiar with 
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the examination protocol. Failure to obtain uniformity in DCE MRI examination and 
analysis will confound the results of cross-sectional and longitudinal studies. 
In the studies presented in this thesis, we evaluated bone marrow perfusion rather 
than bone perfusion per se. Bone marrow perfusion is likely to be akin to the 
perfusion of bone trabeculae as the bone trabeculae are so thin, do not have their 
own inherent blood supply and are nourished via the surrounding marrow. The blood 
supply of cortical bone is different to that of bone marrow and in the bones examined 
(vertebrae and proximal femur) is different to measures as in these bones the cortex 
is relatively thin with a greater reliance on the trabecular network for bone strength at 
thee locations. It may be possible to measure bone blood supply of the thick anterior 
cortex of the tibia.     
Perfusion indices used in dynamic-contrast enhanced MRI. Empirical (semi-
quantitative) measures describe tissue enhancement using a number of parameters 
derived from a time-signal intensity enhancement curve following contrast agent 
injection (Figure 31). Parameters that can be used are (1) onset time (time from 
contrast agent injection to the first increase in tissue signal enhancement), (2) mean 
gradient of the enhancement curve upsweep (Eslope), (3) maximum signal intensity 
(Emax), (4) washout gradient as well as (5) the initial area under the time-intensity 
curve (AUC). Of these five parameters, the two most robust and commonly applied 
parameters are enhancement slope (known as ES or Eslope) and enhancement max 
(known as ME or Emax). (Figure 31) 
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Figure 31: Time-intensity curve. Baseline represents time between injection and 
contrast arriving in tissues. Slope represents contrast in arterioles and capillaries of 
tissues and diffusing into interstitial space. Plateau represents contrast equilibrium in 
tissues. This occurs within the first 60 sec after injection (X-axis). Washout-phase 
occurs over the ensuing five minutes.  
Enhancement slope is defined as the rate of enhancement between 10% and 90% of 
maximum signal intensity post enhancement (Imax) and baseline prior to 
enhancement (Ibase) (Figure 29). Maximal enhancement (E
max) and enhancement 
slope (Eslope) are calculated according to Equation 1,2 . 
Emax = [(Imax – Ibase)/ Ibase] x 100    Equation 1 
Eslope = {[(Imax – Ibase) x 0.8]/[Ibase x (t90%-t10%)]} x 100  Equation 2 
Where t10% and t90% represent the time interval for the signal intensity following 
enhancement to reach 10% and 90% of the maximum signal intensity difference 





Figure 32: Time-intensity 
curve with Emax and Eslope. 
Emax represents maximum 
enhancement while Eslope 
represents the slope of the 
rapidly up-rising part of the 
curve. 
 
Eslope and Emax are derived from the first-pass phase of signal intensity enhancement 
and are considered to represent arrival of contrast material into the arteries and 
capillaries and its diffusion into the extracellular space (Figure 32). Eslope and Emax 
are advantageous parameters in being relatively straightforward to analyse, but do 
have limitations. Maximum enhancement and enhancement slope time-signal 
intensity curve indexes are dependent on many factors, including amount and speed 
of administration of contrast material, blood volume, tissue permeability, and 
available leakage space with elevated interstitial fluid pressure being a likely 
physiological barrier to contrast agent exchange. In other words, Eslope and Emax 
represent indices of perfusion, they are not in themselves a direct measure of 
perfusion. Nevertheless, they have been shown to be strongly predictive of tissue 
vascularity, microvessel density and tissue necrosis (Choyke PL et al. 2003, Knopp 
MV et al. 2001). 
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More detailed pharmokinetic modeling methods for MR perfusion imaging. 
Eslope and Emax represent the simplest methods of analyzing perfusion data using 
time-intensity curves. Largely the same perfusion data acquired from dynamic 
contrast-enhanced MR imaging is also amenable to two-compartment 
pharmacokinetic modeling which can provide a measure of the rates of exchange 
between both compartments. Two such models have been used in perfusion studies 
of brain and breast tissue, namely the Tufts model and the Brix model. Data 
acquisition is very similar to that acquired in our studies although acquisition should 
go on for several minutes instead of the 90-120 sec used in our studies.  
The Tufts model (Figure 33) analyses the concentration of contrast in the tissues 
using a combination of arterial input function (AIF), and rate constants Ktrans, Kex and 
Kel. Arterial input function is a measure of the amount of contrast in the feeding 
artery. Ideally, at the time of image acquisition all the contrast should still be a bolus. 
However, in reality, as it takes time to inject contrast which then mixes with blood, 
the true input function is more like a bell curve. The arterial input function can be 
assessed by knowing the caliber of the main supplying artery and its first pass 
intensity profile. Ktrans refers to the transport constant and is influenced primarily by 
blood flow. Kex refers to capillary exchange and is influenced by capillary space, 
permeability, interstitial pressure and extracellular space. Kel refers to elimination or 
wash-out and is influenced by venous flow and venous return to the heart.   
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Figure 33: Schematic 
representation of Tofts 
model 
 
The Brix model (Figure 34) is in many respects a simpler model than the Tofts model. 
It does not rely on arterial input function (AIF) or Ktrans but still considers Kex and Kel. 
It instead assumes a linear relationship between MR signal enhancement and tissue 
contrast concentration. In other words, it assumes that tissue contrast concentration 
is a direct measure of perfusion.   
 
Figure 34: Schematic 
representation of Brix model 
 
 
There are other methods of measuring tissue perfusion using MR imaging that not 
been used in this study. These are T2*-weighed imaging (also known as blood 
oxygenation level dependent or BOLD imaging) and arterial spin labeling. These 
methods have been used to assess musculoskeletal sarcoma, synovitis and muscle 
perfusion (Lang P et al. 1995, Reddick WE et al. 1999, Reece RJ et al. 2002) though 
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have not been used to evaluate bone marrow perfusion.  
 
Bone perfusion assessed by PET imaging 
PET CT assessment of perfusion is usually undertaken using 
18
F-fluoride which has 
a half-life of 112 minutes. As this tracer is metabolized by bone, PET imaging using 
18
F-fluoride is a combined measure of both bone perfusion and bone metabolism as 
compared to MR perfusion imaging which measures bone perfusion in isolation. 
Pure bone perfusion can be evaluated by PET using the freely diffusible tracer 
15
OH20. However, these studies are not readily available since 
15
OH20 has a half life 
of only 122 seconds and thus requires an on-site cyclotron. Nevertheless, a highly 
significant correlation between blood perfusion measured using 
18
F-fluoride and true 
bone perfusion using 
15
OH20 has been reported [Piert M et al. 2002].  
A standard PET technique using 
18
F-fluoride to assess bone perfusion comprises a 




Ga rods for attenuation correction purposes. 
After injection with 
18
F-fluoride, a 60-minute emission scan is obtained during which 
up to 300 images acquisitions are obtained. At the same time, venous (or arterial) 
blood samples are taken at regular intervals to measure plasma 
18
F-fluoride 
concentration for assessment of arterial input function.  
Skeletal 
18
F-fluoride kinetic parameters are estimated using a three compartmental 
tracer kinetic model, comprising a vascular compartment, an extravascular bone 
compartment and a bone mineral compartment [Hawkins RA et al. 1992] (Figure 35). 
Rate constant K1 describes clearance of fluoride from plasma to bone, K2 describes 
the reverse transport of fluoride from bone extravascular compartment to plasma, 
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and K3 and K4 represent the incorporation and release from the bone mineral 
compartment. A fifth constant Ki can be added to represent fluoride metabolism by 
bone.  
 
Figure 35: Schematic representation of three compartmental PET imaging bone kinetic 
model described by Hawkins et al. showing rate constants K1-K4. Fifth constant Ki is 
not shown.   
One can appreciate that PET perfusion imaging takes a lot longer than MR imaging 
to perform and is more labor intensive. PET also has a notably poorer spatial 
resolution then MRI (>5mms for PET compared to <1mm for MRI) limiting separate 
analysis of smaller areas such as trabecular bone and cortical bone. Also muscle 
cannot be evaluated in the absence of additional CT imaging. Overall, in the 
assessment of skeletal tissue perfusion, PET imaging seems to have many more 
disadvantages rather than advantages compared to MR imaging  
 
Following sections. In the following sections, eight studies we have undertaken to 
determine the relationship between marrow and muscle perfusion, bone marrow fat 
and osteoporosis will be described.     
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STUDY 1:   
What is the relationship between bone perfusion, marrow fat 
and bone mineral density?  
 
Aim: To study whether marrow perfusion is altered in subjects with reduced bone 
mineral density and to see how this relates to marrow fat content  
 
Rationale for doing this study: 
Over the last two decades, increasing indirect evidence has suggested a link 
between osteoporosis and vascular disease. Epidemiological and clinical studies 
have shown how aortic calcification is an independent predictor of hip osteoporosis 
(Bagger YZ et al. 2006); how atherosclerosis is more common in women with 
osteoporosis than those with osteopenia or normal BMD (Ness J et al. 2006) and 
how low BMD independently predicts coronary artery disease in women undergoing 
coronary angiography better than traditional risk factors such as age, hypertension, 
diabetes, smoking, family history, or dyslipidemia (Marcovitz PA et al. 2005). Other 
clinical studies have shown that increased serum-angiotensin converting enzyme 
activity and impaired endothelial function are features of osteoporosis (Sanada M et 
al. 2004, Samuels A et al. 2001). Histological studies have shown how progressive 
occlusion of intraosseous arteries, arterioles or arterial capillaries occurs in patients 
with increasing age (Bridgeman G et al. 1996) and in patients with proximal femoral 
osteoporosis (Laroche M et al. 1995).  
Recent MR-based studies have shown that changes in bone marrow fat content and 
bone marrow perfusion occur with aging. Dynamic contrast-enhanced MR imaging 
studies have shown that vertebral marrow perfusion is reduced in older subjects 
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(Chen WT et al. 2001, Montazel JL et al. 2003, Baur A et al. 1997). Proton (1H) MR 
spectroscopic studies have shown an age-dependent linear increase in vertebral 
marrow fat content (Schellinger D et al. 2001, Kugel H et al. 2001). These studies 
examined the relationship between aging, perfusion and fat content though did not 
specifically examine whether this relationship was related to bone mineral density 
(BMD). Thus the aim of our first study was to use 1H MR spectroscopy and dynamic 
contrast-enhanced MR imaging to measure vertebral body marrow fat content and 
bone marrow perfusion of older male subjects with varying BMD as documented by 
dual energy x-ray absorptiometry (DXA). Male, rather than femles patients were 
investigated as they were attending the hospital as part of a an on-going study  
(MrOS study) investigating the prevalence of osteoporosis and osteoporotic fracture 





















What is the relationship between bone perfusion, marrow fat and 
bone mineral density? 
 
90 elderly male subjects 
 
 Lateral radiograph thoracic and lumbar spines 
 DEXA lumbar spine and right hip 
 MR perfusion imaging lumbar spine - mid-sagittal plane 




 Osteoporotic bone has significantly  perfusion compared to 
osteopenic bone  which in turn has significantly  perfusion 
compared to bone of normal BMD 
 
 Osteoporotic bone contains significantly  fat compared to 
osteopenic or normal density bone. 
 
ABSTRACT  
Purpose: To prospectively use (proton) 1H magnetic resonance (MR) spectroscopy 
and dynamic contrast-enhanced (DCE) MR imaging to measure the vertebral body 
marrow fat content and bone marrow perfusion of older male subjects with varying 
bone mineral density as documented by dual energy x-ray absorptiometry (DXA). 
Materials and Methods: Our Institutional Review Board approved the study and all 
participants provided signed informed consent. Radiography, DXA, 1H MR 
spectroscopy and DCE MR imaging of the lumbar spine were performed on 90 male 
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subjects (mean age 73 years, range 67-101 years). Vertebral marrow fat content and 
perfusion (maximum enhancement and enhancement slope) were compared for 
subject groups of differing bone density (normal, osteopenia, and osteoporosis). t-
test comparison between groups and Pearson test for correlation between marrow 
fat content and perfusion indices were applied. 
Results: Eight subjects were excluded yielding a final cohort of 82 subjects (mean 
age, 73 years; range, 67-101 years) comprising 42 normal bone density subjects 
(mean T score, 0.8  1.1(SD)), 23 osteopenic subjects (-1.6  0.4) and 17 
osteoporotic subjects (-3.2  0.5). Vertebral marrow fat content was significantly 
increased in osteoporotic subjects (mean, 58.23  7.83%) (P = 0.002) and 
osteopenic subjects (55.68  10.2%) (P = 0.034) compared to those with normal 
bone density (50.45  8.73%). Perfusion indices were significantly decreased in 
osteoporotic subjects (enhancement slope, 0.78  0.33 %/sec) compared to 
osteopenic subjects (1.15  0.59 %/sec) (P = 0.007) or those with normal bone 
density (1.48  0.73 %/sec) (P < 0.0001).  
Conclusion: Osteoporotic subjects have decreased vertebral marrow perfusion and 
increased marrow fat compared to osteopenic subjects. Similarly, osteopenic 
subjects have decreased vertebral marrow perfusion and increased marrow fat 
compared to subjects with normal bone density. 
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STUDY DETAILS: 
MATERIALS AND METHODS 
Subject Selection. Between January and June 2004, 90 male subjects above the 
age of 65 years (mean age 73 years, range 67-101 years) were recruited into this 
prospective study. These male patients were part of an on-going larger non-
interventional study in male subjects (MrOS study) investigating the prevalence of 
osteoporosis and osteoporotic fracture in elderly males in Hong Kong. The 
Institutional Clinical Research Ethics Committee approved the study (Appendix) and 
all participants provided signed informed consent. Following clinical assessment, all 
subjects underwent lateral radiographic examination of the thoracic and lumbar 
spines, dual X-ray absorptiometry (DXA) examination of the lumbar spine, 1H MR 
spectroscopy and DCE MR imaging of the lumbar spine. Subjects were either not 
recruited or excluded from further analysis if  (a) there was clinical or imaging 
evidence of metabolic bone disease or metastases; (b) a history of lumbar spinal 
surgery or irradiation; (c) MR imaging evidence of large intravertebral disc herniation, 
haemangioma or fatty rest; (d) a contraindication to MR imaging examination; or (e) 
an incomplete MR examination.  
 
Radiographic and DXA Examination. Lateral radiographic examination of the 
thoracic and lumbar spines was performed on all subjects within one month prior to 
MR examination. Radiographs were obtained to assess the presence of vertebral 
fracture and aid detection of any other bony abnormality that could affect DXA or MR 
measurements. Radiographs were reviewed by a single radiologist with a vertebral 
fracture being diagnosed if vertebral height was decreased by 20% or greater 
(Genant HK et al. 1993). DXA examination of the lumbar region (L1-L4) was 
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performed on all subjects (Hologic QDR-4500W, Hologic, Inc., Waltham, MA) within 
one month prior to MR examination. The in-vitro short and long term CV of DXA 
lumbar spine used in this study was 0.65% while the in-vitro long term CV was 0.398. 
Based on DXA results, subjects were grouped into three categories according to 
their T-score results and World Health Organization criteria (WHO Study Group, 
1994). Normal bone mineral density was defined as a T-score greater than -1.0, 
osteopenia as a T-score between -1.0 and -2.5, and osteoporosis as a T-score less 
than -2.5. 
 
MR Examination. MR examinations were performed on a 1.5-T whole-body MR 
imaging system (Intera NT, Philips, Best, Netherlands) with a 30 mT/m maximum 
gradient capability. A 20-cm diameter circular surface coil, centered at the third 
lumbar vertebra (L3), was used to optimize the sensitivity of both 1H MR 
spectroscopy and DCE MR imaging examination. L3 was chosen as optimal coil 
positioning was facilitated by surface landmarks (iliac crests). For 1H MR 
spectroscopy (Figure 1), VOI size ranged from 8 to 17 cm3 depending on vertebral 
body size. After local shimming and gradient adjustments, data were acquired at a 
spectral bandwidth of 1,000 Hz and 64 non-water suppressed signals were obtained 




74-year-old man with osteoporosis (T score -
3.5). 1H MR spectroscopy examination of the L3 
lumbar spine. (a) Sagittal T2-weighted MR image 
(3500/120) of the lumbar spine showing 
positioning of the VOI for spectroscopy within the 
L3 marrow cavity.  
 
 
Dynamic contrast-enhanced MR imaging was acquired on completion of 
spectroscopy examination at which time the subject would have laid still within the 
scanner gantry for a period of at least fifteen minutes. Dynamic images were 
acquired in the sagittal plane using a short T1-weighted gradient-echo sequence 
(TR/TE, 2.9/1.1; pre-pulse inversion time, 400 msec; flip angle, 15o; section 
thickness, 10 mm; number of slices, one; field of view, 250 mm; acquisition matrix, 
256  256; one signal acquired). A total of 160 dynamic images were obtained from 
the mid-sagittal plane of the vertebral body with a temporal resolution of 540 msec. A 
bolus of gadoteric acid (Dotarem; Guerbet, France) at a concentration of 0.15 mmol 
per kilogram of body weight was injected manually at an injection rate of 
approximately 2.0 mL/sec through a 21-gauge intravenous catheter previously 
inserted in the right antecubital vein. The injection was immediately followed by a 20-
mL saline flush at the same injection rate. Dynamic MR imaging started as soon as 
the injection of contrast medium commenced (time zero). Dynamic contrast-
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enhanced MR images acquired during the first-pass phase of signal enhancement 
were analyzed. On the mid-sagittal T1-weighted image, a region of interest (ROI) 
(Figure 2) encompassing the L3 vertebral body, was drawn manually by a single 
observer using a radiology workstation (Viewforum, Philips Medical System, Best, 
The Netherlands). 
 
Figure 2.  
1H spectrum acquired from this VOI showing a 
relatively intense lipid peak (1.3 ppm) 
compared to the water peak (4.65 ppm) 
indicating increased marrow fat content within 
the vertebral body. Bottom trace is the original 
spectrum while the middle shows the fitted 
spectrum from which peak intensity values 
were derived and top trace is the residual 
spectrum. 
 
Data Analysis. (a) Spectroscopy data. Spectroscopic data were analyzed as per 
Appendix 1.  Specifically, vertebral body fat content, defined as the relative fat signal 
amplitude in percentage of total signal amplitude (water and fat), was calculated 
according to the equation (Schellinger et al, 2001):  
    % 100IIIcontentFat waterfatfat   
where Ifat and Iwater are the peak amplitudes of fat and water, respectively. 
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Figure 3.  
Marrow fat content 
distribution among 
subject groups (normal 
bone density, osteopenia 
and osteoporosis). Mean 
value for each group is 
represented by the 
horizontal bar. 
 
(b) Perfusion Data. Perfusion data was analysed as explained in Appendix 1.  Two 
perfusion parameters were measured namely: maximum enhancement and 
enhancement slope. Maximum enhancement is defined as the maximum percentage 









           
Enhancement slope is defined as the rate of enhancement between 10% and 90% of 











 where t10% and t90% are the time intervals when the rise in signal intensity reaches 
10% and 90% of the maximum signal intensity difference between Ibase and Imax, 
respectively 
Both parameters were derived from the first-pass phase of signal enhancement or 
rapidly rising part of the time-intensity curve and are considered to represent arrival 
of the contrast material into the arteries and capillaries of the vertebral marrow and 
its diffusion into the extracellular space (Cova M et al. 1991).  
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Statistical Analysis. Overall mean values for vertebral marrow fat content, 
maximum enhancement and enhancement slope were obtained in additional to the 
mean values for each of the three bone density groups (normal bone density, 
osteopenia and osteoporosis). Student t test comparison between mean age of each 
group was performed. Pearson correlation test was used to assess correlation 
between marrow fat content, maximum enhancement and enhancement slope and 
bone density (T-score) for the three bone density groups. Analyses were performed 
using SPSS for Windows (Release 11.0, SPSS Inc., Chicago, Illinois). P values of < 




Subjects. Eight subjects were excluded from the 90 male subjects initially recruited, 
due to failed injection in three and motion artifact in five subjects, leaving a final 
cohort of 82 subjects (mean age, 73 years; age range, 67-101 years), all of whom 
successfully completed both 1H MR spectroscopy and DCE MR imaging. No subject 
in the study cohort had a thoracic or lumbar vertebral fracture on radiography. Bone 
mineral density was normal in 42 subjects (T score, 0.8  1.1(SD)), osteopenic in 23 
subjects (T score, -1.6  0.4) and osteoporotic in 17 subjects (T score, -3.2  0.5). 
The mean age for normal bone density group was 72 years (range, 67-82 years), for 
osteopenic group 74 years (range, 67-101 years) and for osteoporotic group 74 
years (range, 68-84 years). Age differences between the three groups were not 
statistically significant (osteoporosis vs normal, p = 0.096; osteoporosis vs 
osteopenia, p = 0.958; osteopenia vs normal, p = 0.194). 
 86 
Vertebral Marrow Fat Content. When analyzed according to bone density, 
osteoporotic subjects (58.23  7.8%) had the highest mean vertebral marrow fat 
content followed by osteopenic subjects (55.68  10.2%) and subjects with normal 
bone density (50.45  8.7%) (Figure 4). The observed difference between 
osteoporotic subjects and those with normal bone density was significant (p = 0.002) 
as was the observed difference between osteopenic subjects and those with normal 
bone density (P = 0.034) subjects (Figure 4). The observed increase in marrow fat 
content in osteoporotic subjects compared to osteopenic subjects was not significant 
(P = 0.394) (Figure 4). 
 
Figure 4. 
Sagittal T1-weighted MR image (450/1) of the 
lumbar spine showing a manually drawn ROI 
positioned just within the cortical margins of 
the L3 vertebral body. Time-intensity data-
points based on this ROI were measured from 
all dynamic images.  
 
Vertebral Marrow Perfusion. When analyzed according to bone density, 
osteoporotic subjects had the lowest mean maximum enhancement (23.52  9.9%) 
compared to osteopenic subjects (28.36  10.8%) and subjects with normal bone 
density (34.49  13%) (Figures 5 & 6). The observed difference in maximum 
enhancement between osteoporotic subjects and those with normal bone density 
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was significant (p < 0.001) as was the observed difference between osteopenic 
subjects and those with normal bone density (p = 0.023) subjects (Figure 5 & 6).  
When analyzed according to bone density, osteoporotic subjects had the lowest 
mean maximum enhancement (0.78  0.3 %/sec) compared to osteopenic subjects 
(1.15  0.6 %/sec) and those with normal bone density (1.48  0.7 %/sec) (Figure 5 
& 6). The observed difference in enhancement slope was significant between 
osteoporotic subjects and those with either osteopenia (P = 0.007) or normal bone 
density (p < 0.0001) (Figure 5 & 6). Osteopenic subjects also had a significantly 
reduced mean enhancement slope compared to those with normal bone density (p = 
0.0279) (Figures 5 & 6). 
 
Figure 5.  
Typical time-intensity curve for subjects with (a) normal bone density showing high 
maximum enhancement and steep enhancement slope, (b)  osteopenia showing 
decreased maximum enhancement and a less steep enhancement slope and (c) 






(a) Maximum enhancement 
and (b) enhancement slope 
indices for the three different 
groups [normal bone density 
(n=42), osteopenia (n=23) 
and osteoporosis (n=17)].  
Mean value for each group 







Correlation between Bone Density, Vertebral Marrow Perfusion and Fat 
Content. With reduction in bone mineral density, both maximum enhancement (r = 
0.263, p = 0.0169) and enhancement slope (r = 0.419, p < 0.0001) decreased while 
marrow fat content increased (r = -0.32, p = 0.0034). The increase in marrow fat 
content correlated strongly with a decrease in both maximum enhancement (r = -
0.727, p < 0.0001) (Figure 7) and enhancement slope (r = -0.545, P < 0.0001) 
(Figure 7).  
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Figure 7.  
Scatter plot to showing 
strong correlation 
between marrow fat 
content and maximum 
enhancement indicating 
that as marrow fat 
increased, perfusion 
decreased. A similar 
trend was observed 
comparing marrow fat 
content and 




SIGNIFICANCE OF THESE RESULTS 
Whilst this first study was on-going, a study was published in Radiology which also 
examined the relationship between perfusion as assessed by MRI and BMD. This 
study by Shih et al found a significant correlation (r = 0.61, p<0.01) between peak 
enhancement ratio and BMD in 37 post-menopausal women patients of varying BMD 
who were not on hormonal replacement therapy suggesting a link between vascular 
disease and osteoporosis (Shih TT et al. 2004).  Study 1 builds on this initial study 
by Shih et al in expanding the paradigm to explore the relationship between vertebral 
marrow perfusion, fat content and bone mineral density. Osteoporotic subjects were 
found to have significantly reduced vertebral marrow perfusion compared to those 
with osteopenia and normal bone density (Figure 2).  Study 1 shows a clear trend of 
decreasing marrow perfusion and increasing marrow fat content in line with reducing 
bone density. It has not been determined in this study whether these represent 
independent or related variables and if a temporal relationship exists i.e. does 
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increase in vertebral marrow fat precede reduction in perfusion or visa versa or do 
these changes predate or postdate changes in bone density.  
This all enhances prior epidemiological, histological and laboratory evidence that 
have suggested a link between osteoporosis and vascular disease. Epidemiological 
studies have shown how osteoporosis in the elderly is associated with an increased 
mortality rate, even when deaths following osteoporotic fractures are not considered 
(Browner WS et al. 1991). Women with osteoporosis soon after menopause have an 
almost two-fold increased risk of cardiovascular mortality, an association that 
persists after adjusting for other cardiovascular risk factors (von der Recke P et al. 
1999).  Histological studies have shown an increase in marrow fat and a reduction in 
marrow arteries and capillary sinusoids in osteoporosis (Burkhardt R et al. 1987). 
Using radio-labeled microspheres to assess blood flow, Bloomfield et al observed an 
age-related reduction in blood flow and bone density in the rat scapula, forelimb and 
femur (Bloomfield SA et al. 2002). Reduced perfusion possibly acting through 
endothelial production of nitric oxide, prostaglandin E2 and prostaglandin I2 can alter 
the balance between osteoblastic and osteoclastic activity (Bloomfield SA et al. 
2002). Mice lacking the glycoprotein osteoprotegerin develop arterial calcification 
and early onset osteoporosis (Bucay N et al. 1998). 
 
MR-based studies have shown vertebral marrow perfusion decreases with age, the 
reverse is true for marrow fat (Chen WT et al. 2001). Vertebral marrow fat content 
increases with age though it is unclear whether this increase is due to an increase in 
adipocyte size or adipocyte number (Rozman C et al. 1989, Justesen J et al. 2001). 
Schellinger et al reported an average vertebral marrow fat content of 20.5% in all 
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subjects aged 15-29 years increasing to 49.4% for all subjects aged 70-89 years 
(Schellinger D et al. 2001). Our results show that vertebral marrow fat content is 
related to bone density. Subjects with osteoporosis or osteopenia have a 
significantly increased marrow fat content compared to those with normal bone 
density. Several potential mechanisms whereby increasing marrow fat could 
interplay with bone strength and density have been proposed. First, an increase in 
marrow fat may simply represent a compensation for trabecular thinning (Schellinger 
D et al. 2001, Justesen J et al. 2001). Second, replacement of the more hydrostatic 
(and less compressible) heamopoetic marrow with the more compressible fatty 
marrow may potentiate vertebral weakening (Schellinger D et al, 2001). Third, as 
osteoblasts and adipocytes share a common pluripotent mesenchymal stem cell in 
the bone marrow, increased adipogenesis may be associated with decreased 
osteoblastogenesis (Schellinger D et al, 2001,Justesen J et al, 2001).  
There are also several potential mechanisms whereby reduced bone perfusion can 
interrelate with increased marrow fat and osteopososis.  It is conceivable for 
example that within the confines of the vertebral body, increasing fat could simply 
compress the intraosseous veins diminishing blood flow.  Alternatively the metabolic 
activity of bone and other marrow constituents may be decreased.  Marrow stem 
cells comprise hematopoietic stem cells, mesenchymal stem cells, and multipotent 
progenitor cells. These stem cells are believed to work together in 
neovascularisation. Differentiated hematopoietic stem cells (also known as 
endothelial progenitor cells) provide vascular endothelial cells while differentiated 
mesenchymal stem cells provide vascular smooth muscle cells (Khakoo AY et al. 
2005) or provide cytokines that are central to the initiation and coordination of 
vascularization (Kinnaird AY et al. 2004).   
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These relationships will be investigated in the following Studies, particularly in Study 
7.  
Limitations of this study. 
1. This study shows a clear trend of decreased marrow perfusion and increased 
marrow fat content paralleling reducing bone density. It has not been 
determined whether these represent independent or related variables and if a 
temporal relationship exists i.e. does increase in vertebral marrow fat precede 
reduction in perfusion or visa versa or do these changes predate or postdate 
changes in bone density. Longitudinal studies will help in this respect.  
2. Due to simultaneous participation in another osteoporosis-related study, only 
males were included although osteoporosis is more common in females. Gender 
age-related differences in vertebral marrow perfusion and also possibly fat 
content do exist (Chen WT et al. 2001). On average, females less than 50 years 
of age demonstrate increased marrow perfusion compared to men of similar age 
while females over 50 years show a more marked decrease in marrow perfusion 
compared to men of similar age (Chen WT et al, 2001). Conversely, across age 
groups, males tend to have more vertebral marrow fat than females (Schellinger 
D et al. 2001). Therefore, the results of this study cannot necessarily be applied 
to females (Chen WT et al. 2001, Schellinger D et al. 2001). 
3. Contrast was injected manually rather than by power injector. Variations in 
injection rate may have affected the enhancement slope though we believe this 
effect to be minimal and all participants were incurred the same potential error.  
4. Sample size was small, particularly for osteopenic and osteoporotic groups, as 
osteoporosis is less common in men. This small sample size may have resulted 
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in some observed trends between groups being within the limits of statistical 
error.  
5. We were not able to determine whether the decrease in perfusion represented 
an intraosseous phenomenon or was a feature of a more generalized systemic 
circulatory impairment.  
 
Conclusion. This first study shows that compared to subjects with normal bone 
density, bone perfusion is reduced in those with osteopenia and further reduced in 
those with osteoporosis. In contrast, vertebral marrow fat content is increased in 
those with osteopenia or osteoporosis. There was a strong inverse relationship 
between decreasing perfusion and increasing marrow fat.  
 
Next phase of study: Following on from this study, we wish to establish whether 
similar changes occur in females (as osteoporosis is more common in females) and 
see whether perfusion abnormalities also occur outside the bone in osteoporosis. 




STUDY 2:  
Vertebral marrow fat content, molecular diffusion, and 
perfusion indices in women with varying bone density, 
including osteoporosis: MR evaluation 
 
Aim: To study whether marrow perfusion is altered in female subjects with reduced 
bone mineral density and how this relates to marrow fat content.  
  
Rationale for doing this study: 
Our previous study (Study 1) showed that bone perfusion was reduced in male 
osteoporotic subjects. In this study, we wanted to determine:  
(a) Whether similar findings occurred in female subjects as osteoporosis is much 
more common in female subjects  
(b) Whether reduced bone perfusion was a localized phenomenon confined to 
bone or a symptom of a more generalized circulatory impairment. We chose to 
do this by comparing perfusion within bone with that of paravertebral muscle 
which has the same blood supply. 
(c) To determine whether molecular diffusion as evidenced by diffusion-weighted 










Is marrow perfusion altered in female subjects with reduced bone mineral 
density and how does this relate to marrow fat content? 
 
110 post-menopausal female subjects 
 
 DXA lumbar spine / right hip 
 MR thoracic and lumbar spine 
 MR perfusion imaging of L3 vertebral body & paravertebral muscle – axial 
plane 
 MR diffusion L3 vertebral body 




 As vertebral BMD , there is a corresponding  in perfusion indices and a 
corresponding  in fat content i.e. trend similar to that seen in male subjects. 
 
 The  in perfusion indices only seen in vertebral body and not in the adjacent 
paravertebral muscle which has same arterial supply. 
 











Purpose: To prospectively use MR imaging and spectroscopy to measure vertebral 
marrow fat content, marrow diffusion, marrow and erector spinae muscle perfusion in 
female subjects of varying bone density.   
Materials and Methods: Following institutional study approval, DXA, proton MR 
spectroscopy, diffusion-weighted imaging, and dynamic contrast-enhanced imaging 
of the lumbar spine and erector spinae muscle was performed on 110 female 
subjects (mean age, 73 years; range, 67-84 years). Marrow fat content, marrow 
apparent diffusion coefficient (ADC) and perfusion parameters of marrow and spinae 
muscle were compared for different bone density groups (normal, osteopenia, and 
osteoporosis). t test comparisons and Pearson correlations were applied.  
Results: Seven subjects were excluded yielding a final cohort of 103 subjects 
comprising 18 normal bone density subjects, 30 osteopenic subjects, and 55 
osteoporotic subjects. Vertebral marrow fat content was significantly increased in 
osteoporotic subjects (67.8  8.5%) compared to those with normal bone density 
(59.2  10.0%) (P = 0.002). Vertebral marrow perfusion was significantly decreased 
in osteoporotic subjects (enhancement slope, 1.10  0.51%/sec) compared to 
osteopenic (1.45  0.51%/sec) (P = 0.01) and normal bone density subjects (1.70  
0.52%/sec) (P < 0.001). Erector spinae muscle perfusion did not decrease with 
decreasing bone density. ADC of vertebral marrow did not change with bone density. 
Conclusion: Females demonstrate decreased marrow perfusion and increased 
marrow fat in line with decreasing bone density. Reduction in perfusion appears to 
occur only within the bone and does not occur in extraosseous tissues with the same 
arterial supply. 
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STUDY DETAIL:  
MATERIALS AND METHODS 
Subject Selection. 110 post-menopausal female subjects over the age of 65 years 
(mean age, 73 years; range, 67-84 years) volunteered to participate in this 
prospective study between March 2004 and February 2005. As part of another on-
going study, recruitment notices were placed in community centers for the elderly 
inviting subjects to attend for dual x-ray absorptiometry (DXA) examination. Informed 
consent was obtained from participating subjects.. The Institutional Clinical Research 
Ethics Committee approved the study (Appendix).  Following DXA examination, all 
subjects were invited to attend for MRI examination for which ethics approval and 
informed consent was additionally obtained. MRI examination, comprising 1H MR 
spectroscopy, diffusion-weighted and dynamic contrast-enhanced MR imaging of the 
lumbar spine, was performed within a mean of 11 days (range 9-13 days) of DXA 
examination. Subjects were not recruited or were excluded from further analysis if 
there was (a) clinical or imaging evidence of metabolic bone disease or metastases; 
(b) a history of lumbar spinal surgery or irradiation; (c) a contraindication to MR 
examination; or (d) an incomplete MR examination. The results of the MRI 
examination were made known to the participating subjects.  
 
DXA Examination. The average of the four levels (L1-L4) from an anteroposterior 
projection of the lumbar spine (Hologic QDR-4500W, Hologic, Inc., Waltham, MA) 
was used to obtain the bone density in g/cm2. Based on reference values derived 
from a local population ((Lynn HS et al. 2005), subjects were grouped into three 
categories according to lumbar spinal T-score and World Health Organization criteria 
(WHO Study Group 1994). The in-vitro short and long term CV of DXA lumbar spine 
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used in this study was 0.65% while the in-vitro long term CV was 0.398. Normal bone 
density was defined as a T score greater than -1.0, osteopenia as a T score between 
-1.0 and -2.5, and osteoporosis as a T score less than -2.5. 
 
MR Examination.  MR examinations were performed on a 1.5-T whole-body MR 
imaging system (Intera NT, Philips, Best, Netherlands) with a maximum gradient 
strength of 30 mT/m. A 20-cm diameter circular surface coil, centered at L3, was 
used. In the event of an L3 vertebral body fracture (Genant HK et al. 1993), or other 
focal lesion, the L2 vertebra was analysed. Following acquisition of scout images in 
axial, coronal and sagittal planes, T1-weighted (repetition time [TR] msec/echo time 
[TE] msec, 450/1) and T2-weighted (TR/TE, 3500/120) sagittal images of the 
thoracic and lumbar spine were obtained to identify vertebral fracture, to help 
exclude metastases and to guide positioning of a volume of interest within the L3 
vertebral body for spectroscopy. 
 
MR spectroscopy technique: For spectroscopy, the width (w), depth (d) and height 
(h) of the L3 vertebral body were measured on MR images to define a volume of 
interest (VOI). A VOI with dimensions w/2  d/2  h/2 cm3 was located centrally in 
the vertebral body (by DKWY with 10 years working experience with MRI). After local 
shimming and gradient adjustments, data was acquired at a spectral bandwidth of 
1,000 Hz with 512 data points and 64 non-water suppressed signals were obtained 
using a point resolved spectroscopic sequence (TR/TE, 3000/25 msec). 
 
MR diffusion imaging technique: Fat-suppressed diffusion-weighted images were 
acquired on a single axial slice through the middle of the L3 vertebral body using a 
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spin-echo single-shot echo-planar imaging sequence (2000/105; section thickness, 
10 mm; field of view, 250 mm; matrix, 128  128; four signals acquired), sensitized to 
incoherent motion by a pair of gradient pulses. Diffusion sensitivity parameters, or b 
values, were altered by varying the gradient amplitude while keeping the duration 
and separation time constant at 30 msec and 50 msec respectively. Six diffusion-
weighted images were acquired with b values of 0, 100, 200, 300, 400 and 500 
sec/mm2. Three diffusion-weighted images were acquired for each b value with the 
diffusion-sensitization gradient along the readout, phase-encoding and slice 
selection directions respectively. Isotropic diffusion-weighted image was calculated 
on a pixel-by-pixel basis using a similar method described elsewhere (Yeung DKW 
et al. 2004).  
 
MR perfusion imaging technique: Dynamic contrast-enhanced MR images were 
acquired in the axial plane through the mid-L3 region. Dynamic images were 
obtained using a short T1-weighted gradient-echo sequence (TR/TE, 2.7/0.95; pre-
pulse inversion time, 400 msec; flip angle, 15o; section thickness, 10 mm; number of 
slices, one; field of view, 250 mm; acquisition matrix, 256  256; one signal acquired). 
A total of 160 dynamic images were obtained from the mid-axial plane of L3 with a 
temporal resolution of 543 msec providing a total interrogation time of 87 sec. A 
bolus of gadoteric acid (Dotarem; Guerbet, Aulnay, France) at a concentration of 
0.15 mmol per kilogram of body weight was injected at a rate of 2.5 mL/sec (Spectris, 
Medrad, Inc., Indianola, PA, USA) through a 21-gauge intravenous catheter inserted 
in an antecubital vein. The injection was followed by a 20-mL saline flush. Dynamic 





(a) Spectroscopy data. Spectra were analyzed on an off-line computer (Dell 
Precision 650 Workstation; Dell, Austin, Tex). Water (4.65 ppm) and lipid (1.3 ppm) 
peak amplitudes were measured to determine vertebral body fat content, defined as 
the relative fat signal amplitude in terms of a percentage of total signal amplitude 
(water and fat) and calculated according to the following equation:  
fat content = [Ifat/(Ifat + Iwat)] · 100, 
where Ifat and Iwat are the peak amplitudes of fat and water, respectively. No 
correction for relaxation losses was applied. 
 
(b) Diffusion data. The ROI was drawn manually (by DKWY) encompassing 
cancellous bone on the isotropic diffusion-weighted image obtained with a b-value 0 
sec/mm2, and the same ROI was then applied to all other isotropic diffusion-
weighted images obtained with different b values. Apparent diffusion coefficient 
(ADC) was calculated with a five-point regression method at b values of 100, 200, 
300, 400 and 500 sec/mm2 using the following equation:  
ADC)b( expII 0b   




(c) Maximum enhancement and enhancement slope. On the mid-axial T1-
weighted image, ROIs separately encompassing the L3 vertebral body and the three 
elements of the erector spinae muscle were drawn manually (by DKWY) on a 
radiology workstation  (Viewforum, Philips Medical System, Best, The Netherlands) 
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(Figure 1). The erector spinae muscle was selected rather than the psoas muscle 
because of its larger muscle bulk.  Time-intensity curves were recorded and 
processed on an offline computer (Dell Precision 650 Workstation; Dell, Austin, Tex). 
As per study 1, two perfusion indices of the time-intensity curve were measured, 
namely maximum enhancement and enhancement slope.  
While these indices are often predictive of perfusion they are not a direct measure of 
perfusion. Maximum enhancement and enhancement slope time intensity curve 
indices are dependent on many factors including bolus contrast concentration, blood 
volume, cardiovascular function, tissue perfusion, tissue permeability and available 
leakage space (Parker GJ et al. 1997, Cova M et al. 1991)  
 
Figure 1. T1-weighted 
(578/12) axial image  
showing a manually 
drawn ROI positioned just 
within the cortical margins 
of the L3 vertebral body 
and the individual 
components of the 
erector spinae muscle for 
time intensity data-points 
measured from dynamic 
contrast-enhanced 
images. Individual 
components of erector 
spinae are spinalis, 
longissimus and 




Statistical analysis. Data are presented as mean and standard deviations. Normal 
Q-Q and box plots were employed to examine normality and identify outliers. 
Logarithmic transformation was used to correct positive skewness of the variable 
 102 
enhancement slope for muscle. Variables were compared amongst the three bone 
density groups (normal, osteopenia and osteoporosis) using the one-way ANOVA 
test. Post Hoc multiple comparisons were then conducted for significant variables 
using a Bonferroni correction. Pearson correlation coefficients were calculated to 
assess the linear relationship between pairs of variables. Statistical analyses were 
done using SPSS 11.0 (SPSS Inc., Chicago). A p-value < 0.05 was considered 
statistically significant.  
 
RESULTS 
Subjects. Seven subjects were excluded from the 110 female subjects initially 
recruited, due to failed injection in two and motion artifact in five subjects, leaving a 
final cohort of 103 subjects (mean age, 72 years; age range, 67-84 years) (Table 1). 
The L3 vertebral body was analysed in all subjects except in two subjects where the 
L2 vertebral body was analysed. Bone mineral density was normal in 18 subjects, 
osteopenic in 30 subjects and osteoporotic in 55 subjects (Table 1). 
 
Vertebral Marrow Fat Content. Vertebral marrow fat content increased with 
decreasing bone density (Table 1, Figure 2). Osteoporotic subjects had, on average, 
a significantly higher vertebral marrow fat content than normal bone density subjects 
(P = 0.002) (Table 1, Figure 2). For paired data, a mild significant negative 
correlation was observed between T-score and vertebral marrow fat content (r = -
0.36, P < 0.01) (Table 2), i.e. marrow fat increased as bone density decreased. 
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Figure 2. Marrow 
fat content for the 












Vertebral Marrow Maximum Enhancement and Enhancement Slope.  Maximum 
enhancement decreased with decreasing bone density (Table 1, Figure 3). 
Osteoporotic subjects had significantly lower mean maximum enhancement than 
normal bone density subjects (P < 0.001) (Table 1, Figure 3). Mean enhancement 
slope also tended to decrease with decreasing bone density (Table 1, Figure 4). 
Osteoporotic subjects had a significantly lower mean enhancement slope compared 
to osteopenic subjects (P = 0.01) and normal bone density subjects (P < 0.001) 
(Table 1). Moderate positive correlation was present between T-score and both 
vertebral marrow maximum enhancement (r = 0.51, P = < 0.001) and enhancement 
slope (r = 0.37, P < 0.001) (Table 2) i.e. bone perfusion indices decreased with 
decreasing bone density. Of all paired variables tested, the strongest correlations 
found were that an increase in vertebral marrow fat content correlated with a 
decrease in marrow maximum enhancement (r = -0.72, P < 0.001) and 
enhancement slope (r = -0.67, P < 0.001) (Table 2, Figure 4). 
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Figure 3. Vertebral 
marrow maximum 
enhancement for the 
three different bone 
density groups 






value for each group. 
 
 
Figure 4. Vertebral 
marrow 
enhancement slope 
for the three different 
bone density groups 






value for each group. 
 
 
Figure 5. Scatterplot 
to show strong 
correlation between 
marrow fat content 
and maximum 
enhancement 
indicating that as 
marrow fat content 
increased perfusion 
decreased (r = -0.72). 
Similar finding was 
present between 
marrow fat content 
and enhancement 




Erector Spinae Muscle Maximum Enhancement and Enhancement Slope. Both 
maximum enhancement and enhancement slope in the erector spinae muscle 
tended to increase in osteoporotic subjects compared to osteopenic subjects and 
normal bone density subjects though these differences were not significant (P = 0.08 
and P = 0.333, respectively) (Table 1, Figure 6). A mild significant negative 
correlation was observed between decreasing bone density and increasing erector 
spinae muscle maximum enhancement (r = -0.24, P = 0.02) (Table 2) i.e. muscle 
perfusion indices tended to increase as bone density decreased. No correlation was 
present between vertebral body marrow perfusion indices and erector spinae muscle 
perfusion indices (P = 0.99 for maximum enhancement and P = 0.71 for 
enhancement slope) (Table 2). 
 
Figure 6. Erector spinae 
muscle maximum 
enhancement for three 
different bone density 
groups [normal bone 
density (n=18), 
osteopenia (n=30) and 
osteoporosis (n=55)]. 
Horizontal bar 
represents mean value 
for each group. As BMD 
decreased, muscle 
perfusion, if anything, 
was increased.  Similar 
results were found 
between erector spinae 
muscle enhancement 
slope (not shown). 
 
Vertebral Marrow Apparent Diffusion Coefficient. No significant difference in ADC 
values was observed between osteoporotic subjects, osteopenic subjects and 
normal bone density subjects (P = 0.51) (Table 1). For paired data, no correlation 
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was present between either bone density or bone perfusion indices and marrow 
ADC (P > 0.05) (Table 2) though a mild positive correlation was present between 
vertebral marrow fat content and ADC (r = 0.24, P = 0.017) (Table 2) i.e. as marrow 
fat content increased, marrow diffusion decreased.  
TABLE 1: MR parameters in different bone density groups 
 All  
(n = 103) 
Normal  
(n = 18) 
Osteopenia 
 (n = 30) 
Osteoporosis 
 (n = 55) 
P Value* 
Age (years) 72.1 ± 3.5 73.4 ± 3.5 71.4 ± 2.9 72.2 ± 3.7 0.150 
T-score -2.34 ± 1.39 -0.05 ± 0.86 -1.82 ± 0.44 -3.37 ± 0.60 <0.001† 
Marrow fat content 
(%) 
65.0 ± 9.6 59.2 ± 10.0 63.3 ± 9.5 67.8 ± 8.5 0.002† 
Marrow maximum 
enhancement (%) 




1.31 ± 0.56 1.70 ± 0.52 1.45 ± 0.51 1.10 ± 0.51 <0.001† 
Muscle maximum 
enhancement (%) 




1.50 ± 1.03 1.20 ± 0.61 1.48 ± 0.97 1.61 ± 1.15 0.333 
Marrow ADC 
(mm2/sec) x 10-3 
0.43 ± 0.12 0.46 ± 0.08 0.41 ± 0.12 0.43 ± 0.12 0.505 
 
Table 1 
Vertebral marrow fat content, maximum enhancement, enhancement slope and ADC values 
and muscle maximum enhancement, enhancement slope for each bone density (normal, 
osteopenia and osteoporosis) group. Numbers shown are mean ± 1 standard deviation (SD). 
*Calculated using one-way ANOVA test.  † Denotes a significant difference between any of 
the three groups. Please refer to Results for details regarding probability significance 
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TABLE 2. Pearson’s correlation coefficient test results. †Denotes significant correlation.  
 
SIGNIFCANCE OF THESE RESULTS  
Study 2 was undertaken to examine the relationship between vertebral bone density, 
vertebral marrow fat content and perfusion indices in women and shows a trend in 
female subjects similar to male subjects (Study 1). Reduction in bone density is 
associated with a corresponding increase in marrow fat (Shih TT et al. 2004, Study 1) 
and a reduction in marrow perfusion indices (Shih TT et al. 2004, Study 1). 
Comparing the results for vertebral marrow fat content of this study to those found in 
male subjects (Study 1), post-menopausal females appear to have a greater 
vertebral fat content than their male counterparts irrespective of whether they have 
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normal bone density (59.2 ± 9.6% versus 50.5 ± 8.7%), osteopenia (63.3 ± 9.5% 
versus 55.7 ± 10.2%) or osteoporosis (67.8 ± 10.2% versus 58.2 ± 7.8%). This is not 
in agreement with an earlier report of lumbar vertebral fat content being higher in 
males than females (Schellinger D et al. 2000), though this earlier report was on 
subjects over a wide age range whose bone density was unknown.   
Maximum enhancement and enhancement slope were used as indices of perfusion. 
Both maximum enhancement and enhancement slope were approximately one-third 
less in osteoporotic subjects compared to normal bone density female subjects, a 
finding similar to that seen in male subjects (Study 1).  Also as shown in Study 1, the 
overlap between marrow fat content and perfusion indices for female subjects 
between bone density groups indicates that fat content, maximum enhancement and 
enhancement slope time measurements on MR imaging cannot be used, in isolation, 
to reliably determine bone density (Study 1). 
We also wanted to investigate in this study whether the decrease in perfusion 
observed with osteoporosis was a phenomenon confined to bone or also affected 
tissues beyond bone.  The vertebral bodies and the erector spinae muscles are both 
supplied by the paired segmental lumbar arteries (Williams A et al. 2005, Kato H et 
al. 1999, Armour KE et al. 2001, Chen WT et al. 2004). If the observed reduction in 
perfusion indices were related to general circulatory impairment or atherosclerosis in 
the aorta or main lumbar arteries, one would expect a similar reduction in perfusion 
indices to occur in the erector spinae muscle. However, rather than decrease, 
perfusion indices for the erector spinae muscle tended to increase as bone density 
decreased. Reduction in bone density is associated with a reduction in maximum 
enhancement and enhancement slope within bone and this effect is not apparent in 
extraosseous tissues supplied by the same artery.  
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The MRI diffusion technique we used is mostly dependent on interstitial fluid flow, 
cellularity, and extracellular water volume and, to a lesser extent, on microvascular 
perfusion (Luypaert R et al. 2001). Increased interstitial fluid flow along bone 
canaliculi from repeated mechanical deformation has been proposed as an 
explanation for the anabolic adaptive responses occurring within bone to mechanical 
stress. Simulated interstitial fluid flow modulates bone growth mediators in bone cell 
cultures (Sterck JGH et al. 1998). Amplification of interstitial fluid flow may explain 
the reduced bone loss seen in post-menopausal women subjected to intermittent low 
magnitude vibrations (Rubin C et al. 2004). As interstitial fluid flow will contribute to 
MR diffusion (Luypaert R et al. 2001, Baur A et al. 2003), we examined the 
relationship between bone marrow diffusion and bone density. Our study was 
performed with the subject at rest and showed no relationship between bone marrow 
ADC and bone density. A weak negative association between marrow ADC and 
marrow fat content was found indicating a reduction in molecular diffusion as marrow 
fat content increased.  This may in part be related to this study being performed in 
subjects of narrow age range. Possibly a different relationship between ADC and 










Limitations of this study. 
1. MR data were acquired from L3 while bone density scores were averaged from 
the four lumbar vertebrae L1-L4 as this is the accepted method of obtaining 
bone density ‘T’ scores. 
2. Subjects were aware of their bone density result from DXA examination prior to 
enrolment for MR examination. This may have lead to a lower number of 
normal bone density subjects being recruited than those with osteopenia or 
osteoporosis.  
3. Results of the MRI examination were made known to participating subjects, 
which may have prompted more subjects with back pain to attend for MRI 
examination.   
 
Conclusion: In post-menopausal females, a decrease in bone density is associated 
with a corresponding increase in vertebral marrow fat content and a decrease in 
maximum enhancement and enhancement slope. This observed decrease in 
perfusion indices occurs within the vertebral body and is not seen in paravertebral 
tissues with the same arterial supply. Only a weak association between vertebral 
marrow diffusion and bone mineral density was found.   
 
Next phase of study: A recent study has shown that as marrow fat increases, this 
can lead to a spurious reduction in BMD measurement by DXA. Could the results of 
Study 1 and Study 2 be influenced by the effect marrow fat has on DXA 
measurement? In other words, could osteoporosis subjects appear to have more fat 
because increased marrow fat is pushing down the measured BMD? This possibility 




STUDY 3:  
Could the results of Study 1 and Study 2 be spurious due to the 
effect of increasing marrow fat lowering BMD estimation by 
DXA? 
 
Aim: Increasing marrow fat can cause an erroneous decrease in BMD measurement 
by DXA. In studies 1 and 2, we showed that increased marrow fat was associated 
with decreased BMD. In what part was this observation due to an effect of increased 
marrow fat falsely lowering the BMD and, in other words, making subjects with 
increased marrow fat appear as they have decreased BMD. The aim of this study 
was to investigate the degree of error introduced to DXA measurements by 
increasing marrow fat.  
 
Relevance of this study: 
Increase in vertebral marrow fat content may cause an erroneous reduction in BMD 
measurements made by dual x-ray absorptiometry (DXA) [Sorenson JA et al. 1990, 
Bolotin HH et al. 1998, Bolotin HH et al. 2001, Bolotin HH et al. 2007]. This is 
because DXA evaluates BMD by measuring the transmission of x-rays at two 
different photon energies [Blake GM et al. 2007]. The mathematical theory of DXA 
(referred to as basis set decomposition) holds that across a broad range of photon 
energies the X-ray transmission factor through any physical object can be 
decomposed into the equivalent areal densities (g/cm2) of any two designated 
materials [Lehmann LA et al. 1981]. For DXA scans, the two materials chosen are 
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bone mineral (hydroxyapatite) and lean tissue. As a result, DXA measurements will 
only accurately reflect true BMD if the object being examined is composed entirely of 
hydroxyapatite and lean tissue. In practice, the human body is made up of not two 
but three main types of tissue, namely bone, lean tissue and fat. Neglecting the 
difference between lean and fat can lead to DXA measurement error.   
 
DXA uses the soft tissues immediately alongside the spine as a reference to infer the 
soft tissue composition along the path of the spine [Sorenson JA et al. 1990]. It 
follows that errors will arise if the amount of fat in the bone marrow increases. As fat 
has a low attenuation value increasing marrow fat will reduce apparent bone mineral 
density [Bolotin HH et al. 1998].  
 
There is disagreement regarding the quantitative effect of increasing vertebral bone 
marrow fat on spine DXA measurements. Igt has even been suggested that DXA 
measurements may be very seriously flawed in the estimation of bone mineral 
density [Bolotin HH et al. 2007]. Sorenson, in the first study to address this, 
estimated that an increase in the amount of fatty marrow within the lumbar vertebral 
bodies from 0 to 100% caused the measured BMD to decrease by a small amount 
from 0.03-0.04 g/cm2 [Sorenson JA et al. 1990]. In contrast, a recent study by Bolotin 
found that an increase in lumbar vertebral body fatty marrow from 0 to 100% caused 
BMD to decrease by as much as 0.26-0.29 g/cm2 i.e. an error about ten times 
greater than that predicted in the earlier study [Bolotin HH et al. 2007]. The 
significance of this difference can be appreciated when if you consider that, as 
shown from Study 1 and Study 2, the standard deviation in L3 marrow fat content is 
approximately 10%. For a normal BMD measurement of 1.0 g/cm2, this standard 
 113 
deviation in marrow fat would translate into a BMD measurement error from as little 
as  0.4% or as much as  3.0% depending on whether the Sorenson [Sorenson JA 
et al. 1990] or Bolotin [Bolotin HH et al. 2007] estimate is adopted. Therefore the first 
question we wished to answer was how much does increasing marrow fat reduce 
BMD measurement by DXA?  
 
In Study 1 and Study 2, significant increases in vertebral marrow fat content were 
found between subjects with normal bone density, those with osteopenia and those 
with osteoporosis. How much of this apparent increase in marrow fat could be 
accounted for by the negative effect of increased marrow fat on BMD actually leading 
to mis-classification of subjects as either osteopenia or osteoporosis according to T-
score criteria?. In other words, subjects with osteopenia and osteoporosis are more 
likely to be classified as such because of the negative effect increasing marrow fat 
has on BMD. Would this same trend still hold true if this negative effect was taken into 
account?  Therefore the second question we wanted to ask was whether the results 
of Study 1 and Study 2 would still hold true after correcting for the effect of increasing 










Could the results of Study 1 and Study 2 be spurious due to the effect of increasing 
marrow fat lowering BMD estimation by DXA? 
 
 25 males and 25 females randomly selected 
 Vertebral body thickness measured. 
 
 Basis set composition model used to determine extent to which BMD is 
underestimated by DXA for each %  in marrow fat from 0-100%. 
 Correction factors determined for males and females. 




 Correction data of 0.0014 g/cm
2
 (females) and 0.0016 g/cm
2  
(males) for each 
percentage  in marrow fat fraction should be applied to DXA (provided marrow fat 
fraction known). 
 




Purpose: Study 1 and 2 show that subjects with lower spine T-scores have 
significantly higher marrow fat content. Care is necessary in interpreting the 
relationship between spine T-score and marrow fat because of a selection effect in 
which subjects with higher marrow fat are more likely to be identified as having 
osteoporosis.  
Methods: We studied both women (n = 103, mean age 73 y; range 67-84 y) and 
men (n = 82, mean age 73 y; range 67-101 y) who had spine DXA scans and 1H-
MRS measurements of L3 marrow fat. The effect of varying marrow fat on BMD was 
modelled using vertebral body thicknesses measured in 50 men and women. Spine 
T-scores in each individual were adjusted for the measured marrow fat. Subjects 
were sorted into WHO categories based on their corrected T-scores, and the 
relationship between marrow fat and T-score status evaluated using regression 
analysis and analysis of variance. The average change in percent marrow fat per T-
score unit was used to infer the fraction of the spine BMD fracture discrimination 
explained by marrow composition.  
Findings: Mean (SD) of L1-L4 vertebral body thickness was 30.2 (2.1) mm for  
women and 33.4 (2.5) mm for men. When marrow fat content changed from 0 to 
100% BMD was estimated to decrease by 0.14 g/cm2 (1.3 T-score units) in women 
and 0.16 g/cm2 (1.3 T-score units) in men. Allowing for this, there was still a trend 
for marrow fat to increase with decreasing T-score with a slope of -1.2 ± 0.7% per T-
score unit (p = 0.078) for women and -1.4 ± 0.6% per T-score unit (p = 0.023) for 
men.  
Conclusion: When marrow fat content is known, DXA estimation of BMD needs to 
be corrected by 0.0014 g/cm2  in women and 0.0016 g/cm2 in men for ever 1% 
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increase in marrow fat about zero. Applying this correction, the results of study 1 and 




MATERIAL AND METHODS 
Quantitative Effect of Vertebral Marrow Fat Content on BMD Measurement. 
BMD is derived from the sum of its individual parts (Figure 1). The error produced by 
varying percentage marrow fat content can be calculated by applying the principle of 
basis set decomposition to a mathematical model designed to represent the size and 
composition of a lumbar vertebra (Figure 1). This method was similar to that 
described by Sorenson [Sorenson JA et al. 1990] and Bolotin [Bolotin HH et al. 
2007], both of whom verified the mathematical model by examining a physical 




The mathematical model used to 
calculate the effect of varying 
marrow fat content on DXA scan 
BMD measurements using basis 
set decomposition [Lehmann LA 
et al. 1981]. X-ray attenuation 
coefficients were those published 
by Hubbell & Seltzer [Hubbell JH 
et al.]. The base materials for 
basis set decomposition were 
hydroxyapatite and ICRU 4-
component soft tissue [Hubbell 
JH et al.]. Bone tissue was 
represented by ICRU cortical 
bone [Hubbell JH et al.]. Marrow 
composition was represented by 
mixtures of water and fat. A 
protein component was included 
based on the marrow composition 
studies of Goodsitt et al. [Goodsitt 
MM et al. 1994]. Total marrow 
thickness was based on 
measurements of vertebral body 
thickness in 25 Hong Kong 
Chinese men and 25 women. Fat 
composition was based on the 
chemical composition adopted by 




Values for mass attenuation coefficients were taken from tables published by 
Hubbell & Seltzer [Hubbell JH et al.], using either data for the relevant material if 
provided, or calculated from the chemical composition using tables of the elements. 
The principle of basis set decomposition was used to resolve the BMD measurement 
into the equivalent areal densities of hydroxyapatite (Ca10(PO4)6(OH)2) and soft 
tissue [Hubbell JH et al.]. Bone marrow was modelled as a mixture of water, fat and 
protein in the ratio 12water:1 protein [Goodsitt MM et al. 1994]. The composition of 
protein was represented by collagen [6]. Fat composition was based on the 
representative fat adopted by Nord & Payne (C55.05H99.26O3) [Nord RH, 1990].  
 
Vertebral body thickness measurements were made from MR images of the lumbar 
spine for a randomly selected group of 25 Chinese men and 25 women. 
Measurements were made of upper and lower vertebral depth (UVD and LVD) for 
each lumbar vertebra using a method similar to that described by Zhou et al. [Zhou 
SH et al. 2000]. The mean value of UVD and LVD for each vertebra was then 
averaged over L1 to L4. Calculations of the quantitative effect of marrow fat content 
on BMD were made for each sex for vertebral thicknesses corresponding to the 
mean and the 2SD upper and lower limits. Marrow thickness was obtained by 
multiplying the vertebral thickness figures by 0.88 to allow for a normal bone volume 
fraction (BV/TV) of 0.12 [ICRP 1995]. Bone volume fracture is the volume of bone 
per unit volume of tissue with BV/TV being an abbreviation for bone volume / total 
volume. Basis set decomposition was used to calculate the expected change in 
measured BMD in each sex when the marrow fat content measured by 1H-MRS 
increased from 0 to 100%. 
 119 
Effect of Marrow Fat Content on T-score Status. Study 1 and Study 2 showed the 
marrow fat content progressively increased between normal bone, osteopenic bone 
and osteoporotic bone. To evaluate how much this relationship was explained by a 
selection effect of subjects with increased marrow fat more likely to be classified as 
osteopenia or osteoporosis, previous analyses were repeated after correcting the 
measured spine BMD for the effect of marrow fat content using the correction factors 
calculated in the previous section. Separate corrections were performed for men and 
women. The measured spine BMD in each individual was corrected for the 
difference between the measured marrow fat content F and the mean fat content 

F S  
for each sex using the relationship: 
BMDcorr   =  BMDobs + 

F F S)    (1) 
Appendix). Subjects were then sorted into their revised WHO categories based on T-
scores calculated from their marrow fat corrected BMD values using local reference 
data [Lynn HS et al. 2005] and the relationship between marrow fat content and 
WHO T-score status re-evaluated using regression analysis and one-way analysis of 
variance (ANOVA). A p-value of 0.05 was required for statistical significance. The 
statistical significance of the difference between individual WHO categories (normal, 
osteopoenic or osteoporotic) was evaluated after adjusting p-values for multiple 
comparisons using the Bonferroni correction.  
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RESULTS 
Quantitative Effect of Vertebral Marrow Fat Content on BMD Measurement. 
When basis set decomposition was used to estimate the effect of varying marrow fat 
content on lumbar spine BMD using the model shown in Figure 2, the change in 
measured BMD when the marrow fat content changed from 0 to 100% was 0.142 
g/cm2 for women and 0.157 g/cm2 for men. The variation in estimated correction 
factor corresponding to ± 2SD limits for vertebral thickness was between 0.123 - 
0.161 g/cm2 for women and 0.134 - 0.181 g/cm2 for men.  
 
Effect of Marrow Fat Content on T-score Status. For the 103 female subjects in 
whom marrow fat content was known  [Study 2],  correlation between L3 marrow fat 
content and T-score changed from r = -0.279 (p = 0.004) to r = -0.175 (p = 0.078) 
after DXA results BMD figures were adjusted for marrow fat content using Equation 
(1). Although performing the fat adjustment did not alter the mean T-score for the 
whole study group, changes did occur in the figures for mean age, T-score and 
marrow fat when the subjects were subdivided into the three WHO categories based 
on their fat corrected T-scores (Table 1). Although there was a highly significant 
difference between the three WHO groups before the correction was applied (p = 
0.002), this level of statistical significance was no longer present afterwards (p = 
0.066). However, there was still a trend for mean marrow fat to increase as T-score 
decreased with the difference between the normal and osteoporotic groups changing 
from 8.6% before correction to 6.2% afterwards (Table 1). When the one-way 
ANOVA analyses were followed up to investigate the differences between the 
individual WHO groups, after adjusting for multiple comparisons the only statistically 
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significant difference was between the mean marrow fat figures for the normal and 
osteoporotic groups before the marrow fat adjustment was made (p = 0.009). After 
marrow fat adjustment this difference was no longer significant (p = 0.105).  
TABLE1: Outline of female cohort before and after marrow fat correction  
Before marrow 
fat correction 










 Age  72.1 (3.5)  73.4 (3.5)  71.4 (2.9)  72.1 (3.7)  0.150 
 T-score  -2.34 (1.39)  -0.05 (0.86)  -1.82 (0.44)  -3.37 (0.60)    – 
 % marrow fat  65.0 (9.6)  59.2 (10.0)  63.3 (9.5)  67.8 (8.5)  0.002 
After marrow  
fat correction 










 Age  72.1 (3.5)  73.5 (3.6)  71.5 (2.9)  72.1 (3.7)  0.179 
 T-score  -2.34 (1.39)  -0.04 (0.95)  -1.70 (0.42)  -3.28 (0.59)    – 
 % marrow fat  65.0 (9.6)  60.4 (10.0)  64.4 (10.1)  66.6 (8.9)  0.066 
1
One way ANOVA test 
 Table 1 . Descriptive statistics (mean (SD)) of female subject cohort  
 
The results of a similar analysis of 82 male subjects [Study 1] are summarised in 
Table 2. The correlation between L3 marrow fat content and L1-L4 T-score changed 
from r = -0.331 (p = 0.002) to r = -0.250 (p = 0.023) when the spine BMD figures 
were adjusted for marrow fat content using Equation (1). The one-way ANOVA 
showed that the statistically significant difference in marrow fat content between the 
3 WHO groups before the marrow fat correction was applied (p = 0.006) was no 
longer significant afterwards (p = 0.086), and there was a similar conclusion when 
the normal and osteoporotic groups where compared (p = 0.006 vs. p = 0.093).  
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TABLE2: Outline of male cohort before and after marrow fat correction  
Before marrow 
fat correction 










 Age  73.4 (5.6)  72.4 (4.3)  74.5 (7.6)  74.2 (5.3)  0.284 
 T-score  -0.67 (1.85)  +0.82 (1.14)  -1.56 (0.41)  -3.16 (0.50)    – 
 % marrow fat  53.5 (9.5)  50.5 (8.7)  55.7 (10.2)  58.2 (7.8)  0.006 
After marrow  
fat correction 










 Age  73.4 (5.6)  73.1 (4.8)  73.4 (7.4)  74.2 (5.3)  0.806 
 T-score  -0.67 (1.85)  +0.66 (1.19)  -1.75 (0.49)  -3.33 (0.46)    – 
 % marrow fat  53.5 (9.5)  52.6 (9.1)  52.2 (10.2)  58.4 (8.4)  0.086 
1
One way ANOVA test  
 
Table 2.  Descriptive statistics (mean (SD)) of the male subject cohort  
 
SIGNIFICANCE OF THESE RESULTS 
BMD results obtained from DXA scanners are only correct if the human body is 
made up solely of bone and lean tissue. The presence of varying amounts of intra- 
and extra-osseous fat can cause errors in BMD measurement. Fat is largely 
composed of repeated methylene groups [(CH2)n], while X-ray attenuation of lean 
tissue is closely approximated by water (H2O). The difference in X-ray attenuation 
between fat and lean tissue is therefore equivalent to the atomic number difference 
between carbon and oxygen.  
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The relationship between bone marrow fat and DXA examination cannot be fully 
interpreted before first considering the effect that increasing marrow fat has on BMD 
measurements. In the two studies that have addresses this issue, a wide variation in 
the reported correction values to be used has been reported [Sorenson JA et al. 
1990, Bolotin HH et al. 2007]. In the present study, the BMD change associated with 
a 0-100% change in marrow fat content was estimated to be 0.14 g/cm2 for women 
and 0.16 g/cm2 for men. These correction factors are substantially smaller than the 
figure of 0.26 g/cm2 reported by Bolotin [Bolotin HH et al. 2007]. The reasons for this 
discrepancy could be different assumptions about composition of red or yellow 
marrow. Bolotin adopted high density polyethylene [(CH2)n] for his standard for 
yellow marrow, which ignores a small but significant contribution from oxygen atoms 
to the X-ray attenuation of fat. On the composition scale of Nord & Payne [Nord RH 
et al. 1990] polyethelene has a fat equivalence of 115%. The remaining factor that 
might explain the difference in marrow fat correction factor is the composition 
standard for red marrow adopted in the Bolotin study. The standard used was an 
epoxy resin mixed with a small percentage of calcium carbonate, making it difficult to 
compare with the water standard used in the present study. It is therefore possible 
that the difference is explained by Bolotin’s standard for red marrow being too lean.  
In an earlier study Sorenson reported that a change in the percentage of yellow 
marrow from 0 to 100% caused a BMD change of only 0.03-0.04 g/cm2. However, 
when evaluated on the composition scale of Nord & Payne [Nord RH et al. 1990] the 
red marrow composition adopted by Sorenson had a fat equivalence of 55% while 
that for yellow marrow was 81%. These figures are inconsistent with direct chemical 
measurements of marrow composition [Goodsitt MM et al. 1994] and the small 
marrow fat correction factor reported in the Sorenson study is explained by the small 
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difference in the percentage fat values between the red and yellow marrow 
composites.  
When the DXA spine BMD measurements were adjusted for marrow fat content 
using the correction factors calculated in the present study, the statistical 
significance of the relationship between marrow fat content and T-score was 
reduced in both women and men. However, there was still a trend for subjects with 
osteoporosis to have a higher marrow fat content with a difference between 
osteoporotic and normal subjects of 6.2% in women and 5.8% in men. The predicted 
relationship of an increase in marrow fat content of around 1.5% for each unit 
decrease in T-score is in good agreement with the marrow fat corrected 1H-MRS 
data.  
Limitations of this study. 
1.  Analysis was based on correcting total spine (L1-L4) T-scores using marrow fat 
content measurement in L3. However, basic conclusions were not altered when 
the statistical analyses were repeated for L3 T-scores.  
2.  By necessity 1H-MRS measurements covered only approximately the central 
two thirds of the vertebral body. It was not possible to include the whole 
vertebral body since the MR spectroscopy voxel has to be cuboidal.  
Conclusion: Increasing vertebral marrow fat content decreases measured BMD 
measurement by DXA. The correction factor for BMD measurement by DXA was 
calculated as 0.14 g/cm2 for females and 0.16 g/cm2 for males for a 100% change in 
marrow fat content. Some of the reported increase in marrow fat seen in subjects 
with reducing BMD is due to the negative effect that increasing marrow fat content 
 125 
has on BMD estimation. Nevertheless, even after correction, previously reported 
trends of increasing marrow fat with decreasing BMD still hold true. Overall, with 
regard to everyday clinical practice, there is little benefit in adjusting DXA BMD 
values for marrow fat content given the known intrinsic accuracy error of DXA due to 
marginal osteophytosis, facet joint arthrosis etc.    
Next phase of study. Following on from this study, we were satisfied that the 
changes seen in Study 1 and Study 2 w.r.t marrow fat and perfusion were true and 
not being unduly influenced by the effect of increasing marrow fat on DXA 
measurement. We therefore, in the next phase, wished to study whether similar 
changes in fat content and perfusion were apparent in the proximal femur, an 
anatomical area very relevant to subjects with osteoporosis. This will be studied in 











Appendix to Study 3 
Predicted relationship between marrow fat content and T-score 
 
Figure 2. Calculation of predicted relationship between vertebral  marrow fat content and T-
score.  
(A) Subjects with a T-score of zero have a mean volume of bone tissue Vb, marrow volume 
Vm, and average marrow fat content F. 
(B) As osteoporosis develops, volume of bone tissue, Vb, decreases being replaced by fatty 
marrow with a fat content of 100% while the composition of original marrow tissue remains  
unchanged. 
 
Let the initial volume of bone tissue be Vb, the marrow volume Vm, and the average 
marrow fat content F (Figure 2A). As osteoporosis develops there is a decrease in bone 
volume to Vb – b and a corresponding increase in marrow volume to Vm + Vb. The 





The new figure for the average marrow fat content is given by: 
 





  =  

(Vm  Vb)F  Vb(1F)
Vm  Vb




  (A1.1) 
 
F can be written: 
 











(Vm /Vb) (Vb /Vb)
    (A1.2) 
 
If we assume that the initial state in Figure 2A represents a patient with a T-score of 
Vb/Vb can be written as 0 where 
T is the change in T- Vb and a 












(Vm /Vb) (T /T0)
      (A1.3) 
 
For the female population, the mean marrow fat content F was 65%, the value of T0 
was 9.3, the volume ratio of marrow to bone tissue was 2.9, and assuming a T-score 
change of -2.5 the ratio 0 F T figure of -1.2% per T-score 
unit. For the male population, the mean marrow fat content was 53%, the value of T0 
was 8.3, the volume ratio of marrow to bone tissue was 3.2, and assuming a T-score 






STUDY 4:  
Are the same changes in perfusion and marrow fat seen in the 
proximal femur as were seen in the lumbar spine (Study 1 & 
Study 2)? 
 
Aim: To determine whether similar changes occur in the proximal femur as 
previously noted in the lumbar spine (Study 1 and Study 2). 
 
Rationale for doing this study: 
Study 1 and Study 2 have shown that bone perfusion decreases as BMD decreases 
in the lumbar vertebrae. The decrease in perfusion seems to only affect bone and 
does not occur within tissues outside of bone which have the same arterial supply 
[Study 2]. The proximal femur is the most common site of non-vertebral osteoporotic 
fracture (Cummings SR et al. 2002, Sambrook P et al. 2006). Proximal femoral 
fractures are more strongly associated with decreased BMD, cost more to repair and 
cause more disability then any other type of osteoporotic fracture (Cummings SR et 
al. 2002). The proximal femur is also an area very prone to avascular necrosis and 
fracture non-union. We therefore undertook this study to further investigate the 
relationship between BMD, bone marrow perfusion and bone marrow fat content in 









Are the same changes in perfusion and marrow fat seen in the proximal femur as were 
seen in the lumbar spine (Study 1 & Study 2)?  
 
120 post-menopausal female subjects of varying BMD 
 DXA right hip 
 MR perfusion imaging of proximal femur (head, neck, shaft), acetabulum and adductor 
musculature.- oblique coronal plane 
 Proton MR Spectroscopy of proximal femur (head, neck, shaft). 
 
MAIN FINDINGS 
 Marrow perfusion is  in the femoral head in all subjects compared to neck, shaft and 
acetabulum irrespective of BMD. 
 Perfusion in all bone areas is  with  BMD. This effect is most noticeable in the femoral 
neck and acetabulum. Adductor muscle perfusion is unchanged with change in BMD. 
 Marrow fat   in femoral head compared to all other areas. 
 Marrow fat ’s in all bone areas with  BMD. 
 Path analysis revealed that  bone perfusion seems more related to  marrow fat rather 
than  BMD. 
 Overall, similar relationship seen between BMD, marrow and muscle perfusion occurs in 







Purpose: Outside of the spine, the proximal femur is the most common site of 
osteoporotic fracture and is also an area prone to avascular necrosis and fracture 
non-union. This study of the proximal femur investigates the relationship between 
bone mineral density (BMD), bone marrow fat content, bone perfusion and muscle 
perfusion.  
Materials and Methods: 120 healthy female subjects (mean age 74 years; age 
range, 67-89 underwent dual x-ray absorptiometry (DXA) examination of the hip, 
proton magnetic resonance (MR) spectroscopy, and dynamic contrast-enhanced MR 
imaging of the right proximal femur, acetabulum and adductor thigh muscle.  
Results: In all bone areas examined (femoral head, femoral neck, femoral shaft, 
acetabulum), perfusion indices (maximum enhancement, enhancement slope) were 
significantly reduced in subjects with osteoporosis compared to subjects with 
osteopenia or normal BMD. Adductor muscle perfusion was not affected by change 
in BMD. As marrow perfusion decreased in the proximal femur, marrow fat increased 
(r = 0.827).  This increase in fat content seemed to account for the decrease in 
marrow perfusion more than a reduction in bone mineral density. For normal bone 
density subjects, perfusion parameters in the femoral head were one-third of those in 
the femoral neck or shaft and one-fifth of those in the acetabulum.  
Conclusion: Perfusion throughout the proximal femur is reduced in osteoporotic 
subjects compared to osteopenic and normal subjects. This reduction in perfusion 
only affects bone and not those tissues outside of bone with the same blood supply. 




STUDY DETAIL:  
MATERIALS AND METHODS 
Subject selection. Recruitment notices were placed in community centers for the 
elderly inviting subjects to attend for dual x-ray absorptiometry (DXA) examination.  
This study cohort was a different cohort to that of earlier studies. Following DXA 
examination, all subjects were invited to attend for MR examination. The Institutional 
Clinical Research Ethics Committee approved the study (Appendix) and signed 
consent was obtained from all participating subjects. Details regarding subject age, 
hip BMD and T-score are provided in Table 1. All participating subjects were 
Chinese. All MR imaging examinations were performed within two weeks of DXA 
examination. Subjects were not recruited or excluded from further analysis if there 
was (a) clinical or imaging evidence of metabolic bone disease or metastases; (b) a 
history of hip surgery or irradiation; (c) a contraindication to MR imaging examination; 
or (d) an incomplete MR examination. 
 
DXA examination. DXA examination of the right hip was performed on all subjects 
using a single DXA system (Hologic QDR-4500W). in-vitro short and long term CV of 
DXA lumbar spine used in this study was 0.65% while the in-vitro long term CV was 
0.398.  Based on total hip T-score and reference values derived from the local 
population (Lynn HS et al. 2005), subjects were grouped into three categories based 
on World Health Organization criteria (Kanis JA et al. 2002, WHO Study Group 
1994). Normal BMD was defined as a T-score greater than -1·0, osteopenia as a T-
score between -1·0 and -2·5, and osteoporosis as a T-score less than -2·5. 
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MR examination. MR examinations were performed on a 1·5-T whole-body MR 
imaging system (Intera NT, Philips) with a maximum gradient strength of 30 mT/m. A 
two-element circular surface coil measuring 20-cm in diameter wrapped around the 
right hip with the proximal tip at the level of the anterior superior iliac spine and 
aligned along the long axis of the thigh was used. A T1-weighted (repetition time [TR] 
msec/echo time [TE] msec, 540/16) oblique coronal image of the proximal femur was 
obtained to guide positioning of region of interests (ROIs) within the proximal femur, 
acetabulum and adductor musculature for spectroscopy and perfusion imaging.  
 
Figure 1 
T1-weighted coronal MR 
image of proximal femur 
showing regions-of-
interest (ROI’s) used to 
measure perfusion in the 
femoral head, neck, shaft, 
acetabulum and adductor 
muscle. For the adductor 
muscle, a best-fit circle 
encompassing an area of 
adductor muscle 
proximally excluding 




Marrow fat content was evaluated using MR spectroscopy. For spectroscopy, three 
separate standardized volumes of interest (VOI) were placed respectively in the 
femoral head (1·5 × 1·5 × 1·5 cm3), femoral neck (1·0 × 1·5 × 1·5 cm3), and sub-
trochanteric region of the femoral shaft (1·0 × 1·0 × 3·0 cm3). After local shimming 
and gradient adjustments, data was acquired at a spectral bandwidth of 1,000 Hz 
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with 512 data points and 64 non-water suppressed signals obtained using a point 




MR image of proximal 
femur showing 
regions-of-interest 
(ROI’s) used to 
measure fat content in 
the femoral head, 
neck, and shaft.  
 
 
Marrow perfusion and muscle perfusion was evaluated using dynamic contrast-
enhanced MR imaging. For dynamic contrast-enhanced MR perfusion imaging, 
images were obtained in an oblique coronal plane aligned along the mid-portion of 
the proximal femur. Dynamic images were obtained using a short T1-weighted 
gradient-echo sequence (TR/TE, 2·7/0·95; pre-pulse inversion time 400 msec; flip 
angle 15o; section thickness 10 mm; number of slices, one; field of view 250 mm; 
acquisition matrix 256  256; one signal acquired). A total of 160 dynamic images 
were obtained with a temporal resolution of 540 msec over an 82 sec timeframe (i.e. 
160 acquisitions x 540 msec per acquisition). A bolus of gadoteric acid (Dotarem; 
Guerbet) at a concentration of 0·6 mmol per kilogram body weight was injected at a 
rate of 2·5 mL/sec (Spectris, Medrad) through a 21-gauge intravenous catheter 
inserted into an antecubital vein. The injection was followed by a 20-mL saline flush. 
 134 




(a) Spectroscopy data. Spectra were analyzed on an off-line computer (Dell 
Precision 650 Workstation) using a time-domain fitting routine. Water (4·65 ppm) 
and lipid (1·3 ppm) peak amplitudes were measured to determine proximal femur 
marrow fat content. Fat content was defined as the relative fat signal amplitude as a 
percentage of total signal amplitude (water and fat).  
 
(b) Perfusion data. On the mid-coronal oblique T1-weighted image, ROIs 
separately encompassing the marrow cavity (excluding the cortex) of the head, neck, 
shaft of proximal femur, the central portion of the acetabulum and the proximal thigh 
musculature were drawn manually on a radiology workstation (Viewforum, Philips 
Medical System) (Figure 1). Time-intensity curves were recorded and processed on 
an offline computer. Two perfusion indices were measured.  These were maximum 
enhancement (Emax), defined as the maximum percentage increase in signal 
intensity from baseline and enhancement slope (Eslope), defined as the rate of 
enhancement between 10% and 90% of the signal intensity difference between 
baseline and maximum signal intensity (Figure 2). Both parameters are derived from 
the first-pass phase of signal enhancement and are considered to represent arrival 
of contrast material into the arteries and capillaries and its diffusion into the 
extracellular space (Cova M et al. 1991). 
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Statistical analysis. Data was presented as mean and standard deviation, unless 
otherwise stated. Subjects were grouped as normal, osteopenia or osteoporosis 
according to total hip T-score. Normal Q-Q plot and box plots were employed to 
examine normality of parameters and identify outliers. Perfusion parameters were 
logarithmically transformed to correct positive skewness. As the fat content 
parameters were negatively skewed, they were all first subtracted by 100 and then 
log-transformed to correct negative skewness. The transformed parameters were 
compared among the three groups- normal, osteopenia and osteoporosis using 
linear trend test and analysis of covariance (ANCOVA) for adjusting age. Post Hoc 
multiple comparisons were conducted for those significant parameters using 
Bonferroni’s correction. Pearson correlation coefficients were calculated to assess 
the linear relationship between different pairs of parameters. Multiple regression 
analysis was performed to uncover variables (age, perfusion indices, fat content) 
significantly associated with bone mineral density. Path analysis was used to 
examine the causal relationships between age, fat content, marrow perfusion and 
BMD. Relationships were modeled using a series of linear structural equations. All 
model tests were based on a covariance matrix and used maximum likelihood 
estimation as implemented in Lisrel 8.50. The validity of the models was evaluated 
and compared using Chi square statistic, goodness-of-fit index (GFI), comparative-fit 
index (CFI), non-normed-fit index (NNFI), root mean square error of approximation 
(RMSEA) and standardized root mean square residual (SRMR). Receiver operating 
characteristic (ROC) analysis was employed to investigate the discriminating ability 
of each parameter for predicting osteoporosis with area-under-ROC curve (AUC) 
being used as a measure of the global performance of each parameter as an 
effective predictor. The value corresponding to the nearest point of the ROC curve to 
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the top left-hand corner was chosen as the optimal threshold in that it maximizes 
both sensitivity and specificity (with equal weighting). Test-retest reliability of each 
measured parameter was assessed using intra-class correlation coefficient on 
absolute agreement. All statistical analyses were done using SPSS 14·0 (SPSS Inc). 




Relationship between marrow fat content and bone mineral density. As BMD 
decreased, marrow fat content tended to increase in the femoral head (r = -0·334, 
p<0·01), femoral neck (r = -0·370, p<0·01) and shaft (r = -0·412, p<0·01) (Table 2). 
Subjects with osteoporosis had a significantly higher marrow fat content in the 
femoral head (p=0·001), femoral neck (p<0·001) and femoral shaft (p<0·001) than 
normal BMD subjects (Table 1). Similarly, subjects with osteopenia had a 
significantly higher marrow fat content in the femoral neck (p<0·001) and femoral 











Table 1.  Characteristics, fat content and perfusion indices of subjects with 
































-1·73 (0·41) -2·98 (0·51) <0·001 <0·001a,b,c 






















































68·62 (15·84) 0·584 0·937 
Enhancement 
slope (%/sec) 






























1·74 (0·76) 2·03 (1·09) 0·292 0·460 
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Data presented as mean (sd) 
# ANCOVA test among the three groups adjusting for age; 
* ANOVA test among the three groups; 
a post hoc test with Bonferroni’s correction showed significant difference between normal 
and osteopenia groups after adjusting for age; 
b post hoc test with Bonferroni’s correction showed significant difference between 
osteopenia and osteoporosis groups after adjusting for age; 
c post hoc test with Bonferroni’s correction showed significant difference between normal 
and osteoporosis groups after adjusting for age. 
 
Relationship between marrow perfusion and bone mineral density.  As BMD 
decreased, there was a corresponding decrease in bone marrow perfusion indices in 
the femoral head, femoral neck, femoral shaft, and acetabulum (Tables 1 and 2). 
This effect was most noticeable in the acetabulum, femoral neck and femoral head 
and least noticeable in the femoral shaft (Tables 1and 2). Except for Emax in the 
femoral head, subjects with osteoporosis had a significantly lower mean Emax and 
Eslope than normal BMD subjects (Table 1). This difference was most noticeable in 
the femoral neck and acetabulum (Table 1). While univariate analysis showed that 
many perfusion indices were associated with reduced BMD, multivariate regression 
analysis showed that, among the variables tested, Emax of the acetabulum and Eslope 











Table 2.  Correlation between perfusion indices, fat content and BMD in femoral head, neck, 
shaft, acetabulum and adductor thigh muscle 
 
 Vs BMD (g/cm2) Vs Fat content (%)  
Enhancement max. (%)   
Femoral head           0.241* -0.614 **, ‡ 
Femoral neck  0.417 ** -0.855 **, ‡ 
Femoral shaft            0.237 * -0.653 **, ‡ 
Acetabulum    0.538 **, † nm 
Muscle          -0.046 nm 
Enhancement slope (%/sec)   
Femoral head    0.382 **, † -0.549 **, ‡ 
Femoral neck  0.396 ** -0.768 **, ‡ 
Femoral shaft            0.168 -0.647 **, ‡ 
Acetabulum 0.512 ** nm 
Muscle          -0.052 nm 
Fat content (%)   
Femoral head         -0.316**  
Femoral neck          -0.367 **  
Femoral shaft          -0.407 **  
nm = not measured; 
**p<0.01 &  *p<0.05 in univariate analysis;  
† independently significantly (p<0.05) associated with BMD in multiple regression analysis; 
 bivariate correlation analysis was done for corresponding fat content at these sites; 








Figure 2A, B,C 
 
Time-intensity curve of femoral 
neck for different subjects with (A) 
normal bone density showing high 
maximum enhancement (Emax) and 
steep enhancement slope (Eslope), 
(B) osteopenia showing 
decreased maximum 
enhancement and less steep 
enhancement slope and (C) 
osteoporosis showing the least 
maximum enhancement and 







Relationship between marrow perfusion and fat content.  As bone marrow 
perfusion decreased, there was a corresponding increase in bone marrow fat 
content for all bone areas examined (r = -0·827). For example, as Emax decreased, 
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there was an increase in fat content in the femoral head (r = -0·614), femoral neck (r 
= -0·855) and shaft (r = -0·653) (Table 2). Similarly, as Eslope decreased, there was 
an increase in fat content in the femoral head (r = -0·549), femoral neck (r = -0·768) 
and shaft (r = -0·647) (Table 2).  
 
Relationship between muscle perfusion and bone mineral density.  Although 
bone perfusion indices significantly decreased, muscle perfusion indices did not 
change with a decrease in BMD (p>0·05) (Table 2). Both Emax (p=0·858) or Eslope 
(p=0·426) of the adductor thigh muscle remained unchanged in subjects with 
osteoporosis, osteopenia or normal BMD (Table 1).  
 
Relationship between marrow perfusion, fat content and bone mineral density. 
Since factor loadings of marrow fat content (0.90) and bone marrow perfusion (0.86) 
of the femoral neck were the largest, the femoral neck was chosen for path analysis. 
The path diagram is shown in Figure 2. All path coefficients were significant (p<0.05). 
The Chi square statistic, goodness-of-fit index (GFI), comparative fit index (CFI), 
non-normed fit index (NNFI), root mean square error of approximation (RMSEA) and 
standardized root mean square residual (SRMR) were respectively 3.287, 0.987, 
0.998, 0.996, 0.025 and 0.051. All the fit indices indicated the model fitted the data 
very well. The model explained 17.8%, 73.1% and 5.5% of the variance in marrow 
fat content, bone marrow perfusion and bone mineral density respectively.  
According to the fitted model, (i) bone mineral density and age, (ii) bone mineral 
density and fat content and (iii) perfusion and fat content are all inversely related as 
previously noted. The model indicated that there was a direct effect of marrow fat 
content on bone marrow perfusion and an indirect effect of age via bone mineral 
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density and then via fat content on bone marrow perfusion (Figure 3). There is no 
significant direct effect of bone mineral density on bone marrow perfusion (Figure 3). 
Increase in fat content seemed to be the main contributor to reduction in bone 
marrow perfusion (Figure 3). 
 
Figure 3. Path analysis of age, BMD, marrow fat content and marrow perfusion. The model 
indicates a direct effect of marrow fat content on perfusion and indirect effect of age via BMD 
and then via fat content on perfusion. There is no significant direct effect of BMD on perfusion. 
An increase in fat content contributes to the reduction in perfusion. 
 
Usefulness of perfusion and fat content indices in predicting osteoporosis.  
The overlap observed in perfusion and fat content indices the three subgroups 
(osteoporosis, osteopenia, normal bone density) indicated that these parameters in 
isolation are not likely to be of clinical use in predicting osteoporosis, osteopenia or 
normal bone density. ROC analysis of all parameters confirmed this impression. 
ROC analysis indicated the two best predictors of osteoporosis to be Emax in the 
acetabulum and neck of femur. An acetabulum Emax of <15·05 yielded a 79% (95% 
CI, 61–91%) sensitivity and 72% (61–81%) specificity in predicting osteoporosis 
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while for the femoral neck an Emax of <9·05 yielded a 70% (61–85%) sensitivity and 
69% (57–79%) specificity.  
 
Relative reduction in perfusion indices between different segments of proximal 
femur  
Relative reduction in MR perfusion indices in osteopenic and osteoporotic subjects 
compared with normal BMD subjects is shown in Fig 2. In both male and female 
subjects, as BMD decreased, perfusion indices in the femoral neck decreased to a 
larger degree than those in the femoral head and shaft. This relative reduction in 
perfusion indices in the femoral neck was more apparent in osteopenic than 
osteoporotic subjects.   
 
Figure 4. Relative reduction 
in (A) Emax and (B) Eslope in 
femoral head, neck and 
shaft in subjects with 
osteopenia (n=47) and 
osteoporosis (n=34) 
compared to those with 
normal BMD (n=39). 
Perfusion indices reduced 
most in the femoral neck 






SIGNIFICANCE OF THESE FINDINGS 
The main finding of Study 4 is showing for the first time that osteoporosis and 
osteopenia of the proximal femur and acetabulum is associated with reduced bone 
perfusion compared to normal bone density subjects. This concurs with our findings 
in Study 1 and study 2 of the lumbar spine.  This study, by providing direct evidence 
of reduced perfusion in osteoporotic bone, strengthens the link between vascular 
disease and osteoporosis.  
 The second main observation of this study is that the reduced perfusion observed in 
osteoporosis of the hip region is an intraosseous occurrence rather than a reflection 
of a more generalized circulatory impairment. While bone perfusion decreased with 
reduced BMD in the proximal femur and acetabulum, no corresponding change in 
perfusion in the adductor thigh musculature was observed. Both the proximal femur 
and the adductor thigh musculature are both supplied by the profunda femoris artery. 
The proximal femur is supplied via the medial circumflex artery, the first branch of 
the profunda femoris artery (Gautier E et al. 2000), while the adductor thigh 
musculature is supplied by perforating muscular branches which arise from the 
profunda femoris just distal to the medial circumflex artery (Angrigiani C et al. 2001). 
The acetabulum is supplied by the internal iliac artery via the superior gluteal, inferior 
gluteal and obturator arteries (Beck M et al. 2003). The reduced perfusion observed 
within bone is of bony rather than systemic or extraosseous origin since if the latter 
were the case, both bone and muscle should have been affected as they have the 
same arterial supply. Bridgeman et al have shown, in an anatomical study, 
progressive occlusion of the intramedullary arteries in the proximal femur with age 
leading to increasing reliance on periosteal circulation for perfusion of cortical bone 
(Bridgeman G et al. 1996), while Laroche et al showed that intraosseous arterioles 
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or arterial capillaries were reduced in number in patients with proximal femoral 
osteoporosis with more frequent arteriosclerotic vascular lesions (rupture of internal 
elastic lamina, medial thickening and fibrosis) (Laroche M et al. 1995). Our study 
confirms that intraosseous perfusion is reduced in osteoporotic and osteopenic bone 
while extraosseous perfusion remains unaffected. These changes are similar to 
those shown in Study 2 of the lumbar vertebrae where vertebral marrow perfusion 
decreased in osteoporosis though paravertebral muscle with the same blood supply 
as the vertebrae remained unaffected. This change in emphasis between 
intraosseous and extraosseous perfusion in normal and osteoporotic patients may 
help explain some of the different patterns of bone deposition and apposition noted 
in osteoporosis. With aging bone resorption occurs preferentially on the trabecular 
and endocortical surfaces while bone apposition preferentially on the periosteal 
surface (Seeman E et al. 2002, Seeman E et al. 2007). 
The third main finding is that as bone marrow perfusion decreased in the proximal 
femur, there was a reciprocal rise in marrow fat content. This reciprocal arrangement 
between marrow perfusion and marrow fat has not been recognized until we 
performed Study 1 and Study 2. Marrow fat content increases with both age and 
osteoporosis. The latter may simply reflect increased size or number of fat cells 
replacing lost bone (Rozman C et al. 1989, Justesen J et al. 2001). This current 
study shows that proximal femoral osteoporosis is associated with reduced marrow 
perfusion and reciprocal increased marrow fat content. An effect of perfusion on 
differentiation of marrow mesenchymal stem cells may account of this observation. 
The mesenchymal stem cell acts as a common precursor for osteoblasts and 
adipocytes in the bone marrow (Gimble JM et al. 2004). Differentiation along 
osteoblast or adipocyte lines is influenced by oxygen tension and oxidative stress 
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(D’lppolito G et al. 2006, Fatokun AA et al. 2006, Shouhed D et al. 2005, Kha HT et 
al. 2004). Decreased oxygen tension or increased oxidative stress favors adiopocyte 
over osteoblast precursor development (D’lppolito G et al. 2006, Fatokun AA et al. 
2006, Shouhed D et al. 2005, Kha HT et al. 2004). Reduced marrow perfusion, as 
shown in this study, is likely to decrease oxygen tension and increase oxidative 
stress within the marrow. This change in microenvironment may effect mesenchymal 
stem cell maturation inducing adipocyte formation (i.e. increased marrow fat) over 
osteoblast formation (i.e. decreased BMD) (Duque G et al. 2007). Path analysis of 
this study indicated that an increase in marrow fat content yielded a greater 
contribution to decreased marrow perfusion than decreased bone mineral density.  
Longitudinal study, rather than cross-sectional study as performed here, should 
clarify this relationship more definitively. Also separate analysis of the trabecular 
bone (rather then cortical bone and trabecular bone as performed in this study) may 
help clarification.  
The femoral head is an area particularly susceptible to avascular necrosis and 
subchondral insufficiency fracture. For normal bone density subjects, perfusion 
indices in the femoral head were approximately one-third of those of the femoral 
neck or shaft and one-fifth of those in the acetabulum. Perfusion indices in the 
femoral head further decreased in osteoporotic subjects thorough the effect was not 
as pronounced as in the femoral neck, shaft or acetabulum. This helps explain why 
avascular necrosis of the femoral head is not an accompaniment of osteoporosis per 
se though is a frequent accompaniment of osteoporotic-induced femoral neck 
fracture.  
The femoral neck shows the most marked reduction in blood perfusion indices 
(Figure 4). One possible explanation of this observation is that the femoral neck 
 147 
region tends to have greater portion of red marrow compared with proximal femur 
shaft and femoral head (Berg et al 1997), and associated reduction in red marrow 
volume is one of the likely causes of reduced bone perfusion seen in osteoporosis 
(Study 7). Osteoporosis is associated with an increased incidence of femoral neck 
fractures with femoral neck BMD being a strong predictor of femoral neck fracture 
susceptibility (Rivadeneira F et al 2007). The femoral neck is strongly dependent on 
trabecular bone for its strength. Trabecular bone receives all of its blood supply from 
the marrow cavity as opposed to cortical bone which has an additional supply from 
the periosteal arteries. Bone perfusion is directly associated with bone remodeling 
activity (Reeve J et al. 1998) which in turn is directly associated with fracture risk 
(Garnero P et al. 2004; Johnell O et al. 2002)  Insufficiency fracture probably results 
from impaired bone remodeling leading to an accumulation of trabecular 
microdamage and microfracture progressing eventually to a clinically apparent 
complete fracture. As repair of any tissue requires an adequate blood supply to 
deliver oxygen and nutrients, impaired blood supply to the femoral neck trabecular 
bone may well be a contributory factor to microfracture accumulation, trabecular 
fracture propagation and eventual insufficiency fracture.   
Delayed union and osteonecrosis due to femoral neck fracture nonunion are also 
relevant in the proximal femur (Matthews V et al. 2004). Nonunion occurs in 30–43% 
(Saito et al 1995, Jackson et al 2002, Hedstrom M et al. 2004) displaced 
intracapsular femoral neck fractures. One prospective multicenter study of 1503 
patients with fractured neck of femur analysed the incidence of delayed union and 
avascular necrosis. In displaced intracapsular fractures of the proximal femur treated 
by reduction and fixation, the prevalence of osteonecrosis was 28% while the rate of 
nonunion was 33% and with only 14% of fractures being united at 6 months (Barnes 
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R et al. 1976).   On the other hand, in another study of patients younger than 50 
years, all proximal femoral fractures healed satisfactorily even those occurring in 
patients with high-energy trauma. Increasing age and low bone mass clearly 
influence the healing of femoral neck fractures and this may be related to an 
underlying perfusion deficit. In other words, impaired perfusion is probably 
influencing both the development of and healing of proximal femoral insufficiency 
fractures  
Limitations of this study. 
1. As this was a cross-sectional study, we could not investigate whether a causal or 
temporal relationship existed between a decrease in bone perfusion, an increase 
in marrow fat and osteoporosis. This study does not explore whether these 
changes are primary or secondary to the development of osteoporosis nor does it 
explore the molecular and cellular events behind these changes as well as the 
effect, if any, on fracture risk.  
2. As DXA was used as a measure of bone density, bone mass measurements for 
specific areas of interest (head, neck, shaft, and acetabulum) were not available. 
Bone densitometry of specific areas of the proximal femur and acetabulum would 
require the use of quantitative computed tomography densitometry. 
3. Muscle perfusion was measured in a similar fashion to marrow perfusion but 
orther local factors which may influence muscle perfusion such as muscle bulk 
and fatty replacement were not evaluated.  
Conclusion. Very similar changes are seen in the proximal femur as previously 
noted in the lumbar spine (Study 1 and Study 2). Reduction in perfusion only affects 
the bone and was not seen to effect the adductor musculature which has the same 
arterial supply. With decreasing BMD, reduced perfusion is most noticeable in the 
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femoral neck. The femoral head has increased marrow fat and decreased perfusion 
compared to all other areas irrespective of BMD.  
 
Next phase of study. Following on from this study, if one wishes to perform 
longitudinal MR-based assessment of marrow fat fraction or perfusion, one would 
first need to know the reproducibility of these MR-based tests. This forms the basis 
of Study 5.   
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STUDY 5  
What is the reproducibility of MR perfusion studies and 
1
H 
spectroscopy of bone marrow?  
 
Aim: This study was performed to examine the reproducibility of MR bone marrow 
1H MR spectroscopy and dynamic contrast-enhanced perfusion studies. 
 
Relevance of this study 
MR proton (1H) spectroscopy is the most commonly used method to quantify marrow 
fat content while dynamic contrast-enhanced imaging is the most commonly used 
method to assess bone marrow perfusion. As shown in Study 1, Study 2 and Study 4, 
cross-sectional observational studies can be performed to study the relationship 
between these physiological features and bone disease. However, when one wants 
to investigate the longitudinal relationship between marrow fat content or perfusion 
and disease onset or progression or alternatively study the effect of intervention, it is 
critical to first know the reproducibility of the test being undertaken. This study was 








What is the reproducibility of MR perfusion studies and 
1
H spectroscopy of bone marrow?  
 
36 healthy subjects (72.9 ± 2.9 years) underwent paired MR examinations at baseline and 
returned for follow-up MRI assessment one week following baseline 
 MR Spectroscopy of proximal femur with assessment of marrow fat in femoral head, neck and 
shaft. 
 Dynamic-contrasted enhanced MR imaging of proximal femur with assessment of perfusion in 




 Reproducibility of MRS ranged from 0.78 – 0.85, being highest in the femoral head and 
lowest in the femoral neck. 
 Reproducibility of MR perfusion imaging ranged from 0.59 – 0.98, being highest in the 
acetabulum and lowest in the femoral head. 
 Overall reproducibility of 1H MR spectroscopy and MR perfusion imaging is sufficiently high 
to warrant use in clinical trials. 





Purpose: MR 1H proton spectroscopy and dynamic contrast-enhanced imaging are 
the most common used methods of quantifying marrow fat volume fraction and 
marrow perfusion respectively. Before longitudinal studies investigating the influence 
of marrow fat content and perfusion on bone diseases are undertaken, one should 
first determine the test reproducibility of these techniques. This study was 
undertaken to measure this reproducibility.    
Materials and Methods:  36 subjects (17 females, 19 males, mean age 72.9 ± 2.9 
years) who underwent  MR spectroscopy and /or dynamic-contrast enhanced  
perfusion study of the proximal femur were asked to return after one week for a 
repeat MR examination.  
Results: Reproducibility of 1H MR spectroscopy in all bone areas tested was high 
ranging from 0.78 to 0.85 with highest reproducibility being in the femoral head and 
lowest in the femoral neck. Reproducibility of paired perfusion measurements ranged 
from 0.59 (enhancement slope femoral head) to 0.98 (enhancement maximum 
acetabulum). Overall reproducibility of proton spectroscopy and dynamic contrast-
enhanced imaging tended to be best in areas with highest inherent fat fraction or 
perfusion. 
Conclusion:  Reproducibility of MR proton spectroscopy or perfusion imaging is 
sufficiently high to warrant these techniques being applied to the longitudinal study of 





STUDY DETAIL:  
MATERIAL AND METHODS 
Patient Selection and Data Collection. Thirty six elderly subjects (17 females, 19 
males, mean age 72.9 ± 2.9 years, range 69-78 years) who underwent 1H MR 
spectroscopy with or without dynamic-contrast enhanced MR perfusion study of the 
proximal femur were asked to return again at the same time the following week for a 
repeat MR examination. All subjects had been recruited from local community 
centers as part of another on-going non-interventional osteoporosis study. The 
Institutional Clinical Research Ethics Committee approved the study (Appendix) with 
all subjects providing informed signed consent.  All subjects were clinically healthy 
with no known systemic metastatic disease or disease in the hip region.  
MR examinations were performed on a 1.5 T whole-body MR imaging system (Intera 
NT, Philips). The MR technique and method of analysis were identical to that 
described in Study 4. A detailed MR protocol was available for reference in the MR 
suite. To simulate clinical practice as closely as possible, the same technologist did 
not perform or oversee all examinations. Similarly, the supervising radiologist did not 
oversee patient positioning, coil positioning etc. The same person did all the data 
analysis for both the first and second visits. Analysis of all regions in each proximal 
femur (spectroscopy and perfusion) took approximately one hour to complete.  
Statistical Analysis.  Prior discussion with a biostatistician indicated that it would 
not be incorrect to include subjects of different gender and BMD in this study as 
large differences in the parameters to be measured (fat content and perfusion 
indices) between these subjects did not exist provided they were around same age 
group. Random selection of 20 ~ 30 subjects is a usual practice when performing a 
test-retest study.  Test-retest reliability of each paired parameter was assessed 
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using intra-class correlation coefficient on absolute agreement. An inter-class 
correlation coefficient (ICC) of >0.8 indicates almost full agreement, 0.6–0.8 
substantial agreement, 0.4–0.6 moderate agreement and <0.4 poor agreement. All 
statistical analyses were done using SPSS 14.0 (SPSS Inc). All statistical tests were 
two-sided. A p-value <0.05 was considered statistically significant. 
 
RESULTS 
All 36 subjects underwent paired MR spectroscopy studies while 29 of the 36 
subjects underwent paired perfusion studies. Regarding the seven subjects who did 
not undergo paired perfusion studies, in four subjects, examination was limited to 
MR spectroscopy due to marginal impairment of renal function while the remaining 
three subjects declined contrast injection on the second MR visit. Results for the 
reproducibility of 1H MR spectroscopy and perfusion indices for paired MR 
examinations performed at one week interval is shown in Table 1. An example of 
paired spectra from the same VOI in the femoral neck in a patient is shown in Figure 
1. Of 36 subjects who underwent paired spectroscopy examinations, satisfactory 
paired spectroscopy spectra were obtained from the femoral head in all cases, from 
the femoral neck in 33 (92%) of 36 cases and from the femoral shaft in 34 (94%) of 
36 cases. The reproducibility of 1H MR spectroscopy in all of these areas was high 
ranging from 0.78 to 0.85 with the highest reproducibility being in the femoral head 




Figure 1. Spectra acquired 
from femoral neck from same 
patient at one week interval 
showing good reproducibility. 
Marrow fat content measured 
at week 0 was 83.1% while 
same measurement was 
82.8% one week later. 
 
 
Of 29 subjects who underwent paired MR perfusion studies, a satisfactory perfusion 
time-intensity curve was obtained from the acetabulum and the adductor thigh 
musculature in all cases. Satisfactory paired perfusion curves were obtained from 
the femoral head in 20 (69%) of the 29 subjects, from the femoral neck in 25 (86%) 
subjects and from the femoral shaft in 24 (83%) subjects. An example of paired 
perfusion time-series data obtained at one week interval from the same ROI drawn 
in the femoral neck is shown in Figure 2. The reproducibility of paired perfusion 
measurements was more variable than those of spectroscopy ranging from 0.59 





Figure 2. Time-intensity 
curves from femoral neck of 
same subject at one week 
interval showing fairly good 
reproducibility. At week 0, 
maximum enhancement and 
enhancement slope were 
19.9% and 0.84 %/sec 
respectively; while at week 
1, these same 
measurements were 17.3% 
and 0.88 %/sec 
respectively.   
 





 (95% confidence intervals) 
  1
st
 test  2
nd
 test  
Fat content (%)     
Femoral head 36 89.39 (3.10) 89.43 (3.71) 0.85 (0.73, 0.92) 
Femoral neck 33 86.01 (5.34) 85.37 (6.33) 0.78 (0.60, 0.88) 
Femoral shaft 34 83.47 (7.89) 82.64 (9.26) 0.83 (0.69, 0.91) 
     
Enhancement max (%)     
Femoral head 20 3.09 (1.17) 2.89 (1.07) 0.77 (0.52, 0.90) 
Femoral neck 25 10.12 (6.84) 9.53 (6.42) 0.94 (0.87, 0.97) 
Femoral shaft 24 11.31 (7.55) 12.64 (7.40) 0.77 (0.54, 0.89) 
Acetabulum 29 17.00 (10.24) 16.68 (9.73) 0.98 (0.95, 0.99) 
Adductor muscle 29 54.48 (25.30) 51.46 (29.26) 0.84 (0.69, 0.93) 
     
Enhancement slope (%/sec)     
Femoral head 20 0.10 (0.07) 0.10 (0.06) 0.59 (0.22, 0.81) 
Femoral neck 25 0.39 (0.32) 0.39 (0.34) 0.90 (0.79, 0.96) 
Femoral shaft 24 0.44 (0.35) 0.46 (0.31) 0.82 (0.62, 0.92) 
Acetabulum 29 0.84 (0.48) 0.78 (0.47) 0.87 (0.75, 0.94) 
Adductor muscle 29 1.93 (1.73) 1.86 (1.85) 0.92 (0.84, 0.96) 
 
Table 1.  Reproducibility of paired MR spectroscopy and perfusion indices of proximal femur. N = 
number of successful paired spectroscopy or perfusion studies who underwent repeat MR 





SIGNIFICANCE OF THESE FINDINGS 
This is the first study to examine the reproducibility of bone marrow MR 
spectroscopy and perfusion imaging. We choose to study the proximal femur rather 
than the vertebral body as inherent segmental variability in perfusion and fat content 
along the proximal femur (Study 4) was likely to yield a more rigorous assessment of 
test reproducibility. 
Functional MR imaging, particularly when assessing perfusion of discrete areas, 
such as a bone segment, differs from standard post-contrast MR imaging in that 
particular care must be exercised to ensure uniformity of positioning and 
examination technique, contrast agent injection rate, dosage and timing of image 
acquisition. The protocol should be clear, precise and detailed, and the examination 
and analysis carried out by experienced personnel familiar with the examination 
protocol. Failure to obtain uniformity in examination and analysis will undermine data 
reproducibility. In addition, optimal shimming at different anatomical locations may 
be difficult to achieve. To ensure good reproducibility care must be taken to ensure 
that both the vertical or lateral positioning of the volume, distance to other structures 
such as large blood vessels and air spaces, and shim settings must be carefully 
controlled. 
This study shows that the overall reproducibility of MR perfusion and single voxel 
spectroscopy of proximal femur bone marrow is high though, as expected, tends to 
be dependent on the fat content or perfusion of the bone area being assessed. For 
example, the success rate and reproducibility of MR spectroscopy was greatest in 
the femoral head where the fat content is higher than the femoral neck or shaft. 
Similarly, perfusion indices were most reproducible for the acetabulum which has the 
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highest perfusion indices and least reproducible in the femoral head which has the 
lowest perfusion indices.  
Limitations of this study: 
 Only two perfusion parameters were evaluated namely maximum 
enhancement (Emax) and enhancement slope (Eslope). These are the two most 
commonly applied parameters. Other more in depth two compartmental 
pharmokinetic models (Brix and Toft) are available though these have not 
been commonly used and have not been evaluated for the bone marrow 
perfusion. 
 Study was performed at 1.5T. The results are likely to be improved at 3T.  
 
Conclusion. The test reproducibility of MR spectroscopic and perfusion studies of 
bone is high though is dependent on the fat content or perfusion of the area being 
measured.  Overall the reproducibility of these techniques is sufficiently high to 
indicate that MR proton spectroscopy or perfusion imaging can be applied 
longitudinally to evaluate either the longitudinal relationship or effect of therapeutic 
intervention between bone disease and marrow fat content or perfusion.    
 
Next phase of study. Study 1, 2 and 4 showed that marrow fat fraction is increased 
in osteoporosis. Does marrow fat composition also change? This is relevant since 
certain long-chain polyunsaturated fats in the diet have been shown to be associated 
with reduced BMD while in culture long-chain polyunsaturated fatty acids have been 




 STUDY 6  
Marrow fat content increases but does the composition of 
marrow fat change in osteoporosis? 
 
Aim: To investigate (a) whether bone marrow fat composition is altered in subjects 
of varying BMD; (b) whether regional differences in marrow fat composition exist and 
(c) whether differences in composition exist between marrow and subcutaneous fat.  
 
Relevance of this study: 
We have shown in Study 1, Study 2 and Study 4 how marrow fat is increased in 
subjects with low bone mass and osteoporosis. This accumulation of marrow fat may 
simply represent a passive process with fat occupying space vacated by trabecular 
bone or it may be indicative of a more active process with marrow fat actively 
accumulating at the expense of bone centered on a change in stromal cell 
differentiation from an osteoblastic to an adipocytic pathway (Duque G et al. 2008). 
This has lead to the suggestion that osteoporosis may be a type of lypotoxic disease 
with osteoporosis being the ‘obesity of bone’ (Duque G et al. 2008, Rosen CJ et al. 
2006). 
 
Marrow fat content increases as BMD decreases but does the composition of 
marrow fat remain the same or does marrow fatty acid composition also change? 
This question is relevant given that fatty acids have been shown to influence bone 
metabolism in vitro (Coetzee M et al. 2007, Poulsen RC et al. 2008, Maurin AC et al. 
2002, Musacchio E et al. 2007, Coetzee M et al. 2007) while animal studies 
(Poulsen RC et al. 2006, Poulsen RC et al. 2007, Watkins BA et al. 2000, Reinwald 
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S et al. 2004) and data in humans from NHANES (Corwin RL et al. 2006) indicate 
that dietary fatty acid composition may affect BMD. Marrow fat is a major component 
of trabecular bone microenvironment. It is conceivable that changes in marrow fat 
composition over and above increases in the amount of marrow fat could affect bone 
metabolism and contribute to the development of osteoporosis. No previous studies 
have investigated the relationship between marrow fatty acid composition and BMD.  
To address this issue, we analyzed the fatty acid composition of bone marrow and 
subcutaneous tissue samples from subjects undergoing orthopedic surgery and 

















Does the composition of marrow fat change in osteoporosis?  
 
126 healthy subjects (98 females 34 males, 69.7 ± 10.5 years) 
 
 Marrow and subcutaneous fat samples obtained from each patient at time of 
orthopedic surgery. 
 DXA examination lumbar spine and right hip within one week of sample 
collection. 





 22 fatty acids identified in marrow and subcutaneous fat. 
 Significant differences in marrow fat composition found between marrow and 
subcutaneous fat as well as between marrow fat obtained from proximal femur 
and proximal tibia. 
 Other than minor differences likely to be inconsequential, no difference in marrow 
fatty acid composition was evident between subject groups of varying BMD 
(normal, low bone mass, and osteoporosis). 
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ABSTRACT: 
Purpose: To investigate the fatty acid composition in subjects of varying bone 
mineral density (BMD).  
Methods: Samples of marrow fat and subcutaneous fat from 126 subjects (98 
females, 34 males, mean age 69.7 ± 10.5 years) undergoing orthopedic surgery 
were analyzed for fatty acid composition using gas chromatography. These results 
were correlated with BMD assessed by DXA.  
Findings: A total of 22 fatty acids were identified in marrow and subcutaneous fat. 
Significant differences in fatty acid composition existed between marrow and 
subcutaneous fat as well as between marrow fat samples obtained from the proximal 
femur and proximal tibia. Other than cis-7-hexadecenoic acid [C16:1 (n=9)] and 
docosanoic acid [C22:0], no difference in marrow fatty acid composition was evident 
between subject groups of varying BMD (normal, low bone mass, and osteoporosis).  
Conclusion: There exists a wide range of individual fatty acids in marrow fat. 
Marrow fatty acid composition differs from that of subcutaneous fat and varies 
between predominantly erythropoetic and fatty marrow sites. Other than cis-7-
hexadecenoic acid [C16:1 (n=9)] and docosanoic acid [C22:0], no difference in 






MATERIALS AND METHODS 
Subjects.  Bone marrow and subcutaneous fat of 126 subjects (94 females, 32 
males, mean age 69.7 ± 10.5 years) of Chinese descent were extracted while 
undergoing elective orthopedic surgery (comprising Austin-Moore hemiarthroplasty 
n= 32; total hip arthroplasty n=6; total knee arthroplasty n=80; transforaminal lumbar 
interbody fusion n=5  and posterior spinal fusion n=3). Subject demographics 
including age, BMD and T-score are shown in Table 1. Informed signed consent was 
obtained from each patient to participate in this study prior to surgery. The study 
protocol and patient consent forms were approved by the Ethics Committee, 
Chinese University of Hong Kong.  
TABLE 1: Demographic and descriptive statistics for male and female subjects 
Demographic data Overall Male Female 
Number of subject  126 32 94 




) 0.89±0.20 1.00±0.19 0.85±0.19 
T-score -0.82±1.54 0.05±1.19 -1.15±1.53 
Cohorts 
Normal 48 20 28 
Low bone mass 29 5 24 





) 0.65±0.15 0.71±0.17 0.63±0.14 
T-score -2.09±1.42 -1.64±1.04 -2.25±1.50 
Cohorts 
Normal 25 9 16 
Low bone mass 46 15 31 
Osteoporosis 49 7 42 
 
Table 1.  Subject age, BMD and T-score data of all subjects (overall, male and female 
subjects) as well as different bone density cohorts (normal, low bone mass and osteoporosis) 
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Collection of bone marrow and subcutaneous fat samples. Marrow fat samples 
were obtained immediately after the bone was transected and prior to cleansing or 
instrumentation. A small quantity of marrow fat (3-5 ml) was extracted from the 
transected bone and transferred to a sterile glass bottle containing no saline, 
preservatives or other solution. For operations around the hip or knee, the marrow 
fat sample was obtained from the diaphyseal end of the transected femur or tibia 
respectively (Figure 1). During the same operation, a small quantity (approximately 
2cm3) of subcutaneous fat was removed from the site of surgical incision prior to 
cleansing and transferred to a separate sterile dry glass bottle (Figure 2). The 
marrow fat sample was stored in a freezer at -80oC while the subcutaneous fat was 
stored at -20oC until both samples were sent to the Chemistry Department for gas 
chromatography analysis within one week of collection.   
 
Figure 1. Aspiration of marrow 
fat from proximal tibia during 




Figure 2. Sample of 
subcutaneous fat removed 




Gas chromatography analysis of fatty acids. Total lipids derived from human 
bone marrow and subcutaneous fat were first extracted in chloroform-methanol (2:1 
vol/vol) containing heptadecanoic acid (C17:0) as an internal standard for fatty acid 
quantification. The fatty acids in extracted lipids were then converted to the 
corresponding methyl esters with 14% boron trifluoride in methanol and toluene (2:1 
vol/vol) under nitrogen gas at 90°C for 60 min. The fatty acid methyl esters were 
analyzed on a flexible silica capillary column (Innowax 19091N-213, 30m × 0.32mm 
internal diameter; J&W Scientific, Folsom, CA, USA) in a Shimadzu gas–liquid 
chromatograph equipped with a flame-ionization detector (GC 2010, Shimadzu, 
Kyoto, Japan). Column temperature was programmed from 150°C to 200°C at a rate 
of 15°C/min, then from 200°C to 250°C at a rate of 2°C/min and then held for 5 min. 
Injector and detector temperatures were set at 220°C and 270°C, respectively. The 
carrier gas used was helium at a head pressure of 15 psi. Each fatty acid methyl 
ester was quantitatively calculated on the basis of the proportion in each 
chromatogram of the internal standard added to each sample (Figure 3). Fatty acid 
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composition was defined as the relative fraction of each type of fatty acid as a 
percentage of the total fatty acid composition.  
 
Figure 3. Gas 
chromatography spectrum of 
marrow fat. Each fatty acid 
methyl ester is quantified 
based on peak high relative 
to internal standard.  
 
 
DXA examination. Dual energy x-ray absorpiometry (DXA) of the lumbar spine (L2-
L4) and right hip (or left hip if patients had operation in right hip/knee) was performed 
on all subjects using the same DXA system (Norland XR-46). Left hip was examined 
if operation had been performed on the right side. DXA was performed 4-5 days 
post-operation in subjects following hip or knee arthroplasty and 6-7 days post-
operation for all other patients. For spinal surgery patients or those with a 
recognizable fracture on DXA, only femoral neck BMD was analyzed. Based on the 
lowest score either from the lumbar spine or the femoral neck, and using local 
reference data, each patient was assigned a T-score (Lynn HS et al. 2005). Subjects 
were grouped into three categories with normal bone mineral density defined as a T-
score greater than -1.0, low bone mass as a T-score between -1.0 and -2.5, and 
osteoporosis as a T-score less than -2.5. 
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Figure 4. DXA examination of 
right hip being performed. If 
right hip had been operated 
upon, contralateral hip was 
examined as well as lumbar 
spine. 
 
Statistical analysis. Paired T-test was used to test for differences in fatty acid 
composition between subcutaneous and marrow fat. Independent T-test was used to 
test for gender and regional differences in marrow fatty acid composition. Analysis of 
variance (ANOVA) was used to compare values in fatty acid composition across 
different bone density groups (normal, low bone mass, and osteoporosis). Pearson 
correlation was used to determine correlation between marrow fatty acid composition, 
individual fatty acid composition and bone mineral density. All statistical analysis was 
performed using the statistical package for social sciences (Version 13) (SPSS Inc., 




Marrow fatty acid composition. Bone marrow fatty acid composition for the whole 
cohort is shown in Table 2. Marrow fat was composed of 29% saturated fat, 51% 
monounsaturated fats and 20% polyunsaturated fats. A total of 22 individual fatty 
acids were identified in marrow fat (Table 2 and Appendix). The three most abundant 
fatty acids in human bone marrow were oleic acid [C18:1 (n-9)], palmitic acid [C16:0] 
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and linoleic acid [C18:2 (n-6)], which accounted for 44%, 23% and 18% of the total 
marrow fatty acids respectively. When gender differences were analyzed, marrow fat 
in males contained significantly higher eicosanoic acid [C20:0] (0.16±0.06% vs 
0.12±0.07%, p=0.011) and significantly higher cis-11-eicosenoic acid [C20:1(n-9)] 
(0.79±0.19% vs. 0.67±0.20%, p=0.004) content compared to females. For the 
remaining fatty acids, no significant gender difference in marrow fat content was 
apparent.   
 
No correlation was found between age and marrow fatty acid composition (p>0.05). 
Similarly the relative amount of n-3, n-6, monounsaturated fatty acids, or saturated 
fatty acids present in marrow fat remained unchanged with age  (p>0.05).  
 
Subcutaneous fatty acid composition. Subcutaneous fatty acid composition for 
the whole cohort is shown in Table 2. Subcutaneous fat was comprised of 23% 
saturated fats, 58% monounsaturated fats and 19% polyunsaturated fats. Similar to 
marrow fat, a total of 22 individual fatty acids were identified in subcutaneous fat 
(Table 2 and Appendix). Also similar to marrow fat, the most abundant fatty acids in 
human subcutaneous fat were oleic acid [C18:1 (n-9)], palmitic acid [C16:0] and 
linoleic acid [C18:2 (n-6)] which accounted for 47%, 19% and 17% of the total 
subcutaneous fatty acid respectively (Table 2 and Appendix). When gender 
differences were analyzed, subcutaneous fat in males contained a significantly 
higher amount of tetradecanoic acid [C14:0] (1.40±0.48% vs. 1.20±0.34%, p=0.037), 
significantly lower amount of cis-7-hexadecenoic acid [C16:1(n-9)] (0.74±0.16% vs. 
0.84±0.16%, p=0.004), significantly higher amount of cis-11-eicosenoic acid 
[C20:1(n-9)] (0.76±0.13% vs. 0.67±0.16%, p=0.006), significantly lower amount of 
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all-cis-5,8,11-eicosatrienoic acid [C20:3(n-9)] (0.17±0.08% vs. 0.24±0.11%, p=0.000) 
compared to females. For the remaining fatty acids, no significant gender difference 
in subcutaneous fat content was apparent.   
 
No correlation was found between age and subcutaneous fatty acid composition 
(p>0.05). Similarly the relative amount of n-3, n-6, monounsaturated fatty acids, or 
saturated fatty acids present in subcutaneous fat remained unchanged with age  
(p>0.05).  
 
Differences between marrow and subcutaneous fatty acid composition. No 
difference in either the polyunsaturated fat content or the n-6/n-3 ratio between 
marrow fat and subcutaneous fat was apparent (Table 2). However, the amount of 
monounsaturated fat content was significantly (p<0.01) lower and saturated fat 
content significantly higher (p<0.01) in marrow fat than subcutaneous fat (Table 2). 
This difference was reflected by a significant difference in the amount of many fatty 
acids between marrow and subcutaneous fat (Table 2).   
 
Differences in marrow fatty acid composition from proximal femur and 
proximal tibia. Marrow fat obtained from the proximal femur had a higher saturated 
fat content (p<0.01) than marrow obtained from the proximal tibia (Table 3). The 
polyunsaturated fat content and the n-6/n-3 ratio were similar in specimens obtained 
from the proximal femur and proximal tibia (Table 3). Significant differences in ten of 
the 22 fatty acids were apparent in samples taken from the proximal femur and 
proximal tibia (Table 3).  
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Marrow fatty acid composition in relation to BMD. The relative content of 
saturated fats, monounsaturated fats and polyunsaturated fats as well as n-6/n-3 
ratio was comparable across all three bone density subgroups (normal, low bone 
mass, and osteoporosis) (Table 4). Neither n-3 or n-6 fatty acid group content or n-
6/n-3 ratio showed significant variation across the three bone density groups. No 
significant correlation was found between marrow fatty acid composition and BMD (p 
> 0.05). Regarding the relationship between individual fatty acids content and BMD, 
the content of all fatty acids, except for cis-7-hexadecenoic acid [C16:1 (n-9)] and 
docosanoic acid [C22:0], was similar in subjects with normal bone density, low bone 
mass and osteoporosis (Table 4). The marrow fat content of cis-7-hexadecenoic acid 
[C16:1 (n-9)] was significantly less in osteoporotic subjects compared to low bone 
mass subjects (p<0.01) and normal subjects (p<0.05), while docosanoic acid [C22:0] 
was significantly lower (p<0.05) in osteopenic subjects compared to osteoporotic 
subjects (Table 4). There was a weak correlation between decreasing cis-7-
hexadecenoic acid [C16:1 (n-9)] and decreasing BMD (r = 0.24, p= 0.01). However, 
no correlation between marrow fatty acid composition and BMD was present for all 
the other fatty acids (p > 0.05). These results were unchanged when separate 
analysis were performed on samples obtained solely from the proximal femur (n=38) 
and the proximal tibia (n = 80) or when separate analysis were performed for male 
and female gender. Similarly, when BMD of the proximal femur was compared with 
marrow obtained only from the proximal femur (n=38), no difference in marrow fatty 
acid composition between normal (n=4), low bone mass (n=7) or osteoporotic (n=28) 
subjects was apparent. Mean subject age for the three BMD groups was significantly 
different (normal: 61.6 years; low bone mass: 67.6 years; osteoporosis: 75.9 years; 
p<0.05). 
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 Fatty acid composition (%) 
Major fatty acid groups Marrow Subcutaneous 
n-3 1.33 ± 0.47 1.36 ± 0.60 
n-6 18.69 ± 3.83 18.06 ± 4.41 
Monounsaturated fatty acid 50.82 ± 3.23 ** 57.74 ± 4.25 ** 
Saturated fatty acid  29.02 ± 4.19 ** 22.62 ± 4.01 ** 
n-3/n-6 (ratio) 15.58 ± 5.68 15.42 ± 6.18 
Individual fatty acids   
C12:0 0.14 ± 0.11 0.13 ± 0.10 
C14:0 1.09 ± 0.31 ** 1.22 ± 0.35 ** 
C16:0 22.53 ± 2.70 ** 18.62 ± 2.96 ** 
C16:1(n-9) 0.85 ± 0.15 0.83 ± 0.15 
C16:1(n-7) 2.62 ± 0.80 ** 6.36 ± 2.07 ** 
C18:0 5.10 ± 1.85 ** 2.54 ± 1.08 ** 
C18:1(n-9) 44.33 ± 3.04 ** 46.98 ± 2.79 ** 
C18:1(n-7) 2.18 ± 0.39 ** 2.75 ± 0.56 ** 
C18:2(n-6) 18.18 ± 3.81* 17.38 ± 4.33* 
C18:3(n-3) 0.74 ± 0.27 ** 0.80 ± 0.31 ** 
C20:0 0.12 ± 0.05 ** 0.09 ± 0.06 ** 
C20:1(n-9) 0.70 ± 0.19 0.69 ± 0.15 
C20:1(n-7) 0.08 ± 0.05 0.09 ± 0.04 
C20:3(n-9) 0.15 ± 0.08 ** 0.23 ± 0.11 ** 
C20:4(n-6) 0.25 ± 0.27 * 0.37 ± 0.19 * 
C20:5(n-3) 0.04 ± 0.04 ** 0.07 ± 0.05 ** 
C22:0 0.04 ± 0.05 ** 0.02 ± 0.02 ** 
C22:1(n-9) 0.07 ± 0.04 ** 0.04 ± 0.03 ** 
C22:4(n-6) 0.15 ± 0.06 0.15 ± 0.08 
C22:5(n-6) 0.11 ± 0.09 ** 0.16 ± 0.12 ** 
C22:5(n-3) 0.27 ± 0.12 ** 0.22 ± 0.13 ** 
C22:6(n-3) 0.29 ± 0.19 0.28 ± 0.23 
.
 
* p<0.05 and ** p<0.01 represent significant differences in fatty acid composition between marrow 
fat and subcutaneous fat. 
†
Data from 123 subjects rather than 126 subjects included as three 
subjects did not have subcutaneous fat samples removed at the time of surgery.  
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Table 3. Comparison of the fatty acid composition (mean ± SD) between marrow fat obtained 
from proximal femur and proximal tibia 
 Fatty acid composition (%) 
 Proximal femur  (n=38) Proximal tibia (n=80) 
Major fatty acid groups   
n-3 1.33 ± 0.77 1.41 ± 0.41 
n-6  18.45 ± 5.16 19.36 ± 2.95 
Monounsaturated fatty acid   49.49 ± 5.53 51.24 ± 2.55 
Saturated fatty acid  30.55 ± 5.55 ** 27.85 ± 2.28 ** 
n-6/n-3 (ratio) 16.36 ± 6.94 15.01 ± 5.04 
Individual fatty acids (%)   
C12:0 0.16 ± 0.12 0.12 ± 0.10 
C14:0 1.06 ± 0.35 1.09 ± 0.28 
C16:0 22.87 ± 3.49 22.11 ± 1.82 
C16:1(n-9) 0.71 ± 0.12 ** 0.92 ± 0.14 ** 
C16:1(n-7) 2.62 ± 0.98 2.55 ± 0.68 
C18:0 6.23 ± 2.54 ** 4.41 ± 0.64 ** 
C18:1(n-9) 42.91 ± 4.93 * 44.93 ± 2.36 * 
C18:1(n-7) 2.33 ± 0.35 ** 2.06 ± 0.34 ** 
C18:2(n-6) 17.66 ± 4.61 18.93 ± 2.95 
C18:3(n-3) 0.63 ± 0.32 ** 0.81 ± 0.21 ** 
C20:0 0.16 ± 0.05 ** 0.10 ± 0.04 ** 
C20:1(n-9)  0.76 ± 0.21 ** 0.65 ± 0.17 ** 
C20:1(n-7) 0.08 ± 0.04 0.07 ± 0.06 
C20:3(n-9) 0.18 ± 0.15 0.14 ± 0.05 
C20:4(n-6) 0.48 ± 1.01 0.20 ± 0.07 
C20:5(n-3) 0.05 ± 0.10 0.04 ± 0.03 
C22:0 0.07 ± 0.08 ** 0.02 ± 0.01 ** 
C22:1(n-9) 0.09 ± 0.05 ** 0.05 ± 0.02 ** 
C22:4(n-6) 0.16 ± 0.10 0.16 ± 0.04 
C22:5(n-6) 0.14 ± 0.10 ** 0.08 ± 0.06 ** 
C22:5(n-3) 0.26 ± 0.14 0.27 ± 0.10 
C22:6(n-3) 0.39 ± 0.50 0.29 ± 0.16  
* p<0.05 and ** p<0.01 represent significant differences in fatty acid composition proximal tibia and 






Table 4.  Fatty acid composition (mean ± SD) and individual fatty acid content of marrow fat in 
126 subjects segregated according to BMD group  
 Fatty acid composition (%) 
 Normal (n=28) 
Low bone mass 
(n=46) 
Osteoporosis (n= 52) 
Major fatty acid groups    
n-3 1.36 ± 0.50 1.32 ± 0.50 1.37 ± 0.64 
n-6 18.36 ± 3.64 18.79 ± 3.93 18.84 ± 4.59 
Monounsaturated fatty acid 51.03 ± 2.63 50.92 ± 2.77 50.30 ± 4.97 
Saturated fatty acid 29.09 ± 3.24 28.83 ± 3.28 29.32 ± 5.21 
n-6/n-3 (ratio) 14.68 ± 3.95 16.06 ± 5.83 15.46 ± 6.24 
Individual fatty acids (%)    
C12:0 0.14 ± 0.10 0.13 ± 0.11 0.14 ± 0.10 
C14:0 1.07 ± 0.33 1.11 ± 0.33 1.06 ± 0.29 
C16:0 22.58 ± 2.11 22.63 ± 2.45 22.44 ± 3.11 
C16:1(n-9) 0.87 ± 0.16 ^ 0.90 ± 0.16 ** 0.78 ± 0.15 ^ ** 
C16:1(n-7) 2.72 ± 0.92 2.37 ± 0.56 2.72 ± 0.88 
C18:0 5.13 ± 1.57 4.82 ± 0.97 5.49 ± 2.50 
C18:1(n-9) 44.35 ± 2.53 44.74 ± 2.64 43.71 ± 4.48 
C18:1(n-7) 2.22 ± 0.43 2.09 ± 0.37 2.22 ± 0.37 
C18:2(n-6) 17.77 ± 3.54 18.37 ± 3.92 18.20 ± 4.23 
C18:3(n-3) 0.72 ± 0.23 0.75 ± 0.26 0.71 ± 0.31 
C20:0 0.14 ± 0.06 0.11 ± 0.04 0.13 ± 0.06 
C20:1(n-9) 0.72 ± 0.21 0.68 ± 0.18 0.71 ± 0.22 
C20:1(n-7) 0.08 ± 0.04 0.07 ± 0.04 0.08 ± 0.07 
C20:3(n-9) 0.16 ± 0.11 0.13 ± 0.05 0.17 ± 0.11 
C20:4(n-6) 0.32 ± 0.47 0.19 ± 0.10 0.37 ± 0.82 
C20:5(n-3) 0.05 ± 0.06 0.04 ± 0.03 0.05 ± 0.07 
C22:0 0.05 ± 0.04 0.03 ± 0.02 * 0.06 ± 0.08 * 
C22:1(n-9) 0.08 ± 0.05 0.06 ± 0.02 0.07 ± 0.05 
C22:4(n-6) 0.17 ± 0.06 0.14 ± 0.05 0.16 ± 0.08 
C22:5(n-6) 0.11 ± 0.10 0.10 ± 0.09 0.12 ± 0.10 
C22:5(n-3) 0.26 ± 0.11 0.26 ± 0.13 0.27 ± 0.12 
C22:6(n-3) 0.32 ± 0.24 0.28 ± 0.18 0.35 ± 0.41 
* p<0.05 represent significant difference between low bone mass and osteoporosis group (22:0 
Behenic acid); ** p<0.01 represent significant difference between low bone mass and osteoporosis 
group (age, 16:1(n-9) (cis-7-hexadecenoic acid)); ^ p<0.05 represent significant difference between 





SIGNIFICANCE OF THESE RESULTS 
This is the first study to investigate the relationship between marrow fatty acid 
composition and bone mineral density. Previous studies have shown how an 
increase in certain fats, in particular long chain polyunsaturated fatty acids, or a 
change in the n-6/n-3 ratio, can affect bone formation or resorption influencing bone 
density and strength. For example, long chain n-6 fatty acids such as arachidonic 
acid and its metabolite prostaglandin PGE2 are pro-inflammatory with PGE2 being a 
potent stimulator of RANKL expression. This can reduce the OPG/ RANKL ratio and 
may increase osteoclastogenesis (Coetzee M et al. 2007). On the other hand, long 
chain n-3 fatty acids such as eicosapentaenoic acid, docosahexaenoic acid and γ-
linolenic have anti-inflammatory activity and may inhibit this PGE2-stimulated 
increase in RANKL expression [Poulsen RC et al. 2008]. Animal studies have shown 
how a diet enriched with γ-linolenic acid and high-dose eicosapentaenoic acid can 
exacerbate the effects of ovariectomy on BMD and how these effects can be 
attenuated by docosahexaenoic acid fatty acid [Poulsen RC et al. 2006, Poulsen RC 
et al 2007]. Rats fed a low n-6/n-3 ratio diet for 42 days showed a reduced level of 
bone PGE2 and increased bone formation markers (Watkins BA et al. 2000) while 
rats fed a diet high in n-3 fatty acids for 28 days reversed prior defects in bone 
remodeling (Reinwald S et al. 2004). 
 
In humans, cross-sectional studies have shown that diets high in polyunsaturated 
fats have a positive effect on bone (Corwin RL et al. 2006, Weiss LA et al. 2005). 
Kruger et al showed how women eating a diet rich in n-3 maintained or increased 
BMD as opposed to women on normal diet who lost BMD (Kruger MC et al, 1998). 
On the other hand, Bassey et al failed to show any effect on BMD in post-
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menopausal women randomized to either an n-3 rich diet or placebo (Bassey EJ et 
al. 2000).  
 
Trabecular bone is the most metabolically responsive component of bone. As 
marrow fat constitutes the main microenvironment of trabecular bone, changes in 
marrow fat may well influence trabecular bone metabolism. Only a few studies have 
analyzed the fatty acid composition of human bone marrow. Lund et al identified 
seven fatty acids in marrow from the femora of 12 patients post-mortem (Lund PK et 
al.). Yeung et al has reported on the fatty acid composition of twelve cadaver bone 
samples analyzed by both high resolution proton magnetic resonance spectroscopy 
and gas chromatography (Yeung DK et al. 2008). Whilst the current study provides a 
more detailed analysis of human marrow fat, the spectrum of marrow fatty acid 
composition is comparable with these two previous studies. 
 
Marrow and subcutaneous fat was obtained from subjects undergoing orthopedic 
surgery. A total of 22 fatty acids were identified in marrow and subcutaneous fat. No 
consistent differences in marrow fatty acid composition for varying BMD were 
apparent. In particular, the overall polyunsaturated fatty acid content, the n-6/n-3 
ratio and the percentage composition of those fatty acids most frequently implicated 
in bone remodeling, namely docosahexaenoic acid, arachidonic acid, γ-linolenic acid 
and eicosapentaenoic acid, were unchanged in subjects with normal BMD, low bone 
mass or osteoporosis.  
 
The failure of this study to find a significant relationship between marrow fatty acid 
composition and BMD would tend to suggest that marrow fat composition is not likely 
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to be having a direct effect on bone metabolism. The two associations found 
between fatty acid composition and BMD are likely to be inconsequential given that 
they account for <1% (for C16:1(n-9)) and <0.1% (for C22:0) of the total marrow fatty 
acid composition. Our results do not, however, refute the possibility of an active 
switch in mesenchymal stem cell differentiation between adiopocytosis and 
osteoblastogenesis (Duque G et al. 2008, Rosen CJ et al. 2006) since such a switch 
would only be expected to affect the amount but not the composition of marrow fat.  
 
Several significant differences were apparent in fatty acid composition between 
marrow fat and subcutaneous fat indicating that subcutaneous fat cannot be reliably 
used as an indicator of marrow fatty acid composition. Considerable differences 
were also present in fatty acid composition in samples obtained from the proximal 
femur and proximal tibia. This is to be expected since proximal femur marrow is likely 
to contain more erythropoetic i.e. red marrow than the proximal tibial marrow which 
is predominantly fatty. Whilst marrow fat is derived mainly from fatty marrow, 
erythropoetic marrow also contains some fat. In rabbits, Tavassoli et al. found that 
predominantly erythropoetic marrow (from the spine) contained more saturated fatty 
acids than fat from predominantly fatty marrow (from the calcanei) (Tavassoli M et al. 
1977). This is similar to the spectrum of change we have shown in specimens 
obtained from the proximal femur and proximal tibiae. Nevertheless, separate 
analyses of samples obtained from the proximal femur or tibia showed no difference 
in marrow fatty acid composition across the different BMD groups.   
The significance of this study for future clinical studies can be appreciated by a 
recent study which examined subcutaneous and marrow fat at 7T.  Ten separate 
spectra (representing ten separate fatty acids) were identified indicating that, in the 
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near future, one should be able to obtain reliable data on both the composition as 
well as the amount of marrow fat.  
 
Figure 5:  Spectra of 
subcutaneous fat and marrow 
fat obtained in vivo at 7T. 
Water signal is suppressed 
[from Ren J et al. 2008]. It is 
increasingly likely that in 
future more revealing spectra 
will be obtainable from 
musculoskeletal tissues in 
vivo using clinical Mr 
scanners. 
 
Limitations of this study.  
1. BMD was obtained at the lumbar spine or proximal femur, while marrow fat 
samples were obtained from different regions and we have shown that marrow 
fatty acid composition can vary from one site to another possibly related to the 
relative red:fatty marrow content. Nevertheless, the results still held true with no 
difference in marrow fat content between normal, low bone mass and 
osteoporotic subjects being apparent when a separate sub-analysis of the 
proximal femur (BMD and marrow fatty acid composition) was performed.  
2. We studied fatty acid composition but did not study the active constituents of 
these fatty acids. Therefore, in this cohort, it is not known whether fatty acid 
metabolism changed with BMD or whether there is a change in the fatty acid 
metabolites with BMD (Watkins BA et al. 2001, Poulsen RC et al. 2007).  
3. Due to the small number of spine samples, no reliable comparison between 
spinal and appendicular marrow could be undertaken. This small number of spine 
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samples reflects the difficultly in obtaining marrow samples at the time of spine 
surgery.    
 
Conclusion. Significant differences in fatty acid composition were evident between 
marrow fat and subcutaneous fat. Significant differences were also evident in 
marrow fat samples obtained from the proximal femur and proximal tibia. However, 
no change in marrow fatty acid composition was evident in samples obtained from 
groups of subjects with different BMD (normal, low bone mass, and osteoporosis).   
 
Next phase of study: We now wished to explore possible reasons behind the 
reduced perfusion seen in osteoporotic bone. This is the basis of Study 7. 
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Appendix to study 6.  
List of individual fatty acids with common name or abbreviation and systematic name 
 
Fatty acid Common name Systematic name 
Saturated   
C12:0 Lauric acid dodecanoic acid 
C14:0 Myristic acid tetradecanoic acid 
C16:0 Palmitic acid hexadecanoic acid 
C18:0 Stearic acid octadecanoic acid 
C20:0 Arachidic acid eicosanoic acid 
C22:0 Behenic acid docosanoic acid 
   
Monounsaturated    
C16:1 (n-9)  cis-7-hexadecenoic acid 
C16:1 (n-7) Palmitoleic acid cis-9-hexadecenoic acid 
C18:1 (n-9) Oleic acid cis-9-octadecenoic acid 
C18:1 (n-7) Vaccenic acid  cis 11-octadecenoic acid 
C20:1 (n-9) Eicosenoic Acid cis-11-eicosenoic acid 
C20:1 (n-7) Paullinic acid cis-13-eicosenoic acid 
C22:1 (n-9) Erucic acid cis-13-docosenoic acid 
   
Polyunsaturated    
C18:2 (n-6) Linoleic acid cis, cis-9,12-octadecadienoic acid 
C18:3 (n-3) α -Linolenic acid all-cis-9,12,15-octadecatrienoic acid 
C20:3 (n-9) Mead acid all-cis-5,8,11-eicosatrienoic acid 
C20:4 (n-6) Arachidonic acid all-cis-5,8,11,14-eicosatetraenoic acid 
C20:5 (n-3) EPA all-cis-5,8,11,14,17-eicosapentaenoic acid 
C22:4 (n-6) Adrenic acid all-cis-7,10,13,16-docosatetraenoic acid 
C22:5 (n-6) Osbond acid all-cis-4,7,10,13,16-docosapentaenoic acid 
C22:5 (n-3) DPA all-cis-7,10,13,16,19-docosapentaenoic acid 






STUDY 7:  
Likely causes of reduced bone perfusion in osteoporosis: novel 
findings in an ovariectomy rat model 
 
Aim: To investigate the cause of reduced vertebral perfusion in a rat ovariectomy 
(OVX) model. 
 
Rationale for doing this study: Studies 1, 2 & 4 showed how bone perfusion 
indices are reduced in osteoporotic bone though the cause of this reduction in 
perfusion indices is not clear. Several potential reasons for decreased bone 
perfusion in osteoporosis have been proposed such as a reduced requirement due 
to decreased bone turnover or an effect of increased marrow fat content impeding 
venous return within the confined marrow cavity. Endothelial function represents 
another potential link between bone perfusion and reduced bone mineral density 
(Sanada M et al. 2004) as does a change in marrow content over and above an 
increase in fat content. The temporal relationship between reduced BMD and 
reduced perfusion is also unknown i.e. do reduced perfusion indices predate a 
reduction in bone mineral density or visa versa.  
 
We undertook this longitudinal animal-based study to investigate the cause of 
reduced bone perfusion in osteoporosis. In particular, we wanted to investigate the 
temporal relationship between bone perfusion and BMD as well as the relationship 
with vascular reactivity and marrow content.  Bilateral ovariectomy (OVX) in the adult 
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female rat is a commonly used model for studying the effects of bone loss (Jee WS 


























What causes the reduced vertebral perfusion seen with reduced BMD? 
 
 
22 Sprague-Dawley rats 
  
ovariectomy sham-surgery 
(11 rats) (11 rats) 
 
 Lumbar spine BMD measured by quantitative CT densitometry 
 Lumbar spine perfusion measured by dynamic contrast-enhanced MRI 
 Endothelial function assessed pharmacologically  




 BMD and marrow perfusion  occur in synchrony rather than one predating the other. 
Post-OVX state also associated with:  
  endothelial dysfunction (in both aorta and femoral artery) 
  fatty marrow (due to  in marrow fat cell number rather than size) 
  erythropoetic marrow 
 
Overall,  perfusion found with  BMD most likely associated with   in the amount of 
erythropoetic marrow ± impaired endothelial function rather than any observed effect in marrow fat 
or bone turnover.  
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ABSTRACT  
Purpose: To investigate the cause of reduced vertebral perfusion in a rat 
ovariectomy (OVX) model. 
Materials and Methods: Twenty two Sprague-Dawley rats were studied. CT bone 
densitometry and MR perfusion imaging was performed at baseline, two, four and 
eight weeks post-OVX (n=11) or sham surgery (n=11). Perfusion parameters 
analyzed were maximum enhancement (Emax) and enhancement slope (ES). After 
euthanasia, the aorta and femoral artery were analyzed for vessel reactivity while the 
lumbar vertebrae were analyzed for marrow content.  
Results: For control rats, BMD, Emax and Eslope remained constant while in OVX rats, 
a comparable reduction in both BMD and perfusion parameters at two weeks post-
OVX (BMD 9.3%, Emax 11.6%, Eslope 9%) was seen with a further reduction in these 
parameters at 4 weeks (BMD 17.5%; Emax 15.6%; Eslope 33%) and again at 8 weeks 
(BMD 18.8%; Emax 14.2%; Eslope 33%) compared to control group. Endothelial 
dysfunction was observed in both the aorta and femoral artery of OVX group but not 
control group. Increased marrow fat area occurred in the OVX group (52.9% vs 
21.6%, p<0.01) due to increase in fat cell number. Decreased erythropoetic marrow 
(32.5% vs 48.6%, p <0.05) was also observed in the OVX group. 
Conclusion: Reduced bone perfusion occurs in synchrony with reduced BMD. The 
most likely causes of reduced bone perfusion are reduction in the amount of 
erythropoetic marrow and endothelial dysfunction rather than a change in bone 






The experimental protocol was approved by the local Animal Experiment Ethics 
Committee. Twenty-two 6-month-old female Sprague-Dawley rats were used in this 
study. The animals were housed 2-3 animals per stainless steel cage at 22°C 
temperature under a 12-hour light, 12-hour dark cycle while receiving a standard rat 
chow diet and water ad libitum. For MRI examination and surgery, rats were 
anesthetized using a combination of xylazine (10mg/kg) and ketamine (90mg/kg).  
 
CT assessment of vertebral bone mineral density. Rat lumbar vertebral BMD was 
measured using a clinical multidetector CT scanner (LightSpeed VCT 64, General 
Electric, USA) employing continuous axial 0.625 mm slice thickness acquisitions. A 
more detailed description of the methodology we used to obtain small animal BMD 
from a clinical CT scanner has been reported (Wang et al. 2009) (Figure 1 & 2). The 
coefficient of variance for BMD assessment was 1.4±0.6%. Lumbar vertebral BMD 
for each rat was defined as the mean BMD of vertebrae L2-L5. To eliminate any 
potential effect of retained gadolinium on bone densitometry, CT was performed 
prior to MR perfusion studies in all cases.  
 
Figure 1. Axial MDCT of L3 vertebral body 
with 0.625mm thick acquisitions. 
Quantitative CT of each lumbar vertebral 
body from L2-L5 was performed and the 
lumbar spine BMD for that rat defined as 




Figure 2. Surface rendering three 
dimensional reconstruction of rat lower 
thorax, lumbar spine and pelvis. The rat 
has got six lumbar vertebrae. Lumbar 
vertebrae L2-L5 were used to determine 
lumbar BMD.  
 
 
MR assessment of vertebral bone perfusion. MRI was performed on a 1.5 Tesla 
clinical MR imaging system (Intera NT, Philips Medical Systems, Best, The 
Netherlands) with a maximum gradient strength of 30 mT/m. Rats were 
anaesthetized, and the tail vein cannulated with a 24G heparinised catheter (Figure 
3). The rat was then placed placed in a specially designed cradle (Figure 4). A 
surface coil with a diameter of 4.7 centimeters (Micro 4.7, Philips Medical Systems, 
Best, The Netherlands) was placed within this cradle under the rat lumbar spine 





Figure 3. Cannulation of rat tail 
vein with 24G heperanised 
catheter.   
 
 
Figure 4 Cradle used to hold rat 




Following a coronal scout scan, a mid-sagittal T1-weighted image of the lumbar 
spine was obtained. A dynamic short T1-weighted gradient echo sequence MR 
series was obtained in the sagittal plane using the following parameters: TR=4 msec, 
TE=1.4 msec, flip angle=15, slice thickness=5 mm, matrix = 12851, in-plane 
resolution=0.6250.625 mm, NEX=1. Temporal resolution was approximately 0.6 
second/ acquisition. After 60 baseline image acquisitions, a gadolinium-based 
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contrast agent (Gd-DOTA, Guerbet Group, Roissy CDG cedex, France at a dose of 
0.3mmol/kg i.e. 0.15ml for a 250-gram rat) was injected into the tail vein followed by 
a bolus flush of 0.5ml normal saline. Bolus injection was completed in less than one 
second. Tail vein cannulation, bolus injection and normal saline flush were carried 
out by the same operator skilled in small animal procedures. Dynamic MRI took 
approximately 8 minutes to complete with 800 images being acquired.  
 
Dynamic MRI images were processed on a radiologic workstation (Viewforum, 
Philips Medical System, Best, The Netherlands). Regions-of-interest (ROIs) was 
drawn over the cancellous part of the lumbar vertebrae from L2-L5 excluding the 
vertebral cortex (Figure 5).  
 
Figure 5. Mid-sagittal T1-weighted image of a rat lumbar 
spine. Regions-of-interest outlining the meduallary canal 
and excluding the cortex of the lumbar vertebrae from L2-
L5. The rat lumbar spine has six rather than five vertebral 
bodies.  
 
Signal enhancement over time was recorded, and plotted as a time-signal intensity 
curve. From this time-signal intensity curve, two MR perfusion indices were analyzed, 
namely, maximum enhancement (Emax) and enhancement slope (Eslope), both of 
them relating to the first rapidly rising part of the curve. Maximum enhancement was 
defined as the maximum percentage increase of signal intensity from baseline. 
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Enhancement slope was defined as the rate of enhancement between 10% and 90% 
of the maximum signal intensity difference between maximum signal intensity (Imax) 
and baseline signal intensity (Ibase). Thus, these perfusion indexes were calculated 





















] 100  
Where Ibase was defined as the mean signal intensity of the first 50 images, Imax was 
defined as the maximum value of the first rapidly rising part of the time-signal 
intensity curve, t10% and t90% were the time when signal intensity reaches 10% and 
90% of the signal intensity difference between Ibase and Imax, respectively. Data from 
four lumbar vertebrae L1-L4 were measured, and the mean value of these four 
vertebrae taken as the results for that animal.  
 
Ovariectomy and sham surgery. After baseline CT densitometry and MR 
examination, 11 rats underwent bilateral ovariectomy (OVX) with surgery being 
performed through a subcostal incision. Ovaries together with surrounding fat tissue 
were removed. Successful ovariectomy was confirmed at necropsy through absence 
of ovarian tissue and atrophy of uterine horns. The remaining 11 rats underwent 
similar sham surgery with exposure of the ovaries though no excision.   
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Figure 6. Right ovariectomy 
performed through subcostal 
incision. A separate incision 




Longitudinal CT and MR assessments of vertebral BMD and perfusion. Repeat 
CT bone densitometry and measurement of lumbar vertebral perfusion with MRI 
were performed at two, four and eight weeks following OVX surgery. After CT and 
MRI examinations at week eight, the animals were sacrificed with cervical dislocation. 
The abdominal aorta and right femoral artery were harvested fresh to assess 
vascular reactivity and the lumbar spine vertebrae were harvested for assessment of 
vertebral marrow content. 
 
Vascular reactivity assessment. For vascular reactivity assessment, the aorta and 
right femoral artery of each rat were dissected and transferred to ice-cold 
oxygenated Krebs solution while being stored. Arteries were dissected free of 
surrounding connective tissues. Two 3 mm wide ring segments were cut from each 
aorta or femoral artery. The endothelium was removed from one ring by gently 
rubbing the luminal surface with stainless steel wire. The endothelium was left intact 
on the other one ring. Each aortic ring was mounted between two stainless steel wire 
hooks submerged in an organ bath while each femoral ring was mounted in a 
myograph chamber held between two tungsten wires (40 μm diameter) in a multi-
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myograph system. Each arterial ring was kept in Krebs solution (pH 7.2-7.4) at 37 °C 
with 95% O2 and 5% CO2. A resting tension of 2.5g was applied to the aorta and 
0.5g to the femoral artery (as determined by length-maximum tension relationship 
measurements) and one hour allowed for both rings to assume a stable resting 
tension. To investigate endothelium-dependent relaxation, which is mediated by 
nitric oxide (NO) from the endothelium, endothelium-intact rings were first contracted 
using 1μM phenylephrine to establish a stable constricted tone and then 
acetylcholine was added cumulatively to the bathing solution to induce relaxation. 
Relaxation was expressed as percentage reduction in arterial contraction. To 
investigate endothelium-independent relaxation or vascular smooth muscle 
sensitivity to nitric oxide, endothelium-denuded phenylephrine-constricted rings were 
relaxed by sodium nitroprusside, a nitric oxide (NO) donor. Phenylephrine-induced 
contraction was also assessed in both the OVX and control groups, as was the 
degree to which this was abolished by L-NAME (N(G)-nitro-L- arginine methyl ester) 
at 100μmol/L. L-NAME, a nitric oxide synthase inhibitor, inhibits the synthesis of NO 
from L-arginine.  
 
Figure 7. Organ bath setup for 
measuring isometric forces 
generated by large arteries such 




Figure 8. Myograph setup for measuring isometric forces generated by smaller arteries 
such as the rat femoral artery.  
 
Histological assessment of vertebral marrow cavity. For histology, the excised 
lumbar spine was fixed with 10% buffered formalin for three days and then 
decalcified with 10% formic acid for four weeks. All the decalcified samples were 
embedded in paraffin, and cut into 6mm thick axial sections. Sections were stained 
with hematoxylin and eosin (H&E). For vertebral marrow fat, trabecular bone and 
erythropoetic marrow analysis, four vertebral sections from each of the four 
vertebrae (L2-L5) under a magnification of 200× were randomly selected for 
evaluation. In other words, a total of 16 sections were analyzed from each rat. 
Percentage area of marrow fat, trabecular bone and erythropoetic marrow was 
measured in each histological section using imaging processing software (Image-Pro 
Plus 5.1, Media Cybernetics Inc., Bethesda, MD, USA). The mean values of all fields 
measured from each animal were used for statistical analysis.  
 
Statistical analysis. CT, MRI, and histological data was expressed as mean ± 
standard deviation (SD) while vascular reactivity data was expressed as mean ± 
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standard error of mean (SEM). All statistical analyses were performed using SPSS 
14.0 (SPSS Inc., Chicago, IL, USA). Mann-Whitney U test was used for paired 
comparison and Wilcoxon Signed Ranks Test was used for non- paired comparison. 




One rat died during OVX surgery while four rats died during the course of the study 
due to anesthesia or infection. The total number of control and OVX rats available for 
analysis at various time points is shown in Table 1.  
 
Table 1: Animals Available for Analysis 
 Experiment Time Course* 
  baseline  week 2 week 4 week 8 
Control group for BMD measurement   11 6 11 10 
OVX group for BMD measurement   11 5 8 7 
Control group for MRI measurement   11 6 10 10 
OVX group for MRI measurement  11 5 8 7 
Control group for myograph & histology assessment n/a n/a n/a 10 
OVX group for myograph & histology assessment n/a n/a n/a 7 
*Number of rats available for analysis during the course of the study. Five of the 22 rats died due to 
surgery, anesthesia or infection.   
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Vertebral bone mineral density. 
 
Figure 9. Rat lumbar 
vertebral BMD during the 
course of the study. BMD 
values remained constant 
for control rats while BMD 
in the OVX rats started to 
decrease by week 2, and 
further decreased by week 
4 and week 8.  
 
BMD values remained consistent in the control rats with no significant difference 
seen over the four time points (p>0.05). On the other hand, in the OVX rats, BMD 
decreased significantly from baseline by 9.3% at week 2 post OVX (p=0.043), by 
17.5% at week 4 post OVX (p<0.001), and by 18.8% at week 8 post OVX (p<0.001). 
The difference between week 4 and week 8 was not significant (p=0.536) (Figure 9). 
 
Vertebral perfusion. At baseline there was no difference in maximum enhancement 
(Emax) (p=0.71) or enhancement slope (Eslope) (p=0.8) between control and OVX rats. 
For control rats, both Emax and Eslope remained stable during the course of the study 
(p>0.05) (Figure 10 and 11). At week 2, Emax of OVX group was 11.6% less than that 
of control group, and Eslope was 9% less that of control group though these 
differences did not reach statistical significance (p=0.31 and 0.54, respectively) 
(Figure 10 and 11). At week 4, Emax of OVX group was 15.6% less than that of 
control group (p=0.027), and Eslope was 33.6% less that of control group (p=0.03) 
(Figures 10 -12). At week 8,  Emax of OVX group was 14.2% less than that of control 
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group (p=0.02), and Eslope slope was 32.9% less that of control group (p=0.01) 
(Figures 10 – 12). No significant difference between week 4 and week 8 was present 
for both Emax and Eslope in the OVX group.  
 
 
Figure 10. MRI 
perfusion indices of 
maximum 
enhancement 
(Emax) during the 
course of the study. 
For control rats, 
Emax remained 
constant, while in 
OVX rats, Emax 
started to decrease 
by week 2 and 
further decreased 
by week 4.  
 
 
Figure 11. MRI 
perfusion indices of 
enhancement slope 
(Eslope) during the 
course of the study. 
For control rats, 
Eslope remained 
constant, while in 
OVX rats, Eslope 
started to decrease 
by week 2 and 
further decreased 




Figure 12. Typical time-intensity enhancement curve from rat lumbar vertebra (L3) 
at baseline (top trace) and 4 weeks post-OVX (bottom trace). Time-intensity curve 
in OVX rat shows reduced Emax and a less steep Eslope. X-axis: time in seconds, Y-












Vascular reactivity. Acetylcholine-mediated endothelium-dependent relaxation in 
phenylephrine constricted aortic and femoral arterial rings was impaired in OVX 
group when compared to the sham-operated control group; while endothelium-
independent relaxation by sodium nitroprusside (SNP), a NO donor, was comparable 
between the two groups (Figure 13). Phenylephrine-induced contraction was greater 
in OVX group than in control group; while this discrepancy was abolished in the 
presence of L-NAME, a nitric oxide synthase inhibitor (Figure 13).  
 
Figure 13: (A) Acetylcholine-mediated endothelium-dependent relaxation in phenylephrine 
constricted aortic rings was significantly impaired in OVX group compared to controls (p<0.05). 
(B) Endothelium-independent vasodilatation by sodium nitroprusside was comparable between 
two groups. (C) Phenylephrine-induced contraction was significantly greater in OVX group than 
controls (p<0.05). (D) This effect was abolished by L-NAME. Only results for aortic ring are 
shown since very similar results were observed in femoral rings. 
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Histological assessment of vertebral marrow cavity. The vertebrae of OVX rats 
contained significantly less trabecular bone, more marrow fat and less erythropoetic 
marrow than control rats (Figure 14). In the control group, marrow fat cell area was 
21.6% ± 4.2% (p<0.01), bone trabecular area was 29.8% ± 3.9% (p<0.01) and 
erythropoetic marrow was 48.6% ± 4.5% (p<0.05). In the OVX group, marrow fat cell 
area was 52.9% ± 4.6%, bone trabecular area was 14.6% ± 3.7% and erythropoetic 
marrow was 32.5% ± 4.8% (Figure 14). In other words, the increase in fat cell area in 
the OVX groups was accompanied not just by a reduction in the amount of 
trabecular bone but also be a decrease in the amount of erythropoetic marrow.  
 
The fat cell (adipocyte) number in the control group was 39 ± 5 per (200×) field while 
the fat cell number in the OVX group was 92 ± 6 per (200×) field. Therefore the 
increase in fat cell area by a factor of 2.45 (52.9% vs. 21.6%) in the OVX group was 
accompanied by a corresponding increase in fat cell number by a factor of 2.35 (92 
vs. 39). This indicates that the increase in fat in the marrow space that accompanies 
OVX is essentially all due to increase of fat cell number rather than an increase in 











sections (H&E stain; 
magnification 200×) of 
lumbar vertebral body 
medullary canal in (A) 
control and (B) OVX rat.  
More fat cells were in the 
inter-trabecular space in 
the OVX rat than the 
control rat. This is also a 
notable reduction in the 
amount of erythropoetic 
marrow of the OVX rat 













SIGNIFICANCE OF THESE RESULTS 
In this study, we used a 1.5T clinical MR scanner and a small surface radiofrequency 
coil, both available in most clinical institutions, to study vertebral perfusion in a rat 
ovariectomy model. The relationship between bone perfusion, bone mineral density, 
arterial reactivity and marrow content was studied.  
 
As expected, sex hormone deficiency led to a reduction in vertebral bone mineral 
density. At the first assessment with CT and MR two weeks post-OVX, a comparable 
reduction in both vertebral BMD and perfusion parameters was observed with a 
further reduction in both parameters being seen at 4 weeks post-OVX and again at 8 
weeks post-OVX. At two week post-OVX, a reduction in BMD as well as both 
perfusion parameters by a factor of about 10% was observed. There was no 
indication that reduced bone perfusion either pre- or post-dated reduced BMD. It 
would seem most likely reduced bone perfusion occurs concurrently with a reduction 
in BMD rather than one particular parameter predating the other.  
 
We also investigated the relationship bone perfusion and vascular reactivity. OVX-
induced endothelial dysfunction is known to occur in the aorta but this effect has not 
been previously shown in the femoral arteries (Wong CM et al, 2008, Taddei S et al. 
1996). Endothelial dysfunction resulting from decreased nitric oxide (NO) 
bioavailability was observed in the aorta and femoral arteries of OVX rats though not 
in the control rats. This endothelial dysfunction could through impaired vasodilatation 
or enhanced vascular tone lead to reduced blood flow and is therefore a likely cause 
of the reduced perfusion seen with reduced BMD post-OVX. These results are 
supportive of those described by Prisby et al who, using radiolabelled microspheres, 
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demonstrated a reduction of 21% in metaphyseal blood flow in old rats compared to 
young rats (Prisby RD et al. 2007). This reduction in blood flow was associated with 
impaired endothelium-dependent vasodilatation and decreased nitric oxide 
bioavailability (Prisby RD et al. 2007). Decreased release of endothelium-derived 
substances such a nitric oxide (NO) or PGI2 is of particular interest in osteoporosis 
as both NO and PGI2 have a potential downstream effect of promoting bone 
formation and limiting resorption (Samuels A et al, 2001). Endothelial dysfunction is 
not likely however to be the sole cause of reduced bone perfusion in the presence of 
reduced BMD since the effects of endothelial dysfunction are more likely to be 
systemic with the aorta and femoral artery seen to be equally affected in this study.  
Another possible cause of reduced bone post-OVX as shown in this study is an 
alteration in marrow content. The medullary cavity is composed mainly of marrow fat, 
trabecular bone, erythropoetic marrow with a small component occupied by vascular 
channels (arterioles, venules and capillary sinusoids). Within the confined space of 
the vertebral body, an increase in one component can only occur at the expense of 
another component. Clinical MR spectroscopic studies have shown that as BMD 
decreases, there is a reciprocal increase in marrow fat content. The rat vertebral 
body is too small to allow proton MR spectroscopy at 1.5T though we were able to 
study the effect of OVX on marrow content histologically. Following ovariectomy, 
increased marrow fat area of 31.3% (from 21.6% to 52.9%) was observed secondary 
an increase in fat cell number rather than fat cell size. This increased fat cell number 
may be the result of mesenchymal stem cell differentiation switching more towards 
adipocytosis rather than osteoblastogenesis (Duque G 2008, Rosen CJ et al 2006).  
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The relative increase in marrow fat area was coincident, not just with a reduction in 
the amount of trabecular bone which decreased by 15% (from 29% to 14%), but also 
with a reduction in the amount of erythropoetic marrow which decreased by 16% 
(from 48% to 32%). This reduction is erythropoetic marrow may be akin to the ‘senile 
anaemia’ which has not to our knowledge previously being assessed or quantified in 
an experimental animal model (Takasaki M et al. 1999, Justesen J et al.  2001, 
Verma S et al. 2002, Steiniche T et al. 1995). Both the increase in marrow fat and 
decrease in erythropoetic marrow may be related to estrogen depletion given that 
the post-menopausal state is recognized to be associated with both increase in body 
mass and anemia (Hartsock RJ et al. 1965). It appears, therefore, that the increase 
in fat content post-OVX is not simply due to fat occupying the space vacated by not 
just reduced amount of trabecular bone but also a reduced amount of erythropoetic 
marrow. A preliminary PET imaging study has indicated that the metabolic activity of 
erythropoetic marrow is up to six times greater than that of fatty marrow (Chahal HJ 
et al. 2007). Overall, it seems most likely that this erythropoetic marrow may be 
accounting for the reduced bone perfusion seen accompanying reduction in BMD. 
To our knowledge, this is the first study to show that there is a decrease in the 









Limitations of this study. 
1. The study cohort is small and the findings need to be validated in larger pre-
clinical as well as clinical studies.  
2. We studied the cause of reduced perfusion in a rat-OVX model. This equated to 
an abrupt withdrawl of estrogen. Although frequently  used a model for post-
menopausal and senile osteoporosis in humans, the pathophysiological 
processes behind both entities may not be strictly comparable.  Further study in 
human is indicated. This study provides a good indication as to the direction this 
further study should take.    
3. More in-depth MR-based perfusion models such as those used by Brix and Tofts 
(Basu S et al. 2007, Tofts PS et al. 1997) would help to provide information on 
specific elements of perfusion such as arterial input, available extracellar space, 
capillary exchange and contrast elimination permeability.    
 
Conclusion. This pre-clinical study is the first post-OVX osteoporosis model to 
consider bone loss in unison with changes in perfusion, endothelial function, red and 
fatty marrow. As bone loss clearly does not occur in isolation, this more 
encompassing paradigm may well be the model that best serves future osteoporotic 
research. Rather than pre- or post-dating change in BMD, reduced bone perfusion 
seems to occur in synchrony with reduced BMD. Likely causes of reduced bone 
perfusion that occurs in association with reduced BMD include endothelial 
dysfunction and, more particularly, a hitherto non-quantified reduction in the amount 
of erythropoetic marrow. This decrease in erythropoetic marrow post- OVX 
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accompanies an increase in marrow fat, the latter occurring as a result of increase in 
fat cell number rather than fat cell size.  
Next phase of study:  At this stage sufficient time has elapsed since Studies 1,2 
and Study 4 were undertaken to study whether if increased marrow fat or decreased 
perfusion at baseline could predict future accelerated bone loss. This forms the basis 
of Study 8.  
 
Subjects from Study 4 rather than Study 1 or 2 were chosen for longitudinal follow up 
as in this age group (> 65 years),  serial DXA examination of the lumbar spine (as 
per  Study 1 and 2) is not that reliable and often increases rather the decreases on 




STUDY 8  
Do perfusion indices or marrow fat content predict rate of bone 
loss?  
Aim: To determine if marrow fat content or perfusion indices at baseline are related 
to subsequent rate of bone loss.  
Rationale for doing this study:  In Study 1, 2 and 4, we showed that osteoporosis 
was associated with increased marrow fat content and decreased marrow perfusion 
indices both for the lumbar spine and the proximal femur. Within each bone density 
group (normal bone mineral density, osteopenia and osteoporosis), a wide range of 
fat content and perfusion indices were  observed (Figure 1 and 2) although the 
overall trend was for subjects with osteoporosis to have increased marrow fat and 
decreased perfusion indices (Emax and Eslope) compared to normal subjects. No 
difference in muscle perfusion indices across bone mineral density groups (normal, 
osteopenia, osteoporosis) was apparent (Figure 2).  
To help determine whether increased marrow fat content or decreased perfusion 
predict bone loss, we undertook this longitudinal study of subjects who had 
undergone marrow fat content assessment and perfusion imaging of the proximal 
femur at baseline (i.e. subjects from Study 4)    
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Figure 1. Enhancement slope (Eslope) of femoral neck, acetabulum and adductor muscle 
in 120 subjects with normal BMD, osteopenia and osteoporosis at baseline (from Study 
4). Enhancement maximum (Emax) showed a similar trend (not shown). Note how a 
range of perfusion indices were present for each group.  
 
 
Figure 2. MR spectroscopy of femoral neck in 120 subjects with normal BMD, 
osteopenia and osteoporosis at baseline (from Study 4). MR spectroscopy was not 
performed in the acetabulum or adductor muscle at baseline. Note how range of values 













To determine whether increased marrow fat or decreased perfusion at baseline could 
predict future accelerated bone loss?  
 
 
 120 post-menopausal female subjects (Study 4 cohort) 
MRS and DCE MRI plus DXA of hip region at baseline 
 Subjects separated into two groups according to marrow fat content and perfusion 
indices i.e. whether: 
      < or > median marrow fat content 





 DXA examination of hip repeated in 52 subjects at two and four years to determine 






 Subjects < median marrow or muscle perfusion indices had significantly  bone loss in 
ensuring four years. 
 Subjects > marrow fat content also tended to have  bone loss though this did not 
reach statistical significance. 
 Perfusion and marrow fat parameters were comparable to known risk factors at 
predicting bone loss 
 Acetabulum E
max
 > median had a sensitivity of 89% in distinguishing between slow 





PURPOSE: To determine if marrow fat content or perfusion indices at baseline can 
predict bone loss.  
MATERIALS AND METHODS: 120 post-menopausal female subjects underwent hip 
BMD at baseline following by marrow fat content assessment of femoral neck by MR 
spectroscopy and MR perfusion imaging of femoral neck, acetabulum and muscle. 
Of these 120 subjects, 52 subjects were followed-up with repeat BMD at two and 
four years.   
RESULTS: Percentage decline in femoral neck BMD at two and four post-baseline 
was greater in subjects with increased marrow fat or decreased perfusion indices 
after adjusting for baseline BMD, age, weight and weight change. Most MR 
parameters correlated better with 4 year decrease in BMD than currently applied risk 
factors. Acetabulum Eslope , femoral neck Emax, Eslope and marrow fat content had a 
sensitivities of 89%, 81%, 75% and 72% respectively for distinguishing between fast 
and slow bone losers.  
CONCLUSION: Perfusion indices and to a lesser degree marrow fat content were 
comparable to known risk factors at predicting bone loss. Selected perfusion indices 









MATERIALS AND METHODS 
The initial cohort consisted of 120 post-menopausal female subjects the details of 
which are outlined in Table 1. These subjects were recruited by placing notices in 
community centers for the elderly inviting subjects to attend for DXA examination. 
Following DXA examination of the right hip, subjects were invited to attend for MR 
spectroscopy and perfusion imaging of the right hip. These results are presented in 
Study 4 and outlined in Figure 1 and 2.  










Age (years) 73·79 (4·28) 72·90 (3·75) 73·38 (4·65) 75·38 (4·00) 
Hip BMD(g/cm
2
) 0·71 (0·12) 0·85 (0·06) 0·70 (0·04) 0·57 (0·06) 
T-score -1·63 (1·15) -0·33 (0·58) -1·73 (0·41) -2·98 (0·51) 
     
Followed-up  









Age (years) 72.37 (4.16) 71.80 (3.98) 72.04 (4.26) 74.75 (3.99) 
Hip BMD(g/cm
2
) 0.74 (0.10) 0.84 (0.04) 0.71 (0.05) 0.58 (0.03) 
T-score -1.38 (0.95) -0.43 (0.39) -1.67 (0.43) -2.89 (0.29) 
Table 1. Details of cohort at baseline and cohort follow-up at 2 & 
4 years. Follow-up cohort contained less osteoporotic subjects 
but was otherwise unchanged from baseline cohort. 
 
From the cohort of 120 subjects examined at baseline, 52 subjects were suitable and 
available to return for repeat DXA at both two and fours years post-baseline. This 
DXA examination of the right hip at two and four years was performed on the same 
DXA machine (Hologic QDR-4500W) as baseline by the same experienced DXA 
technologists. Characteristics of the 52 subjects followed up at two and four years 
are shown in Table 1. No repeat MR examination was performed. The remaining 64 
subjects were not followed up or were not included in the current analysis as they 
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had either started osteoporotic medication (n=24), were non-contactable (n=2), had 
died (n=1), did not wish to return for further DXA study (n=15) or are not scheduled 
to return for four year follow up until two years later (n=26).  
The median level for marrow fat content in the femoral head and perfusion indices 
(Emax and Eslope) in the femoral neck, acetabulum and muscle across all bone mineral 
density groups at baseline was determined.  For each particular area and parameter, 
follow-up subjects were divided into two cohorts according to whether their original 
marrow fat content or perfusion index (Emax and Eslope) was greater than or less than 
the overall median value.   
Statistical analysis.  Data was presented as mean and standard deviation, unless 
otherwise stated. All statistical analyses were done using the statistical package SAS, 
version 9.1 (SAS Institute, Inc., Cary, North Carolina). Spearman partial correlation 
coefficient was used to determine association between MR-based parameters and femoral 
neck percentage BMD change at two and four years. Analysis of covariance (ANCOVA) 
was performed to examine the mean femoral neck BMD change between the above and 
below median of the MR-based parameters. Pearson correlation coefficient was used to 
assess the relationship between traditional risk factors and percentage femoral neck BMD 
change. Linear regression was applied to examine how MR-based parameters and other 
potential risk factors predict femoral neck bone loss. Parital R2 was shown for comparing 
effects contributed from different factors. Fisher exact test was used to test the sensitivity 
of MR parameters in distinguishing slow from fat bone losers. Slow bone losers were 
defined as subjects with on average <1% decline in femoral neck BMD per annum. Fast 
bone losers were defined as subjects with on average >1% decline in femoral neck BMD 
per annum. All statistical tests were two-sided. A p-value <0·05 was considered 
statistically significant.  
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Results 
(a) BMD reduction at femoral neck between different cohorts. Percentage 
decline in femoral neck BMD from baseline at two and four years was greater in 
subjects with increased marrow fat at the femoral neck and in subjects with 
decreased perfusion indices at the femoral neck, acetabulum and adductor muscle 
after adjusting for baseline BMD, age, weight and weight change. The same trend 
was observed in all areas with a greater reduction in BMD between cohorts at four 
years than two years (Table 2 and Figures 1-4). The difference between cohorts was 
significant for acetabulum Eslope and muscle Emax at four years (Table 2 and Figures 
3B and 4A).      




Time period Estimated mean (SE) of 
femoral neck BMD% change 
p-
value 
< median ≥ median  
Femoral neck fat content (%)  
[median= 85.5] 
    
year 0  year 2 [n=51] -0.342 (0.768) -1.560 (0.807) 0.2985 
year 0  year 4 [n=44] -1.310 (1.270) -4.722 (1.334) 0.0603 




(%) [median =10.9] 
year 0  year 2 [n=47] -0.945 (0.864) -0.752 (0.800) 0.7212 
year 0  year 4 [n=41] -4.870 (1.378) -0.971 (1.276) 0.0780 





year 0  year 2 [n=47] -1.053 (0.877) -0.659 (0.810) 0.8685 
year 2  year 4 [n=41] -4.191 (1.446) -1.558 (1.336) 0.4868 





year 0  year 2 [n=52] -1.011 (0.830) -0.855 (0.771) 0.6536 
year 2  year 4 [n=45] -4.010 (1.387) -1.970 (1.287) 0.4987 





year 0  year 2 [n=52] -2.017 (0.748) 0.210 (0.767) 0.2248 
year 2  year 4 [n=45] -5.624 (1.192) -0.097 (1.221) 0.0141 





year 0  year 2 [n=52] -1.961 (0.750) 0.060 (0.732) 0.0721 
year 2  year 4 [n=45] -5.741 (1.174) -0.226 (1.147) 0.0091 





year 0  year 2 [n=52] -1.161 (0.769) -0.705 (0.752) 0.6654 
year 2  year 4 [n=45] -4.413 (1.262) -1.496 (1.234) 0.1354 
 
Table 2: Estimated mean (SE) of BMD% change from year 0 to year 4.  
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ANCOVA adjusted for covariates including age, weight, weight change  
and baseline BMD. Bold: p-value<0.05 
 
(b) Correlation between perfusion indices and marrow fat at baseline and 
percentage reduction in femoral neck BMD at two and four years. A mild to 
moderate significant correlation (ranging from 0.23 to 0.52) was present between 
perfusion indices in the femoral neck, acetabulum and muscle and percentage 
reduction in femoral neck BMD at four years (Table 3). This correlation (r= 0.52) 
was greatest for acetabulum Eslope. The correlation between marrow fat content 
and percentage reduction in femoral neck BMD at four years did not reach 
statistical significance (Table 3).  
Table 3: Relationship between MR based parameters at basleine and subsequent bone 
loss  
Parameter 
Femoral neck BMD % change 








fat content (%) -0.1155 0.4244 -0.2293 0.1391 
E
max
(%) 0.0039 0.9795 0.3924 0.0123 
E
slope




(%) 0.1908 0.1800 0.2356 0.1237 
E
slope




(%) 0.1900 0.1817 0.3065 0.0430 
E
slope
(%/sec) 0.1205 0.3995 0.2794 0.0662 
 
Table 3: Relationship between marrow fat, bone and muscle perfusion and  
femoral neck bone loss adjusted for baseline BMD from 0  2 years and  
from 0  4 years. Bold: p-value<0.05. 1Spearman partial correlation coefficient 
 
 
(c) Correlation between selected known risk factors and percentage BMD 
change of femoral neck. Analysis of the present cohort using risk factors known 
to be associated with more rapid reduction in femoral neck BMD (Lau EMC et al 
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2006) showed that this association was strongest with age, weight, weight 
change for past two years and baseline femoral neck BMD (Table 4).  
Table 4. Relationship between bone los and clinical risk factors 
Parameter 
Femoral neck BMD % change 
year 0 year 4 
Coefficient1 p-value 
Age -0.0575 0.7110 
Weight 0.4259 0.0039 
Weight change for past 2 years -0.2586 0.0901 
Height -0.0254 0.8702 
Baseline femoral neck BMD 0.2118 0.1676 
Grip strength -0.1410 0.3613 
Physical activity (PASE) -0.1045 0.4995 
Calcium/ Calories -0.0801 0.6054 
Diabetes 0.2345 0.1254 
Fracture after 50 years -0.1242 0.4218 
Height change from 25 years old -0.0645 0.7443 
Smoker  0.1529 0.3218 
Daily alcohol intake 0.0097 0.9504 
 
Table 4: Relationship between femoral neck bone loss for 4 years and 
clinical risk factors. Bold: p-value<0.05.
 1
Pearson correlation coefficient. 
 
 
(d) Comparison of known risk factors with perfusion indices in predicting 
regarding correlation with percentage reduction in femoral neck BMD.  
Analyzing the effect of these variables and the two perfusion indices most 
strongly associated with percentage reduction in femoral neck BMD, showed that 
perfusion indices had a comparable association with percentage reduction in 
femoral neck BMD than all of the previously identified variables such as subject 
age, weight, weight change over two years and baseline femoral neck BMD 
(Table 5).  
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Table 5; Multivariate regression analysis of MR-based paramenters and clinical 
risk factors  
Parameter 
Femoral neck BMD % change 
year 0 year 4 
Coefficient p-value Partial R2 
Muscle Fat content (%) > median -2.2482 0.1292 0.0628 
Age -0.0419 0.8119 0.0016 
Weight 0.3150 0.0020 0.2348 
Weight change for past 2 years -0.5686 0.0238 0.1341 
Baseline femoral neck BMD -0.1073 0.4471 0.0162 
   R2 =0.3715 
Muscle Emax (%) > median 3.2933 0.0184 0.1412 
Age -0.1562 0.3595 0.0227 
Weight 0.2893 0.0027 0.2181 
Weight change for past 2 years -0.6597 0.0066 0.1828 
Baseline femoral neck BMD -0.0991 0.4498 0.0155 
   R2 =0.4226 
Acetabulum Eslope (%/sec) > 
median 3.0006 0.0392 0.1100 
Age -0.1013 0.5492 0.0098 
Weight 0.2486 0.0158 0.1476 
Weight change for past 2 years -0.5544 0.0210 0.1357 
Baseline femoral neck BMD -0.1518 0.2481 0.0359 
   R2 =0.4017 
 
Table 5:  Multivariate linear regression analysis showing predictive ability of three 
selected MR parameters (muscle Emax (%/sec) < median, acetabulum Eslope (%/sec) 
< median and marrow fat content (%) >median) compared with traditional risk 
factors in determining femoral neck bone loss over 4 years. Partial R2 depicts 
relative effect of each variable individually while summation reflects total effect. 
Bold: p value <0.05. 
 
(e) Sensitivity of marrow fat and perfusion induces in identifying subjects as 
slow or rapid bone losers.   
Of the various MR parameters analyzed, acetabulum Eslope proved the most sensitive 
indicator for differentiating subjects as fast or slow bone losers with a sensitivity of 
89% (Table 6).  Next most sensitive were the various femoral neck Emax, Eslope and 
marrow fat content with sensitivities of 81%, 75% and 72% respectively. Muscle 
enhancement did not prove to be sensitive in distinguishing between fast and slow 
bone losers.  
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Rapid loser  
Sensitivity 








Femoral neck fat content (%)     
<median (= 85.5%) 18 (69.2%) 5 (27.8%) 0.722 (0.46, 0.89)* 0.0132 
≥median 8 (30.8%) 13 (72.2%)   
     
Femoral neck E
max
 (%)      
<median (= 10.9%)  6 (24.0%) 13 (81.3%) 0.813 (0.54, 0.95) 0.0005  
≥median 19 (76.0%) 3 (18.8%)   
Femoral neck E
slope 
(%/sec)     
<median (= 0.36 %/sec) 7 (28.0%) 12 (75.0%) 0.750 (0.47, 0.92) 0.0046 
≥median  18 (72.0%) 4 (25.0%)   
     
Acetabulum E
max
 (%)     
<median (= 16.8%) 10 (37.0%) 11 (61.1%) 0.611 (0.36, 0.82) 0.1376 
≥median 17 (63.0%) 7 (38.9%)   
Acetabulum E
slope
 (%/sec)     
<median (= 0.87 %/sec) 7 (25.9%) 16 (88.9%) 0.889 (0.64, 0.98) <0.0001  
≥median 20 (74.1%) 2 (11.1%)   
     
Muscle E
max
 (%)     
<median (= 68.8%) 11 (40.7%) 11 (61.1%) 0.611 (0.36, 0.82) 0.2307 
≥median 16 (59.3%) 7 (38.9%)   
Muscle E
slope
 (%/sec)     
<median  (= 1.57 %/sec) 11 (40.7%) 11 (61.1%) 0.611 (0.36, 0.82) 0.2307 
≥median 16 (59.3%) 7 (38.9%)   
 
Table 6. Sensitivity of marrow fat content and perfusion indices in predicting rapid decline in femoral neck 
BMD
.
 Rapid loser defined as femoral neck BMD decline of > 1% per annum. *Sensitivity refers to marrow fat 





Figure 1. Mean %  reduction in femoral neck BMD over four year period in subjects with < or > 
the median fat content (=85.5%).  BMD in subjects with <median fat content declined 1.3% while 














Figure 2. Mean %  reduction in femoral neck BMD over four year period in subjects with < or > 
the median E
max
 (= 10.9%) or E
slope
 (= 0.36 %/sec) at the femoral neck. (A) BMD in subjects with 
<median E
max
 declined 4.9% while while BMD in subjects with >median E
max
 declined 1.0%. (B) 
BMD in subjects with <median E
slope
 declined 4.2% while while BMD in subjects with >median 
E
slope





Figure 3. Mean %  reduction in femoral neck BMD over four year period in subjects with < or > 
the median E
max
 (= 16.8%) or E
slope
 (= 0.87 %/sec) at the acetabulum. (A) BMD in subjects with 
<median E
max
 declined 4.0% while while BMD in subjects with >median E
max
 declined 1.9%. 
(B) BMD in subjects with <median E
slope
 declined 5.6% while while BMD in subjects with 
>median E
slope





Figure 4. Mean %  reduction in femoral neck BMD over four year period in subjects with < or > 
the median E
max
 (= 68.8%) or E
slope
 (= 1.57 %/sec) at the acetabulum. (A) BMD in subjects with 
<median E
max
 declined 5.7% while while BMD in subjects with >median E
max
 declined 2.2%. 
(B) BMD in subjects with <median E
slope
 declined 4.4% while while BMD in subjects with 
>median E
slope
 declined 1.5%. 
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SIGNIFICANCE OF THESE RESULTS 
Rather than all subjects of the same age and gender losing bone at the same rate, 
some subjects loose bone at a faster rate. A means of identifying subjects more 
likely to loose bone at a faster rate would be helpful in allowing such individuals to be 
targeted for specific anti-osteoporotic medication. Ideally one would hope to 
recognize these subjects at the outset before bone loss occurs. At the moment, 
clinical and densitometry measures at baseline provide the best predictors of further 
bone loss. Recognized useful parameters are age and weight at baseline, weight 
loss over two years and baseline BMD. The predictive value of urinary and serum 
bone turnover markers is limited by wide inherent variability [Garnero et al 1999]. 
The aim of this study was to see if the presence of increased marrow fat or 
decreased perfusion at baseline could predict future bone loss. For the purpose of 
this study, we defined slow losers as <1% decline in femoral neck BMD per annum 
and fast losers as >1% decline in femoral neck BMD per annum.  Higher marrow fat 
content and lower perfusion indices (both in bone and muscle) at baseline was 
associated with more severe bone loss over a four year period. Several of the MR 
parameters assessed were comparable wirth currently applied clinical risk factors in 
predicting bone loss at the femoral neck. The parameter with the highest correlation 
was acetabulum Eslope. This higher correlation with acetabular and not femoral neck 
perfusion may reflect the relatively better bone perfusion and possible truer 
assessment of bone in the acetabulum compared to the proximal femur (Study 4, 
Study 5). For all bone areas examined in Study 4 (femoral head, neck, shaft and 
acetabulum) perfusion indices were highest in the acetabulum (with Emax and Eslope 
being about 50-100% higher than those in the femoral neck, Study 4). 
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We also found a moderate correlation found between muscle Emax and subsequent 
bone loss. This was unexpected since previous cross-sectional studies (Study 2 and 
Study 4) had shown no relationship between decreasing BMD and muscle perfusion. 
It emphasizes that we cannot ignore the potential role of a generalized vascular 
problem such as endothelial function being involved in bone loss.    
MR perfusion parameters also proved to be useful at distinguishing between fast and 
slow bone losers. Acetabulum Eslope values larger than 0.87%/sec (median value) 
had a sensitivity of 89% for distinguishing between slow and fast losers at baseline 
while the sensitivity of femoral neck perfusion median parameters was 75-81% and 
that of femoral neck marrow fat content was 72%. The predictive ability of muscle 
perfusion indices were less than those of bone.  
It was also surprising how some perfusion parameters such as Acetabulum Eslope 
showed good correlation and predictive power, whilst very closely related 
parameters such as Acetabulum Emax did not show as good correlation or predictive 
ability. Emax is considered to be more related to total uptake of gadolinium contrast 
agent into the interstitial space, and is dependent on blood flow, micro-vessel density, 
and interstitial fluid movement (Reddick WE et al. 1999, Taylor JS et al. 2000, 
Choyke PL et al. 2003) while Eslope tends to be more dependent on blood flow and 
vessel permeability (Reddick WE et al. 1999, Taylor JS et al. 2000, Choyke PL et al. 
2003). More research into the factors influencing these parameters and more 
detailed analysis of marrow perfusion imaging using pharmokinetic compartmental 
modeling needs to be undertaken.    
This is the first study to assess the predicative value of marrow fat and perfusion 
indices. We are certainly not advocating that MR be applied at this stage as a means 
to predict bone loss. The predictive ability of MR is only compable to but no better 
 221 
than clinical risk factors. MR would been to be substantially better than clinical 
evlation for it to be a clinically useful measure. In addition, many epidemiological as 
well as cost-effectiveness issues have not been addressed in this study. The 
findings, nevertheless, are sufficiently encouraging to say that bone perfusion and 
also probably marrow fat are integrally related to bone loss and do show potential in 
the prediction of bone loss.    
 
Limitations of this study.  
1. The main limitation of this study is the relatively small sample size of 52 subjects 
being followed up over a four year period out of an initial cohort of 120 subjects. 
Nevertheless, statistical significance was achieved with many perfusion 
parameters and close to statistical significance for other perfusion parameters 
and marrow fat content.  
2. This study was performed solely on female subjects. Perfusion indices in the 
proximal femur tend to be higher in female post-menopausal subjects than male 
subjects of comparable age (Study 4). Whether a similar predictive potential is 
seen in male subjects is not known.  
3. Due to the small cohort size, we did not determine fracture prevalence in this 
study. Although low femoral neck BMD is a strong predictor of proximal femoral 
fracture (Cummings et al. 1994), predicting BMD loss is not the same as 
predicting fracture risk.  
Conclusion. Perfusion parameters, and to a lesser degree, marrow fat content, are 
predictive of the severity of bone loss. These MR indices correlated with subsequent 
bone loss similar to currently applied risk factors. Selected perfusion parameters had 





A finely tuned equilibrium that exists between bone deposition by osteoblasts and 
resorption by osteoclasts helps maintain skeletal bone mass. After peak bone mass is 
attained in the third to four decade of life, progressive bone loss occurs throughout 
the skeleton preferentially affecting the trabecular rather than the cortical component 
of bone. As a result, those bone parts with relatively more trabecular bone (vertebral 
bodies, neck of femur and distal radius) sustain the greatest loss in bone strength and 
become particularly susceptible to fracture often with minimal or no trauma. This state 
of increased bone fragility is known as osteoporosis which is defined as a skeletal 
disorder characterized by compromised bone strength predisposing to an increased 
risk of fracture.   
Currently, we rely on either bone density or the occurrence of a low energy fracture to 
diagnose osteoporosis. This approach is inherently flawed since bone needs to be 
lost or a fracture needs to occur before we can identify a patient with osteoporosis. 
And once bone is lost it does not necessarily recover with treatment. Treatment can 
improve bone density and improve bone strength but bone quality will probably never 
return to normal and treatment effect is not necessarily sustained. It would be much 
better if a means existed of recognizing the early stage of the osteoporotic process 
before bone loss occurs. Another limitation with current osteoporosis management is 
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the delay involved in evaluating new treatments. Currently used end-points to test 
treatment efficiency are bone loss or fracture as no reliable predictors of future bone 
loss have been identified. The result is that many years relapse before the effect of 
treatment can be evaluated. Finally, many risk factors for osteoporosis and 
osteoporotic fracture have been identified though no unifying etiology regarding the 
pathophysiology of this disorder exists.  
Recent research utilizing high resolution imaging techniques such as CT and MR 
have gone a very long way to improving our understanding of bone architecture, bone 
quality and fracture risk prediction. Recent developments in MR imaging technology 
have also allowed non-invasive evaluation of bone marrow. While, to date, most 
osteoporotic research has concentrated on the mineralized component of bone, it 
may well be that study of the bone marrow could provide answers to some of the 
on-going questions about osteoporosis pathophysiology and management. After all, 
metabolically active trabecular bone is bathed in bone marrow and is likely to react to 
changes in this bone microenvironment. We undertook the studies presented in this 
thesis with a view of bettering our understanding of the physiological processes 
occurring within the bone marrow in osteoporotic subjects with the ultimate aim of 
being able to indentify features which would point to the initiation of the osteoporotic 
process before bone loss occurs. A simple analogy would be the recognition and 
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treatment of early coronary artery disease before heart failure or myocardial infarction 
ensues.   
In these studies we have shown that perfusion seems to be reduced in osteoporotic 
bone, that this effect is seen in both males and females (Study 1, 2 & 4) and affects 
the proximal femur in a similar fashion to the vertebral body (Study 1,2 & 4). The 
apparent reduced perfusion seen in osteoporotic bone occurs within the bone and is 
not a reflection of a more generalized circulatory disturbance (Study 2 & 4). In line 
with this decreased perfusion is an increase in marrow fat which can be quantified by 
MR spectroscopy (Study 1,2, 4 and 7).  We have been able to quantify the error of 
increasing marrow fat on BMD estimation by DXA (Study 3). This effect is not large 
and does not affect the findings of our studies. We have shown that the perfusion of 
the femoral head is inherently poor in normal subjects while in osteoporosis perfusion 
in the femoral neck region tends to diminish relatively more than in the femoral head 
and shaft (Study 4). Bone perfusion decreases soon after estrogen depletion and 
occurs in line with rather than pre-or post-dating bone loss (Study 7). The most likely 
causes of decreased perfusion are, primarily, a previously unrecognized concomitant 
reduction in the red cell mass accompanying estrogen depletion and secondarily 
endothelial dysfunction (Study 7). Increase in marrow fat seems to occur as a result of 
increase in fat cell number rather than fat cell size (Study 7) and is most likely due to a 
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switch in mesenchymal stem cell differentiation from osteoblastogenesis to 
adipocytosis. Although long chain polyunsaturated fatty acids in diet or co-culture 
have been shown to affect bone metabolism, the fatty acid composition of marrow fat 
is not altered between subjects with normal bone mineral density, low bone mass 
(osteopenia) or osteoporosis (Study 6). Hence, it is unlikely that fatty acids in the 
marrow have a direct effect on bone formation. Clear differences do exist between 
subcutaneous and marrow fat so that the former cannot be used a mirror of the latter 
in future studies (Study 6). Longitudinal study using either serial MRS or perfusion 
imaging of the bone marrow is feasible as the reproducibility of these techniques is 
high (Study 4), particularly in areas with either high fat content or relatively good 
perfusion (Study 4). Independent of baseline BMD level, the presence of high marrow 
fat content or reduced perfusion either in bone or muscle at baseline does predict 
accelerated bone loss over the ensuing 4 years (Study 8). Elderly subjects with 
increased marrow fat content or decreased perfusion tend to loose bone at an 
average rate of 1.25% per annum compared to those with decreased marrow fat 
content or increased perfusion who loose bone at an average rate of 0.25% per 
annum (Study 8).           
Bone loss clearly does not occur in isolation. Instead in occurs in conjunction with 
changes in fat, other marrow constituents and perfusion. A more encompassing 
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paradigm which looks at bone as well as its microenvironment is likely to be the 
model that best serves future osteoporotic research. We are continuing with this line 
of research, studying in greater detail the type of perfusion abnormalities occurring in 
bone; the reasons behind these changes; the change in marrow composition with 
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ABBREVIATION LIST (in alphabetical order) 
 
AIF: Arterial input function 
ANCOVA: Analysis of covariance  
AUC: Area under the curve 
BOLD: Blood oxygen level dependent 
BMC:Bone mineral content 
BMD: Bone mineral density  
C: carbon 
Ca: calcium 
CFA: Comparative fit index 
CT: Computed tomography 
DCE: Dynamic contrast enhanced 
DXA dual x-ray absorbiometry 
Emax: Enhancement maximum 
Eslope: Enhancement slope 
F: Fluroride 
FDG: Flurodeoxyglucose 
G: Glomerular filtration rate 
Ge: Germanium 
Ga: Gallium 
GFI: Goodness of fit index 
H: Hydrogen 
IDEAL: Iterative Decomposition of water with Echo Asymmetry and Least-squares 
estimation.   
Imax: Intensity maxium 
Ibase: Intensity baseline  
K: Potassium 
L: Lower vertebral depth 
Mg: Magnesium 
MR : magnetic resonance 
MRI: magnetic resonance imaging 
MUFA: Monounsaturated fatty acids 
MVP: Metabolic volumetric product 
N: Nitrogen 
Na: Sodium 
NHANES: National Health and Nutrition Examination Survey 
NNFI: Non-normed fit-index 
NSF: Neprogenic sclerosing fibrosis  
O: Oxygen 
OPG: Osteoprotegerin 
QCT: Quantitative CT 
PET: Positron Emission Tomography  
PPM: parts per million 
PRESS: point-resolved spectroscopy 
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PQCT: Peripheral quantitative CT 
PUFA: Polyunsaturated fatty acids 
RANK: receptor-activated nuclear-kappa 
RANKL: receptor-activated nuclear-kappa ligand 
RMSEA: Root mean square error of approximation 
ROC: Receiver operating characteristic 
ROI: Region of interest 
P:Phosphorus 
SNR: Signal to noise ratio 
STEAM: Stimulated echo acquisition mode 
SRMR: Standardized root mean square rsidual 
S: Sulphur 
SD: standard deviation 
SUV: standardized uptake value  
TE: Time to echo 
TR: Time to repetition 
U:Upper vertebral depth 
VOI: Volume of interest 










Ethics approval and Consent forms 
On the following pages, the forms for Ethics Approval on human studies granted by 
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Kong, Animal Experimentation Ethics Committee are also presented.  
Samples of consent forms used for the clinical studies in this Thesis are also 

































Patient consent form for  
Functional Magnetic Resonance Imaging of Osteoporosis 
 
 
Perfusion, diffusion and spectroscopy are new magnetic resonance 
imaging (MRI) techniques that are believed to be useful in obtaining physiological 
information from bones.  The information obtained could be valuable in 
understanding bone diseases, in particular, osteoporosis and could lead to better 
prevention of this disease as well as new treatments. 
 
Perfusion measures the blood flow in the bones. Diffusion measures how 
easily small particles (molecules) can move around inside your bone. 
Spectroscopy measures the content of fat and other substances inside your 
bones. We will be looking only at the bones in the lumbar spine (i.e. the lower 
back) during this examination. 
 
We would like to obtain your consent to perform this MRI examination to 
examine the bones in your spine.  An injection will be given during the 
examination. The substance injected is a very standard, safe agent to show up 
blood flow better. It is used every day in clinical practice. Otherwise, there will be 
no pain or discomfort involved and you will not notice anything unusual during the 
examination. There will be no side effects or late effects from the examination. 
Magnetic resonance imaging is a very safe imaging test that has been used in 
routine clinical practice for over 10 years. It does not involve any X-ray irradiation.   
 
We will write a report on our findings regarding any changes in your lumbar 
spine and send this report to your clinicians at the osteoporosis centre.   
 
The information gathered will be kept confidential and will be used solely 
for research. We would like to obtain your consent for us to use the information for 
that purpose.  Whether you decide to join the study or not is entirely your 
decision and is not going to affect your treatment.  You can decide to withdraw 
from the study at any time and your treatment or management will not be affected 




I have read the explanatory statement and agree to participate in the above 
study.  The nature and the purpose of the study has been explained to me. I 








___________________________   ___________________________ 




___________________________   ___________________________ 




___________________________   ___________________________ 
Date         Date  
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Patient consent form:   
 
Reproducibility of functional MR imaging techniques in bone and relationship to endothelial 
function studies 
 
Magnetic resonance imaging (MRI) is a safe investigation that can provide information about bones. 
This MRI examination would look at your lumbar spine (‘lower back’) and right hip. It would look at 
the fat within your bones and well as the blood flow. This would involve you having an injection into a 
vein on the back of your hand or forearm. This injection is safe provided your kidneys are working 
properly so we will check that before you have the examination. The MRI examination will take 
approximately about 35 minutes. It does not involve any X-ray irradiation. We will examine your 
lumbar spine and hip.  We will let you and your clinician know the results of the examination.  
 
We will also look at how healthy your arteries are by checking your endothelial function and intimal 
thickness. Both of these tests look at whether there is any atherosclerosis (hardening) of your 
arteries.  It is an ultrasound test which does not involve any infections. You will have to take a tablet 
under your tongue before one part of the examination to dilate your arteries temporarily. This effect 
will only last a short time. We will let you and your clinician know the results of the examination. 
 
The information obtained could be valuable in better understanding osteoporosis and could lead to 
better treatment of this disease as well as better prevention. The information gathered will be kept 
confidential and will be used solely for research. We would like to obtain your consent for us to use 
the information for this purpose.  Whether or not you decide to join the study is entirely your 
decision and is not going to affect your treatment.  You can decide to withdraw from the study at any 
time and your treatment or management will not be affected in any way. 
 
If you have any questions regarding these issues, please feel free to contact Prof James Griffith, 




I have read the explanatory statement and agree to participate in the above study.  The nature and the 
purpose of the study have been explained to me by Dr.       . I understand that the examination 




             
Patient’s signature   Doctor’s signature 
 
 
               
Patient’s name and ID no. Doctor’s name 
 
 
            


































病人姓名及身份證號碼:    醫生姓名: 
 
 









































































見証人姓名______________ 見証人簽名 _____________ 日期 ______________ 
 
